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Abstract 
  
There has been an increased interest in the development of nerve repair devices to 
improve peripheral nerve regeneration following injury. The aim of this study was to 
investigate whether nerve repair devices containing genetically modified cells 
overexpressing VEGF-A165 would augment regeneration. An in vitro proof-of-concept 
study was carried out to deliver marker genes (luciferase and eGFP) to a rat Schwann 
cell line (SCL4.1/F7) using a lentiviral vector. The transduced cells were used to produce 
engineered neural tissue and bioluminescence imaging was used to assess cell viability 
in the constructs. It was initially thought the presence of the luciferase gene in the 
expression cassette would allow real-time and sustained imaging of the cells in the 
engineered neural tissue. However, while bioluminescence imaging provided an 
indication of cell viability in vitro, it proved to be ineffective for in vivo and ex vivo 
imaging. Having established that SCL4.1/F7 cells were amenable to lentiviral 
transduction, a lentiviral vector delivering the VEGF-A165 gene was designed and 
produced. The VEGF-A165 produced by the transduced SCL4.1/F7 cells increased 
endothelial cell viability, migration and tube formation in vitro. It also increased 
SCL4.1/F7 cell proliferation and migration. SCL4.1/F7 cells overexpressing VEGF-A165 
were found to increase endothelial cell network formation and neurite length in 3D co-
culture models. Foetal human neural stem cells and rat adipose derived stem cells were 
also successfully transduced with the lentiviral vector delivering VEGF-A165.  Based on 
the in vitro results, it was postulated that EngNT made from SCL4.1/F7 cells 
overexpressing VEGF-A165 implanted into a rat model of sciatic nerve injury would 
enhance regeneration. Unexpectedly, a pilot study revealed that this did not result in 
improved functional recovery or increased axon and blood vessel counts compared to 
controls. The results from this study highlight that attention needs to be paid to the dose 
and duration of expression of VEGF-A165 to optimise both its angiogenic and 
neurotrophic effects.  
 
 
 
The research work disclosed in this publication is partially funded by the Endeavour Scholarship Scheme 
(Malta).  Scholarships are part-financed by the European Union - European Social Fund (ESF) - 
Operational Programme II – Cohesion Policy 2014-2020 “Investing in human capital to create more 
opportunities and promote the well-being of society”. 
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Impact statement 
 
Peripheral nerve injuries affect ~5% of trauma patients (Li et al., 2014) and may have a 
serious impact on patient quality of life, resulting from loss of motor, sensory or 
autonomic function. Despite refinement in surgical techniques, insufficient functional 
recovery after peripheral nerve injury remains a significant clinical challenge, with only 
40-70% of adults regaining some functional activity following injury (Rochkind et al., 
2014a). Further, the current clinical gold standard, the nerve autograft, is associated 
with several other disadvantages, including the sacrifice of a functioning nerve and 
possible neuroma formation at the donor site (Grinsell et al., 2014).  
 
The limited efficacy of current treatment has propelled the development of tissue 
engineered constructs as an alternative to the nerve autograft (Gu et al., 2014). 
However, while biomaterial conduits have already been approved for clinical use, none 
of them offer complete functional recovery (Belanger et al., 2016). Supplementing the 
biomaterial conduits with therapeutic cells is thought to enhance peripheral nerve 
engineering strategies, as cells provide structural and trophic support. However, tissue 
engineering is currently limited by the inability to adequately vascularise tissues 
following implantation (Lovett et al., 2009). Therefore, additional strategies for 
enhancing vascularisation are essential to ensure the survival of tissue engineered 
constructs in vivo as insufficient vascularisation can lead to improper cell integration or 
cell death (Rouwkema et al., 2008).  
 
Angiogenic factors are currently being investigated as a means of inducing 
vascularisation in tissue engineered constructs (Novosel et al., 2011). In order to 
overcome problems with the delivery of such factors, the current study investigates the 
use of genetically modified cells which overexpress vascular endothelial growth factor 
(VEGF). Once incorporated into tissue engineered constructs used for peripheral nerve 
repair, these cells can provide a local and sustained release of VEGF. It is thought that 
the combination of tissue engineering and gene delivery may provide the optimal 
environment for axonal regeneration, and following further investigation and 
refinement, may be applicable to translational research to promote peripheral nerve 
regeneration.  
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Chapter 1. Introduction  
 
1.1 Background 
 
Damage to the peripheral nervous system can have a serious impact on patient quality 
of life, resulting from loss of motor or sensory function. Despite an improved 
understanding of the complex neuropathophysiology following peripheral nerve 
injuries, clinical treatments have remained largely unchanged over the past 30 
years (Faroni et al., 2015). Surgical procedures aim to restore the connection between 
the proximal and distal stumps in transection injuries, either through a primary repair or 
a nerve autograft. However, these procedures often result in poor clinical outcomes, 
with patients unlikely to regain full function (Geuna et al., 2009). This highlights the need 
for continued research to provide more efficacious treatment strategies.   
 
In recent years, there has been considerable interest in developing tissue engineered 
constructs as an alternative to current treatment modalities (Gu et al., 2014). While 
nerve guidance conduits have already been approved for clinical use, none of them offer 
complete functional recovery (Belanger et al., 2016). Supplementing biomaterial 
conduits with therapeutic cells can provide structural and trophic support by recreating 
key features of nerve architecture, thus enhancing peripheral nerve engineering 
strategies. However, tissue engineering is limited by the inability to adequately 
vascularise tissues due to nutrient perfusion and mass transport limitations (Lovett et 
al., 2009). In fact, vascularisation is currently regarded as one of the main hurdles 
hindering the translation of tissue engineering to clinical applications (Grounds, 2018).  
This has prompted the investigation of methods to successfully connect the tissue 
engineered construct to the host vasculature following implantation (Rouwkema and 
Khademhosseini, 2016). 
 
1.2 Study rationale 
 
Angiogenic growth factors are effective initiators of vascularisation by activating 
endothelial cells and stimulating them to migrate towards the factor gradient. They also 
promote vessel formation and maturation. The main factors in upregulating angiogenic 
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processes are vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF) and hepatocyte growth factor (HGF) (Nomi et al., 2006).  Angiogenic factors can 
be exploited as a means of inducing vascularisation in tissue engineered constructs 
(Novosel et al., 2011) and there has been an interest in the development of strategies 
for the delivery of these factors to the implant site. Angiogenic factors are inherently 
unstable in vivo, precluding their administration by bolus injection (Nomi et al., 2002). 
Furthermore, vascularisation is implicated in tumour growth and metastasis (Horch et 
al., 2013), making the widespread and uncontrolled delivery of angiogenic factors 
undesirable. Consequently, efforts are being made to create a spatially restricted and 
stable delivery system. One such approach is the use of genetically modified cells that 
overexpress these factors. Once incorporated into tissue-engineered constructs, these 
cells can provide a local and sustained angiogenic factor release (Novosel et al., 2011).   
  
Viral gene delivery has been established as a highly effective means of genetically 
modifying cells for patient benefit and has been suggested as a means of enhancing 
peripheral nerve tissue engineering strategies (Busuttil et al., 2017). The combination of 
gene delivery and cell therapy is an emerging strategy that has yielded clinical success 
in other medical conditions. A noteworthy example is the regulatory approval of 
StrimvelisTM, the first ex vivo autologous stem cell gene therapy to treat patients with 
severe combined immunodeficiency due to adenosine deaminase deficiency (Ylä-
Herttuala, 2016).   
  
In addition to increasing cell survival in implanted tissue engineered constructs, 
vascularisation is also important for the process of peripheral nerve regeneration itself. 
Cattin et al. (2015) have showed that following injury, new blood vessels guide migrating 
Schwann cells across the injury site, a process that is essential for axonal regeneration. 
Further, angiogenic factors such as VEGF exhibit neurotrophic effects (Sondell et al., 
2000). Neurotrophic factors control the survival, migration, proliferation and 
differentiation of various types of cells that are involved in nerve repair (Sebben et al., 
2011). The overexpression of VEGF may augment peripheral nerve tissue engineering 
strategies by providing the optimal environment for axonal regeneration and 
reestablishment of functional circuits.  
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To fully evaluate the performance of tissue engineered constructs in vitro and in vivo, it 
is necessary to obtain information on cell distribution and cell fate. This has traditionally 
been done by histological analysis using in vitro samples or explanted specimens after 
in vivo applications (Leferink et al., 2016).   However, this requires destruction of the 
samples, excluding the possibility of longitudinal monitoring (Nam et al., 2015). In order 
to overcome the limitations of destructive endpoint analysis, imaging modalities capable 
of monitoring the tissue engineered constructs over a period of time are being 
investigated (Nam et al., 2015).  
 
Molecular imaging may allow the longitudinal, non-invasive and quantitative imaging of 
tissue engineered constructs. This can be achieved by genetically modifying cells to 
express a reporter gene. Commonly used reporter genes in cell-based therapies include 
enhanced green fluorescent protein (eGFP) for fluorescence imaging and luciferase for 
bioluminescence imaging (Li et al., 2018).  Bioluminescence imaging is a popular means 
of assessing cell viability and tracking cells in pre-clinical studies (Strohschein et al., 
2015). Additionally, it can also provide valuable information about cell behaviour in 
three-dimensional (3D) tissue engineered constructs (Vila et al., 2016).  
 
1.3 Aims and objectives   
 
The overarching hypothesis of this project is that the combination of tissue engineering 
and gene delivery can be used to augment peripheral nerve regeneration. This 
hypothesis will be tested by:  
 
 Labelling cells with a bioluminescent tag to monitor cell viability in the tissue 
engineered constructs in vitro and in vivo.   
 Modifying cells to overexpress VEGF-A165, thereby improving vascularisation to 
the implanted tissue.  
 Improving peripheral nerve regeneration by creating a microenvironment 
conducive to axonal regrowth as VEGF-A165 also has neurotrophic effects.  
  
 In order to reach these aims, this project has the following specific objectives: 
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 To produce lentiviral vectors to deliver therapeutic and reporter genes.    
 To assess the ability of the lentiviral vectors to efficiently deliver genes to a 
variety of cell types in vitro.    
 To determine whether the transduced cells can produce functional proteins in 
vitro.    
 To ensure that the transduced cells remain viable and can be used to produce 
tissue engineered constructs.  
 To monitor cell viability in the tissue engineered constructs in vitro and in vivo.  
 To determine whether tissue engineered constructs containing cells 
overexpressing VEGF-A165 improve axonal regeneration and functional recovery 
in a rat model of sciatic nerve injury.  
 
1.4 Organisation of thesis 
 
Chapter 2 provides a literature review covering peripheral nerve injury and 
regeneration. This chapter evaluates the use of tissue engineered constructs containing 
genetically modified cells in enhancing peripheral nerve regeneration as well as the 
importance of vascularisation of tissue engineered constructs. Chapter 3 details the 
materials and methods used in this study. Chapter 4 presents the results of an in vitro 
proof-of-concept study describing lentiviral mediated gene delivery to a rat Schwann 
cell line. Chapter 5 investigates the use of bioluminescence imaging to monitor the 
viability of cells in engineered neural tissue (EngNT), both in vitro and in vivo. Chapter 6 
describes the genetic modification of cells to overexpress VEGF-A165 and the assays used 
to assess the functionality of the protein in vitro. Chapter 7 explores the transduction of 
clinically relevant stem cells. Results from a pilot study investigating the efficacy of 
EngNT containing cells overexpressing VEGF-A165 in a rat model of sciatic nerve injury 
are also presented. Chapter 8 summarises the main findings of this study along with the 
study limitations and future work.   
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Chapter 2. Literature review  
 
2.1 The peripheral nervous system  
 
The nervous system in vertebrates comprises the central nervous system (CNS) and the 
peripheral nervous system (PNS) (figure 1). The CNS consists of the brain and spinal cord 
whereas the PNS includes the cranial, spinal, autonomic, enteric and peripheral nerves. 
The PNS connects the CNS to the sensory and motor pathways (Raimondo et al., 
2011).   Sensory nerves transmit impulses to the CNS from sensory receptors while 
motor nerves transmit neural signals from the CNS to effectors (glands, organs and 
muscles). These impulses are generated and directed via the sequential process of 
axonal depolarisation and subsequent repolarisation, a process dependent on sodium 
and potassium channel flux.  The PNS derives from the neural crest and develops in a 
tightly controlled process that involves the migration of multipotent precursor cells that 
progressively differentiate into neurons and glial cells (Prendergast and Raible, 2014). In 
order to fully understand how to effectively develop strategies to enhance peripheral 
nerve regeneration, an understanding of peripheral nerve organisation, glial function 
and blood supply is needed and will be discussed in this section.  
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Figure 1. The central and peripheral nervous systems. The PNS includes afferent neurons that 
relay sensory information from receptors in the periphery toward the CNS and efferent neurons 
that transmit information away from the brain to the peripheral tissues. Image taken from 
https://www.nf2is.org/peripheral_nerve_damage.php (accessed 25th May 2019). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.1 Peripheral nerves  
 
Peripheral nerves extend throughout the body, forming a complex network. Sensory 
nerve fibres generally originate from pseudounipolar neurons located in the sensory 
ganglia while motor nerve fibres originate from somatic and autonomic motor neurons 
located in the CNS. Somatic motor fibres directly reach the target skeletal muscle fibres 
whereas autonomic motor fibres create synapses in an ortho- or parasympathetic 
ganglion where the second‐order autonomic neuron is located and the axon of which 
reaches the target visceral organs (Geuna et al., 2009).  
 
Peripheral nerves are complex tissues composed of Schwann cells, perineurial cells and 
neuronal processes (axons), surrounded by connective tissue elements. The smallest 
functional unit of a peripheral nerve is the nerve fibre. Nerve fibres can be myelinated 
or unmyelinated. Large mammalian axons are myelinated whereas axons smaller than 1 
μm in diameter are generally unmyelinated. Myelination allows the fast conduction of 
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action potentials by insulating the axons (Geuna et al., 2009). Nerves in different parts 
of the body vary in fibre composition and in the presence and number of fascicles. 
However, nerve morphology (figure 2) is comparatively similar in nearly all regions.  
 
Figure 2. Peripheral nerve anatomy. A nerve consists of axons embedded in a collagenous 
matrix (endoneurium), forming fascicles. Fascicles are ensheathed by connective tissue 
(perineurium) and wrapped by an external connective layer (epineurium). Nerves can be 
myelinated or unmyelinated. Image taken from Jessen et al. (2015). 
 
 
A heterogenous and highly specialised combination of cells and extracellular matrix 
(ECM) protects the nerves and provides resistance to stretch and compression forces 
during body movements. This intrinsic part of nerve structure is arranged in three layers, 
namely the epineurium, perineurium and endoneurium (figure 2) (Peltonen et al., 2013). 
The epineurium is the outermost layer of supporting and protective tissue and 
surrounds the entire nerve and its individual fascicles. It contains fibroblasts, collagen 
(types I and II) and variable amounts of fat, and thus contributes to the tensile strength 
of the nerve. It carries the main intraneural vascular system, which passes across the 
perineurium and into the endoneurium (Geuna et al., 2009). 
  
The perineurium is a dense and mechanically strong sheath that surrounds each fascicle, 
consisting of alternating layers of flattened polygonal cells and collagen (Richner et al., 
2014). The number of perineurial cell layers varies according to the number and size of 
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the fascicles in the nerve (Peltonen et al., 2013). The perineurium, together with the 
blood–nerve barrier described below, plays an essential role in maintaining the osmotic 
milieu and the fluid pressure within the endoneurium (Mizisin and Weerasuriya, 2011).  
  
The endoneurium is a loose, soft, connective tissue that surrounds and supports the 
fascicles, protecting them during the movements of an extremity and from external 
trauma. The cell population in the endoneurium consists mostly of Schwann cells and 
endothelial cells that form capillary networks (Geuna et al., 2009). Endoneurial blood 
vessels isolate the endoneurium from the circulating blood, forming the blood-nerve 
barrier that consists of tight junctions between endothelial cells (Mizisin and 
Weerasuriya, 2011).  Tight control of ion and water concentrations within peripheral 
nerves is required to maintain the internal microenvironment needed for axonal signal 
transmission.  
 
2.1.2 Schwann cells  
 
Schwann cells and satellite glia are two types of glial cells found in the PNS (Rasband, 
2016). Whereas satellite glia are found within ganglia in close association with neuronal 
cell bodies, Schwann cells are found in close contact with axons in peripheral nerves. 
Both Schwann cells and satellite glia derive embryologically from the neural crest, which 
comprises multipotent cells migrating away from the dorsal neural tube (Nitzan et al., 
2013).  
 
Neural crest cells differentiate into Schwann cell precursors, which migrate and 
proliferate along tracts of axons that have already extended into the periphery.  
Schwann cell precursors then embark on a process of cellular differentiation into  
immature Schwann cells to eventually become either myelinating or nonmyelinating 
(Remak) Schwann cells (Jessen et al., 2015) (figure 3).  Only large-diameter axons, which 
conduct impulses at the highest speed, become myelinated. Myelinated nerve fibres 
consist of a single axon that is enveloped by Schwann cells. The Schwann cell 
membranes wrap around the nerve fibre to form a multilaminated myelin sheath. Small-
diameter axons are surrounded by nonmyelinating Schwann cells, forming Remak 
bundles (Campana, 2007).  
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Figure 3. The Schwann cell lineage. The embryonic phase of Schwann cell development involves 
three transient cell populations: migrating neural crest cells, Schwann cell precursors and 
immature Schwann cells. All these cells are considered to have the same developmental 
potential, and their fate is determined by the axons with which they associate. Schwann cells 
that envelop large‐diameter axons will be induced to myelinate, while those cells that ensheath 
small‐diameter axons progress to become mature non‐myelinating cells. Image taken from 
Jessen and Mirsky (2016).  
 
 
 
Schwann cells are able to undergo phenotypic modulation in order to support the axons 
they are associated with. This is most notable after peripheral nerve injury (Zhang et al., 
2017).  The myelin and non-myelin (Remak) Schwann cells distal to the nerve injury site 
undergo an extensive change in gene expression, resulting in a change in function from 
myelinating axons to facilitating nerve regeneration (Jessen and Mirsky, 2016).  
 
2.1.3 Vasculature 
 
Peripheral nerves have a unique vascular network due to their anatomical 
compartmentalisation (Ubogu, 2013). This vascular network, the vasa nervorum, 
consists of two separate, functionally independent, but anastomosing, systems: an 
extrinsic epineurial system and an intrinsic endoneurial system (Wigley, 2008) (figure 4).  
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Figure 4. The vasa nervorum. The circulation of peripheral nerves derives from regional extrinsic 
vessels (EV) which give rise to branch radicular vessels (RV) that supply the intrinsic circulation 
of the vasa nervorum. The intrinsic circulation consists of longitudinally oriented vessels that run 
through the epineurium (Epi), down to the perineurium (Peri) and join with vessels in the 
endoneurium (Endo) via transperineurial connections (arrow). Image taken from Mizisin and 
Weerasuriya (2011).  
 
 
 
 
 
 
 
 
 
 
The extrinsic system is composed of small arteries and veins from neighbouring tissue 
space and muscular blood vessels, which run parallel along peripheral nerves (Gao et al., 
2013a). The epineurial blood vessels lack tight junctions, have numerous fenestrations 
and are highly permeable. These vessels therefore provide nutrients, oxygen and blood 
flow to the intrinsic vascular system (Ubogu, 2013). The endoneurial microvasculature 
consists of tight junction-forming endothelial cells that, together with the perineurium, 
form the blood nerve barrier. This restricts the passive diffusion of macromolecules and 
cell entry from the blood circulation, and maintains the stability of the endoneurial 
microenvironment (Ubogu, 2013).  
Structural and functional changes in the blood-nerve barrier are thought to be involved 
in the pathogenesis of peripheral neuropathies. Therefore, re-establishing blood-nerve 
barrier function may enhance peripheral nerve regeneration after injury by restoring the 
endoneurial microenvironment needed for axonal regeneration, remyelination and 
signal transduction (Ubogu, 2013).  
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2.2 Peripheral nerve injury  
 
2.2.1 Incidence and aetiology  
  
As the PNS lies primarily outside the skull and vertebral column, it is prone to damage 
from trauma. Consequently, peripheral nerve injuries (PNIs) are common and are 
reported in approximately 3% of all trauma patients, increasing to 5% if plexus and root 
avulsion cases are included (Taylor et al., 2008). Scholz et al. (2009) reported that 81% 
of PNIs occur in the upper extremities, 11% in the lower extremities and the remaining 
8% in other locations. The incidence of PNI is estimated to be between 13 and 23 per 
100,000 persons per year in the developed countries (Li et al., 2014). However, the 
incidence of PNI is thought to be largely underestimated (Rodrigues et al., 2012), 
principally due its diverse aetiology and subsequent intervention from different clinical 
disciplines (Pfister et al., 2011). Retrospective studies by Kouyoumdjian (2006) and Eser 
et al. (2009) have revealed that PNI is predominantly reported in young men of working 
age, which has considerable social and economic impacts (Shen and Wang, 2014).   
  
Traumatic injuries, such as collisions, motor vehicle accidents, gunshot wounds, 
fractures and lacerations, are the most common causes of PNI (Mukhatyar et al., 2009). 
Stretch-related injuries are the most frequently encountered form of PNI (Campbell, 
2008). Although peripheral nerves are viscoelastic because of their collagenous 
endoneurium, injuries can still occur if they are exposed to large strain rates (Burnett 
and Zager, 2004). Lacerations are another common cause of PNI (Campbell, 2008). 
Whereas complete transections can occur following a laceration, partial nerve 
continuity usually remains (Burnett and Zager, 2004).  Compression is another 
frequently   encountered cause of PNI (DeLisa et al., 2005). These injuries do not involve 
a tearing of the neural elements and are generally reversible (Burnett and Zager, 2004). 
Other causes of PNI include diabetes (Callaghan et al., 2012), Guillain-Barré syndrome 
(van den Berg et al., 2014), compression syndromes (Keir and Rempel, 2005), cancer 
(Antoine and Camdessanché, 2007) and surgery (Kömürcü et al., 2005).  
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2.2.2 Pathophysiology  
 
2.2.2.1 Neuronal response  
 
After PNI, the proximal and distal stumps of the injured nerve undergo structural and 
molecular changes (Menorca et al., 2013) (figure 5). Within an hour of injury, dieback in 
both the proximal and distal stumps is mediated by channel-mediated calcium influx and 
activation of calpains that cleave neurofilament and microtubular-associated 
components such as tubulin (Sulaiman and Gordon, 2013). This stage is followed by a 
longer period of disassembly of cytoskeletal proteins by calcium-activated calpains and 
the ubiquitin-proteasome system (Zhai et al., 2003).  
 
Figure 5. Regenerative response after nerve injury. After injury, regeneration-associated genes 
are transiently upregulated in the neurons while genes associated with normal synaptic 
transmission are downregulated. Wallerian degeneration occurs in the distal nerve stump, 
creating a microenvironment conducive to axonal regrowth. Image taken and adapted from 
Sulaiman et al. (2013).  
 
Proximal stump 
The cell body in the proximal nerve stump undergoes chromatolysis within hours of the 
injury. This is characterised by the loss and dispersion of the Nissl bodies (Geuna et al., 
2009), enabling changes in gene expression that lead to a decrease in the synthesis of 
neurotransmission-related proteins (such as choline acetyltransferase, 
acetylcholinesterase and neurofilament) and an increase in the synthesis of neuronal 
growth-associated proteins (such as cytoskeletal proteins and neurotrophic factors) 
(Deumens et al., 2010). Axotomized neurons are thus characterised by a shift from a 
  35 
 
‘‘transmitting’’ state to a ‘‘regenerative’’ state (Navarro et al., 2007). Additionally, each 
injured axon produces a great number of collateral and terminal sprouts. Continuous 
pruning of misguided axons occurs and those that remain begin the process of 
elongation through the distal nerve stump (Menorca et al., 2013). Long Schwann cell 
processes have been observed proceeding in front of the regenerating axons in the 
proximal stump and these processes allow axon extension across the nerve bridge 
following a transection injury (Dun and Parkinson, 2015). The initial stage of axonal 
regeneration is sustained by both the availability of locally produced cytoskeletal 
materials (Sulaiman and Gordon, 2013) as well as anterogradely transported 
cytoskeletal proteins. Axon regeneration proceeds at a rate of 1-3 mm/day (Gordon and 
English, 2016), the rate corresponding with the rate of transport of the cytoskeletal 
materials (Sulaiman and Gordon, 2013). This slow rate of regeneration implies that re-
establishment of a functional motor unit may be delayed, resulting in chronic muscle 
denervation and atrophy (Romeo-Guitart et al., 2017).  
 
Distal stump 
Immediately after PNI, the distal segment begins to undergo Wallerian degeneration 
(Geuna et al., 2009). This process involves myelin breakdown, proliferation of Schwann 
cells and recruitment of macrophages (Raimondo et al., 2011). Myelinophagy, a form of 
selective autophagy, is an important mechanism by which Schwann cells initiate the 
degradation of myelin proteins and lipids after nerve injury (Gomez-Sanchez et al., 
2015). Macrophages are also recruited to phagocytose the myelin and cellular debris in 
order to clear the inhibitory factors released (Hirata and Kawabuchi, 2002).  Additionally, 
proliferating Schwann cells form columns, termed bands of Bungner, which selectively 
guide regrowing axons from the proximal stump (Ribeiro-Resende et al., 2009). Further 
elongation and regeneration through the distal nerve stump are dependent on the 
bands of Bungner (Allodi et al., 2012).  Thus, Wallerian degeneration serves to create a 
microenvironment that favours axonal regrowth distal to the injury site (Allodi et al., 
2012).  
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2.2.2.2 Schwann cell response 
 
Loss of axonal contact following PNI causes Schwann cells within the distal stump to 
transdifferentiate to a pro-regenerative phenotype (Kim et al., 2013). Schwann cells lose 
their differentiated morphology, downregulate myelin genes (such as MPZ and MBP), 
upregulate markers of immature Schwann cells and re-enter the cell cycle. They also 
upregulate genes implicated in promoting axon growth, neuronal survival and 
macrophage invasion. Thus the expression of neurotrophic factors (such as nerve 
growth factor, brain-derived neurotrophic factor, and glial-derived neurotrophic factor), 
their receptors (such as p75, GFRA-1, GFRA-2) and adhesion molecules (such as neural-
cell adhesion molecule) is increased. Schwann cells also activate mechanisms to break 
down their myelin sheaths and transform morphologically into cells with long, parallel 
processes, forming the bands of Bungner, which guide regenerating axons (Arthur-Farraj 
et al., 2012).  
 
Schwann cells play a major role in the removal of the axonal debris. They also secrete 
chemoattractant factors, such as monocyte chemoattractant protein-1, which recruit 
macrophages into the denervated distal nerve stumps where they phagocytose 
remaining axon and myelin debris. The axon debris releases mitogens that promote 
mitotic Schwann cell division. It also results in the upregulation of cytokines and 
transcription factors that stimulate myelin breakdown and macrophage invasion 
(Sulaiman and Gordon, 2013).  
 
Arthur-Farraj et al. (2012) used mice with selective inactivation of the transcription 
factor c-Jun in Schwann cells to show that c-Jun is a global regulator of the Schwann cell 
injury response (figure 6) that specifies the characteristic gene expression, structure and 
function of the denervated Schwann cell. c-Jun determines the expression of trophic 
factors, adhesion molecules, the formation of the bands of Bungner, myelin clearance 
and controls the distinctive regenerative potential of peripheral nerves. This was further 
corroborated by Hung et al. (2015), who used ChIP-sequencing to measure changes in 
histone H3K27 acetylation, a mark of active enhancers, to identify injury-induced 
enhancers in rat peripheral nerves following injury. Hung et al. (2015) also suggested 
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that other transcription factors, in addition to c-Jun, maintain active enhancer status 
after nerve injury. Epigenomic changes may thus mediate the effects of transcription 
factors that control Schwann cell responses following PNI. The extracellular-regulated 
kinase 1/2 pathway (Harrisingh et al., 2004), Pax-3 (Doddrell et al., 2012) STAT3 (Benito 
et al., 2017) and Sox2 (Roberts et al., 2017) have also been shown to be involved in 
Schwann cell injury response.  
 
Figure 6. The Schwann cell injury response. Nerve injury triggers the conversion of myelinating 
and Remak Schwann cells to a cell phenotype specialised to promote repair. These repair 
Schwann cells provide the necessary signals and spatial cues for axonal regeneration. Image 
taken from Jessen and Mirsky (2016).  
 
 
After prolonged denervation, Schwann cells stop maintaining the bands of Büngner and 
the basal lamina tubes break down and disappear (Scheib and Höke, 2013). Besides 
these structural changes, the upregulation of neurotrophic factors and their receptors 
induced by Schwann cells after injury is not maintained and declines (Hall, 2005). By 6 
months in experimental animals, expression has been noted to decrease, thereby losing 
the growth-supportive environment for regenerating axons. This time-limited 
upregulation of genes supports the view that nerve repair should not be delayed 
following injury (Hall, 2005). 
  38 
 
 
2.2.3 Clinical peripheral nerve repair  
 
2.2.3.1 Types of injury 
 
Seddon (1943) described three types of nerve injuries, namely neurapraxia, axonotmesis 
and neurotmesis. Neurapraxia is the mildest type and causes temporary conduction 
block without disruption of the axon or perineurium. Clinically, it results in sensory 
dysfunction. Recovery may occur within hours up to twelve weeks. Axonotmesis leads 
to axonal loss without disruption of the connective tissue layers, leading to motor and/or 
sensory dysfunction. Decreased nerve conduction velocity and regional muscle 
denervation occur. Neurotmesis is the most severe nerve injury and causes disruption 
of both the axon and connective tissue, resulting in compromised sensory and functional 
recovery. Conduction is not observed and spontaneous recovery is extremely unlikely 
without surgical intervention (Kaya and Sarikcioglu, 2014).   
 
Sunderland (1951) further stratified the three injury types described by Seddon (1943) 
into five categories according to severity (table 1). A first-degree injury is equivalent to 
Seddon's neurapraxia and a second-degree injury is equivalent to axonotmesis. Third-
degree nerve injuries occur when there is disruption of the axon (axonotmesis) and also 
partial injury to the endoneurium. Functional recovery may be possible depending on 
the extent of endoneurial damage. Sunderland divides Seddon's neurotmesis into 
fourth- and fifth-degree injuries. In a fourth-degree injury, all portions of the nerve are 
disrupted except the epineurium. A fifth-degree injury involves complete severance of 
the nerve. Recovery for fourth- and fifth-degree injuries is not possible without surgical 
intervention (Burnett and Zager, 2004).   
 
 
 
 
 
 
 
  39 
 
Table 1. Seddon and Sunderland classifications for peripheral nerve injuries. Taken and 
adapted from Mitchell et al. (2017). 
Seddon Sunderland Injury type 
Neurapraxia I Intrafasicular oedema with 
conduction block, possible 
segmental demyelination 
Axonotmesis II Severed axon, intact  
endoneurium 
III Severed axon, disruption 
of endoneurium 
IV Disruption of 
endoneurium and 
perineurium 
Neurotmesis V Complete nerve 
discontinuity  
 
 
2.2.3.2 Surgical interventions 
 
Unlike the adult CNS, the PNS has an intrinsic, albeit limited, ability to spontaneously 
regenerate after injury (Huebner and Strittmatter, 2009). However, despite this and 
improvements in surgical techniques for nerve repair (figure 7), functional restoration 
in patients is often incomplete (Rochkind and Nevo, 2014). This sub-optimal recovery is 
mainly associated with chronic axotomy, chronic Schwann cell denervation or severe 
damage of endoneurial tubes that inhibits the regenerative process. Muscular 
denervation often occurs secondary to the injury of the corresponding peripheral nerve 
and is a consequence of neurogenic atrophy and structural fibrosis (Alvites et al., 2018). 
The clinical outcome following a peripheral nerve injury is largely dependent on the 
amount of cellular damage, the site of the lesion, the degree of disruption of the 
connective-tissue elements surrounding the nerve, the extent of associated injuries, 
particularly vascular injuries and the age and health of the patient (Hall et al., 2005).  
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Figure 7. Surgical interventions for nerve repair. Nerve allografts are used for large, otherwise 
irreparable injuries. Nerve transfer use redundant nerve fibres for a proximal nerve injury. The 
autograft is used to reconstruct a nerve gap. Direct repair is used when there is no intervening 
nerve gap to create tension. Both end-to-side and nerve conduits are used for noncritical 
sensory injuries. Image taken from Ray and Mackinnon (2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several factors influence the choice of treatment following a peripheral nerve injury. 
These include the width of the nerve gap, the length of elapsed time from injury to 
treatment, the patient’s age and comorbidities affecting the nervous and circulatory 
systems. Treatment options include a direct epineurial and/or group fascicular end-to-
end repair or bridging the nerve defect with an autograft, allograft or nerve conduit 
(Gaudin et al., 2016). Direct repair is only useful in small gaps since tension across the 
suture lines is known to inhibit regeneration, possibly due to impaired activation of 
Schwann cells and a higher amount of apoptotic Schwann cells (Yi and Dahlin, 2010).  
Further, epineurial repairs can increase the local pro-inflammatory innate immune 
response and tissue remodelling that results in scar tissue (Ren et al., 2018). The 
current clinical gold standard treatment for nerve damage that extends over a few 
centimetres in length is the autologous nerve graft (Patel et al., 2018). When a large gap 
cannot be repaired by anatomic reconstruction, other means of functional 
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reinnervation, such as nerve transfers or end-to-side coaptations, may be used. These 
procedures are currently limited to cases without other reconstruction options 
(Battiston et al., 2017).   
 
The autologous nerve graft (figure 8) bridges the nerve gap and provides a physical 
scaffold over which axonal outgrowth may occur. Furthermore, it supplies Schwann cells 
necessary for regeneration. However, it is also associated with several disadvantages. 
Autografts sacrifice a functioning nerve and may result in sensory loss, scarring and 
neuroma formation at the donor site (Battiston et al., 2017).  Additionally, size and 
fascicle mismatch, scarring and fibrosis may occur at the repair site, leading to poor 
regeneration (Grinsell and Keating, 2014).  
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Figure 8. The autologous nerve graft. For eﬀective peripheral nerve repair, the gap resulting from injury must be structurally bridged to promote correct 
reinnervation and functional regeneration. The autologous nerve graft is the gold standard for gaps extending over a few centimetres in length. It provides 
autologous Schwann cells, aligned connective tissue as well as neurotrophic factors. Image taken from Lackington et al. (2017).  
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Cadaveric nerve allografts are abundantly available and allow size/length and 
motor/sensory matching. They contain both Schwann cells and the endoneurial 
microstructure provided by nerve autografts and support repair in the absence of 
sufficient autologous material (Moore et al., 2011). However, they require long-term 
use of immunosuppressant therapy that increases the risk of infection (Daly et al., 2012). 
In order to ensure immunotolerance, there has been an increased interest in processing 
nerve allografts to render them acellular while still maintaining the supportive 3D 
endoneurial microstructure (Thompson et al., 2017). 
 
In 2015, AxoGen received Food and Drug Administration (FDA) approval for Avance® 
Nerve Graft, an off-the-shelf processed human nerve allograft manufactured from 
donated human peripheral nerve tissue. The tissue undergoes detergent processing to 
selectively remove cellular components and debris and is terminally sterilised (Moore et 
al., 2011). Brooks et al. (2012) reported that in a study of 76 nerve injuries in humans, 
the use of Avance® yielded results comparable to those reported in the literature for 
nerve autografts and more favourable results than those reported for nerve conduits. 
Despite the evidence in support of acellular allografts, the gap length over which this 
technology remains effective has not been established. This is because acellular 
allografts lack Schwann cells that are essential for nerve repair. It has been shown in 
animal models, that following implantation, in vivo host Schwann cells from the 
connecting nerve stumps migrate into the graft (Hayashi et al., 2007). However, 
populating long acellular allografts places a proliferative demand on host Schwann cells, 
which may lead to stress and Schwann cell senescence (Saheb-Al-Zamani et al., 2013). 
This Schwann cell senescence is thought to be the limiting factor to axonal regeneration 
in acellular nerve allografts (Thompson et al., 2017). 
 
Nerve guidance conduits constructed of natural or synthetic materials have been 
developed to eliminate the donor site morbidity and immunosuppressant therapy 
requirement associated with nerve autografts and allografts, respectively (Daly et al., 
2012). The FDA has approved several nerve guidance conduits used to repair nerve 
defects (Kehoe et al., 2012) (table 2). According to Dixon et al. (2018), nerve guidance 
conduits should exhibit the following properties:  
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 Mechanical support to keep the proximal and distal nerve ends aligned 
 Porosity to allow the diffusion of nutrients and waste  
 Low immunogenicity to limit the inflammatory response 
 Biodegradability to eliminate the need for secondary surgery for removal and to 
prevent the occurrence of nerve compression.  
 
Additionally, nerve guidance conduits should prevent fibrous tissue ingrowth into the 
injury site to reduce scarring and retain neurotrophic factors secreted by Schwann cells 
and nerves (Kehoe et al., 2012). Even with optimised biomaterial characteristics, hollow 
nerve guidance conduits do not achieve functional recovery equivalent to nerve 
autografts and have been unsuccessful in repairing defects over 3 cm in length (Dixon et 
al., 2018). 
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Table 2. Examples of FDA approved nerve guidance conduits. 
 
Product Company Material  Structure FDA-
approval 
Treated  
nerves in 
humans 
Study 
size 
Outcome  Reference 
NeuroTube® Synovis Micro 
Companies 
Polyglycolic acid   Bioabsorbable, tight-
weave mesh rolled into 
a 2-mm diameter tube 
1999 Digital 
nerves 
98 
patients 
Resulted in improved 
sensation compared with 
end-to-end repair and 
nerve grafts for deficits <3 
cm in length 
Weber et al., 
2000 
NeuraGen® Integra 
LifeSciences 
Co.  
Bovine type I 
collagen 
Semipermeable, 
fibrillary tube of 
varying calibre 
2001 Digital 
nerves and 
large-
calibre 
nerves 
96 
patients 
Resulted in sensory 
recovery in the 35–45% 
range 
Wangensteen  
and Kalliainen, 
2010 
Neurolac® Polyganics 
Innovations 
Poly (DL-lactide-
ε-caprolactone) 
Synthetic transparent 
tube 
2003 Nerves in 
the arm and 
hand 
23 
patients 
Did not result in overall 
favourable outcomes  in 
repairing hand nerve 
defects 
Chiriac et al., 
2012  
NeuraWrapTM  Integra 
LifeSciences 
Co. 
Bovine type I 
collagen 
Porous  conduit with a 
longitudinal slit in wall 
2004 Median 
nerve 
10 
patients 
Patients showed 
improvement of clinical 
symptoms 
Kokkalis et al., 
2016 
SaluTunnelTM Salumedica 
LLC 
Polyvinyl 
alcohol  
Nonresorbable 
hydrogel 
2010 No information to date Gaudin et al., 
2016 
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2.3 Regenerative medicine for peripheral nerve repair   
 
According to Faroni et al. (2015), a purely microsurgical approach to nerve repair does 
not address the complex cellular and molecular events of peripheral nerve regeneration. 
This highlights the need for new therapeutic strategies that will maximise functional 
nerve regeneration and improve patient outcomes. The UK Medical Research Council 
(2017) defines regenerative medicine as “an interdisciplinary approach that seeks to 
repair or replace damaged or diseased human cells or tissues to restore normal 
function”.  It encompasses several fields, including but not limited to soluble 
molecules, gene therapy, stem cell transplantation, tissue engineering and 
reprogramming of cell and tissue types (Greenwood et al., 2006).  
 
2.3.1 Tissue engineering  
 
Tissue engineering aims to produce tissue replacement material purposely tailored to 
promote repair and regeneration at the implant site (Carletti et al., 2010).  In the context 
of peripheral nerve regeneration, tissue engineering can be used to produce devices 
consisting of a biomaterial-based structure as well as an array of cellular and/or 
molecular components which increase their regenerative potential (Gu et al., 2014). 
  
2.3.1.1 Conduits  
 
Conduits represent the space available for the tissue to develop and provide the physical 
support for cell growth (Carletti et al., 2010). Conduits can be manufactured from a 
range of natural and synthetic materials. The materials used for nerve repair devices 
confer different physical properties that may influence repair (de Ruiter et al., 2009). 
Synthetic materials have advantages such as a defined chemical composition and 
mechanical properties that can be fine-tuned (Knight and Przyborski, 2015). However, 
synthetic materials often lack sites for cellular adhesion. This may require coating the 
surface of the scaffold with ECM proteins, such as laminin or fibronectin, in order to 
provide a suitable environment for the cells (Subramanian et al., 2009).   
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The main synthetic material used in early nerve repair devices was silicone (Braga-Silva, 
1999). Silicone is non-degradable and can provoke a foreign body response, leading to 
inflammation and scarring (de Ruiter et al., 2009) and can potentially cause nerve 
compression (Dahlin and Lundborg, 2001). It also requires surgical removal from the 
implant site after nerve repair occurs (Belanger et al., 2016). Biodegradable synthetic 
polymers, including aliphatic polyesters, poly(phosphoesters), polyurethanes, 
piezoelectric polymers and some electrically conducting polymers are being investigated 
(Gu et al., 2014).   
 
Natural materials are often based on various components of the ECM such as collagen 
(Klein et al., 2016) and fibrin (Pettersson et al., 2010) but can also include other naturally 
derived materials such as alginate (Novikova et al., 2006), silk (Wang et al., 2018) and 
chitosan (Meyer et al., 2016). Natural materials are an attractive source of material for 
tissue engineering as they are biocompatible, biodegradable and contain cell adhesion 
sites (Knight  and Przyborski, 2015). Despite their advantages, clinical-grade sources of 
natural materials can be challenging to obtain and they tend to exhibit batch-to-batch 
variation. There are also limitations associated with controlling their mechanical 
properties. Additionally, biodegradation of natural materials may be difficult to control 
and may influence cell activity in unknown ways (Knight  and Przyborski, 2015).    
 
Current (first and second generation) nerve guidance conduits have yet to reach similar 
efficacy to the nerve autograft. However, there has been considerable interest in the 
development of a third generation of conduits to enhance nerve regeneration (Lin et al., 
2013) (Figure 9). According to Gaudin et al. (2016), experimental third generation 
conduits incorporate controlled release of neurotrophic factors, electroconductive 
material, therapeutic cells, surface micropatterning or luminal fillers serving as guidance 
structures. The use of neurotrophic factors, therapeutic cells and luminal fillers will be 
discussed in subsequent sections. 
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Figure 9. Generations of nerve conduits.  Efforts are being made to develop artificial nerve 
guidance conduits to replace autografts. Several first- and second-generation conduits have 
regulatory approval while third-generation conduits are currently still in experimental stages. 
Third generation conduits attempt to mimic the features of a natural nerve and may include 
neurotrophic factors, cells and ECM molecules. Image taken from Gaudin et al. (2016).  
 
 
2.3.1.2 Luminal fillers  
 
Regenerating axons develop growth cones that explore and recognise growth and 
guidance cues within the surrounding environment. Growth cone adhesion and 
attachment to a solid surface is required for axon growth. Thus, the microarchitecture 
of the conduit interior is thought to be crucial for promoting regeneration across a gap 
(Sarker et al., 2018). Filling hollow conduits with a substrate that supports axonal growth 
may enhance the regenerative process (Ezra et al., 2016). The use of polysaccharides, 
ECM molecules, proteins and peptides to prepare a hydrogel matrix for use in hollow 
conduits has been documented (Carballo-Molina and Velasco, 2015).  ECM proteins such 
as fibrin, laminin and collagen contain attachments sites that can be used by advancing 
axonal growth cones. The inclusion of these proteins can thus promote directional 
growth of axons, leading to improved nerve regeneration (Sarker et al., 2018). Further, 
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the degradation products of ECM based materials have been demonstrated to be 
bioactive and chemotactic for Schwann cells (Prest et al., 2018).  
 
Around 90% of nerve ECM is composed of type I collagen, making this material a popular 
choice for nerve tissue engineering (Gao et al., 2013b). Wei et al. (2013) implanted a 
silicone conduit filled with type I collagen into a rat model of sciatic nerve injury (10 mm 
gap).  Compared to animals that received physiological saline as a negative control, 
animals that received type 1 collagen had an increased number of myelinated axons and 
improved electrophysiological outcomes after 8 weeks. The findings of this study were 
corroborated by Maturana et al. (2013), who reported that polycaprolactone conduits 
filled with a collagen matrix resulted in superior axon suprastructural organisation 
compared to nerve autografts and empty polycaprolactone conduits 60 days following 
a sciatic nerve transection in a rat model (6 mm gap).  
 
In the early stages of peripheral nerve regeneration in a hollow conduit, Williams et al. 
(1987) noted the formation of an acellular fibrin cable between the proximal and distal 
stumps. Schwann cells, fibroblasts and endothelial cells then migrated into the nerve 
gap from both nerve stumps and aligned along the fibrin cable, guiding subsequent 
axonal regeneration from the proximal to the distal end. Inspired by this finding, several 
authors have investigated the effect of filling hollow conduits with longitudinally aligned 
fibrin in order to accelerate the regenerative process. Du et al. (2017) implanted a 
chitosan conduit filled with a 3D aligned fibrin nanofiber hydrogel into a rat model of 
sciatic nerve injury (10 mm gap). This device was found to support Schwann cell cable 
formation, accelerate axonal regrowth and improve motor functional recovery after 12 
weeks. Morphological analysis and electrophysiological examination revealed 
regenerative outcomes that were comparable to those achieved by autologous nerve 
grafts and superior to hollow chitosan tubes or chitosan tubes filled with random fibrin 
nanofiber hydrogel. Similar results were previously reported by Nakayama et al. (2007).  
 
As shown in the study by Du et al. (2017), the longitudinal alignment of ECM based 
material in a nerve conduit may further enhance axonal regeneration. This is because 
aligned ECM can support and guide regenerating neurites from the proximal to the distal 
side of the repair site (de Ruiter et al., 2009). Additionally, failure to recreate the aligned 
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ECM architecture limits clinical repair and reconstruction, often leading to scarring and 
poor restoration of mechanical properties (Brown and Phillips, 2007). Several 
approaches have been used to produce aligned ECM architecture in nerve conduits, 
including the use of aligned fibres (Kim et al., 2016) or channels (Sridharan  et al., 2015), 
magnetic or electrical fields (Gessmann et al., 2016) and patterned surfaces (Hoffman-
Kim et al., 2010).  
 
2.3.1.3 Vascularisation  
 
Vascularisation refers to the process by which blood vessels, especially capillaries, 
develop within a tissue. It is an essential factor which determines tissue viability as well 
as characteristics such as size, cell density, innervation and lymphatic supply of the tissue 
(Jeyaraj et al., 2015). In vivo, living cells must be within 100–200 μm from a blood 
capillary in order to survive due to nutrient perfusion and mass transport limitations 
(Lovett et al., 2009) (figure  10).  
 
Figure 10. Schematic representation of the diffusion and transport processes in tissues in vivo.  
The blood supply provides tissues with oxygen and nutrients and removes waste produces. 
However, the efficiency of this system is only maintained over a maximum distance of 200 µm. 
Image taken and adapted from Novosel et al. (2011).  
 
 
 
 
 
 
 
 
 
 
 
Inadequate vascularisation is still a major limitation for the clinical application of tissue-
engineered constructs (Novosel et al., 2011; Jundziłł et al., 2017). After implantation of 
tissue engineered constructs, a spontaneous vascularisation of the implant is usually 
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seen. However, vessel growth in vivo is a slow process and depends on host cells 
colonising the construct and building a new capillary network in response to angiogenic 
factors at the implant site. Further problems arise if the development of the capillary 
network is poorly organised, leaky and does not properly integrate with the host’s 
vascular system (Avolio et al., 2017). This induced vessel ingrowth is often too slow to 
provide adequate nutrient transport to the cells in the interior of the transplanted tissue 
and can lead to improper cell integration or cell death in tissue-engineered constructs. 
Additional strategies for enhancing vascularisation are therefore essential to ensure the 
survival of large tissue-engineered grafts (Rouwkema et al., 2008). Moon and West 
(2008) suggested that vascularisation may be increased by the coordinated use of 
angiogenic factors, cells and biomaterials.  
 
Two main strategies have been suggested to increase vascularisation in tissue 
engineered constructs (Laschke and Menger, 2012). The first approach involves the 
stimulation of angiogenesis by host endothelial cells that colonise the construct post-
implantation. The physical characteristics of the construct as well as the incorporation 
of angiogenic factors (table 3) can serve to encourage host endothelial cell invasion. The 
second approach relies on the creation of prevascularised tissue engineered constructs 
in vitro. Once implanted, the pre-formed vascular network can inosculate with the host 
vasculature. This process can be facilitated by the manufacture of biomaterials able to 
guide the formation of new tubular structures (Avolio et al., 2017).  
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Table 3. Angiogenic factors currently used in tissue engineering. Table adapted from Lovett et 
al. (2009). 
 
Growth/signalling 
factor 
Function Disadvantages 
Vascular endothelial 
growth factor 
Most important family of cytokines in 
neovascularisation; initiator of 
endothelial capillary formation 
Rapidly degraded due to 
short half-life; excessive 
amounts cause vascular 
leakage 
Basic fibroblast 
growth factor 
Heparin-binding protein; induces 
proliferation of endothelial cells; 
initiator of endothelial capillary 
formation 
Rapidly diffuses, requires 
controlled release; mitogen 
for wide variety of cell 
types 
Hepatocyte growth 
factor 
Mitogen of hepatocytes and other 
various cell types; stimulates growth of 
endothelial cells 
Short half-life, rapid 
diffusion; large amounts of 
protein required for 
response 
Platelet-derived 
growth factor 
Mitogen for connective tissue cells, 
released from platelets; promotes 
vessel maturation 
High levels result in vessel 
destabilisation; increased 
activity linked with several 
diseases 
Angiopoietin-1 Plays key regulatory role in regulating 
vessel homeostasis; promotes 
endothelial cell migration and 
stabilisation of newly formed 
capillaries 
Overexpression induces 
endothelial hyperplasia and 
reduced vessel leakage 
 
The delivery of angiogenic factors has resulted in a significant improvement of 
vascularisation in tissue-engineered constructs in several animal models (Chang and 
Niklason, 2017). In spite of promising results, there remain major challenges in 
angiogenic factor delivery namely, their inherent instability in vitro and in vivo and 
limited control over their spatial and temporal distribution (Jabbarzadeh et al., 2008). 
Gene therapy has been proposed as an alternative to conventional protein delivery 
strategies and has demonstrated a significant improvement of biomaterial 
vascularisation in vivo (Iwaguro et al., 2002; Qu et al., 2011; Cucchiarini et al., 2016). 
This will discussed in subsequent sections.  
 
Vascularisation is especially important in the context of peripheral nerve tissue 
engineering. Cattin et al. (2015) reported that endothelial cells guide the regeneration 
of peripheral nerve axons, indicating a direct relationship between nerve regeneration 
and blood vessels. Following a nerve transection, the two stumps are connected by a 
tissue structure referred to as ‘the bridge’ that consists of a mixture of inflammatory 
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cells and ECM (Jurecka et al., 1975). Macrophages in the area release VEGF-A, which 
induces vascularisation in the bridge region. These newly established blood vessels act 
as a guiding path to Schwann cells, allowing them to migrate across the bridge region. 
The physical surface of the blood vessel allows Schwann cells to efficiently migrate and 
form bands of Büngner that help axonal regeneration. Regenerating axons can then use 
the Schwann cells to migrate from the proximal stump through to the distal stump. 
Misdirection of blood vessels causes Schwann cells to migrate into surrounding tissues 
and blood vessels have been shown to be essential to direct the migration of Schwann 
cells (Cattin et al., 2015).  
 
2.3.2 Cell therapy  
 
In addition to the use of aligned ECM luminal fillers, several authors have investigated 
the use of cells in nerve guidance conduits to further enhance regeneration (McGrath et 
al., 2018). Studies have shown that tissue engineered constructs seeded with Schwann 
cells can enhance axonal regeneration in animal models (Mosahebi et al., 2002). These 
cells create an environment conducive to axon regeneration through the secretion of 
neurotrophic factors and the production of ECM molecules. However, the routine 
clinical use of Schwann cells is limited as their isolation requires invasive biopsies and 
they display limited in vitro expansion capability (Gu et al., 2014). Therefore, one of the 
goals of peripheral nerve regenerative medicine is to identify therapeutic cell types that 
could act as supporting cells in a tissue engineered construct. 
 
Kabiri et al. (2015) proposed olfactory ensheathing cells as a viable cell type for 
peripheral nerve engineering. Scaffolds seeded with olfactory ensheathing cells have 
been successfully employed in a rat model of sciatic nerve injury (10 mm gap). Functional 
analysis and histological assessment at 9 weeks revealed results comparable with the 
nerve autograft group and superior to the cell-free scaffold group. Although promising 
results were reported in this study, there is limited data supporting the use of olfactory 
ensheathing cells following peripheral nerve injury. Further, aggravation of 
hyperalgesia following olfactory ensheathing cell transplantation in spinal cord 
injuries has been reported (Nakhjavan-Shahraki et al., 2018). 
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Therapeutic benefits of stem cell therapy have been shown in several experimental 
models of peripheral nerve injury (Bhangra et al., 2016). Different sources of stem cells 
have a potential application in PNI (Walsh and Midha, 2009; Lehmann and Höke, 2016). 
These include adipose derived stem cells (ADSCs) (Georgiou et al., 2015; Sowa et al., 
2016), bone marrow stem cells (Mimura et al., 2004; Ding et al., 2010), umbilical cord 
stem cells (Matsuse et al., 2010; Peng et al., 2011), skin-derived precursor cells (Park et 
al., 2012; Grochmal et al., 2014), hair follicle stem cells (Lin et al., 2011), dental pulp 
stem cells (Sanen et al., 2017), induced pluripotent stem cells (Liu et al., 2012), 
embryonic stem cells (Cui et al., 2008; Ziegler et al., 2011) and neural stem cells 
(O'Rourke et al., 2018). As ADSCs and neural stem cells have been used in the current 
study, these two cell types will be discussed in more detail.  
 
Adipose tissue is largely comprised of adipocytes as well as a smaller stromal vascular 
fraction which includes ADSCs (Mizuno et al., 2012). These mesenchymal stem cells have 
been extensively studied as an adjunct to nerve repair (Bhangra et al., 2016) and have 
also been differentiated into Schwann cell-like cells (di Summa et al., 2010). di Summa 
et al. (2010) compared adult rat ADSCs and bone marrow stem cells, each differentiated 
to a Schwann cell-like phenotype, for the repair of a sciatic nerve injury in a rat model 
(10 mm gap, 2 weeks). The cells from both sources enhanced regeneration but, unlike 
bone marrow stem cells, ADSCs can be harvested less invasively with a higher yield, can 
be rapidly expanded in vitro and show low immunogenicity (Faroni et al., 2013). Erba et 
al. (2010) investigated the effects of undifferentiated rat ADSCs in a poly-3-
hydroxybutyrate nerve conduit on peripheral nerve regeneration as well as their ability 
to differentiate in situ in a rat sciatic transection model (10 mm gap, 2 weeks). While the 
ADSCs increased regeneration and Schwann cell proliferation compared to controls, a 
lack of viable implanted cells was observed 14 days of transplantation. Consequently, 
the authors were unable to detect any in situ differentiation of ADSCs into neuronal or 
glial cell types. Santiago et al. (2009) reported that the transplantation of human ADSCs 
in a rat sciatic nerve defect promoted nerve regeneration and a decrease in muscle 
atrophy, but that the ADSCs did not differentiate to Schwann cell-like cells at the site of 
injury. The results of these studies suggest that the regenerative effect of transplanted 
ADSCs is likely due to an initial release growth factors as well as an indirect effect on 
host Schwann cell activity. Further evidence for peripheral nerve regeneration through 
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the paracrine effects of ADSCs was presented by Kingham et al. (2014).   Georgiou et al. 
(2015) used differentiated rat ADSCs to construct engineered neural tissue through a 
combination of cellular self-alignment and plastic compression in a collagen hydrogel. 
The sheets of aligned cellular collagen supported axon regeneration over a critical length 
gap (15 mm, 8 weeks) in rat sciatic nerves. Interestingly, the phenotype of the cells 
changed when they were transferred to the 3D collagen environment from two-
dimensional (2D) monolayers, with an increase in expression of key growth factors 
associated with the support of regeneration. 
 
Neural stem cells have been isolated from both the embryonic and the adult central 
nervous system (Ernst et al., 2014). Fu et al. (2011) used two recombinant mammalian 
vectors delivering the rat GDNF or BDNF genes to transfect adult mouse neural stem 
cells. The transfected cells were seeded onto poly(D,L-lactide) conduits and implanted 
into a rat model of sciatic nerve transection (15 mm gap). After 8 weeks, improved 
regeneration, myelination and functional recovery were observed in the animals treated 
with the transfected cells compared to those treated with untrasfected cells. Liard et al. 
(2012) transplanted adult pig subventricular zone neural stem cells inside an autologous 
venous graft into a 30 mm femoral nerve gap in an adult pig model and reported 
improved functional recovery at 6 months compared to empty vein grafts. Post-mortem 
immunohistochemistry revealed that the transplanted cells survived inside the venous 
graft from 10 to 240 days and all displayed a neuronal phenotype. Further, the authors 
reported that neural stem cell transplantation resulted in activation of host Schwann 
cells. O’Rourke et al. (2018) implanted a clinically relevant human neural stem cell line 
(CTX0E03) in stable aligned sheets of cellular hydrogel within a collagen conduit into 
a 12 mm gap in a rat sciatic nerve. The nerve repair device supported growth of 
neurites and vasculature through the injury site and facilitated reinnervation of the 
target gastrocnemius muscle. The findings reported by the authors are significant, as 
the use of such a cell line could help over the limitations associated with the nerve 
graft or the culture of autologous cells.  
 
A significant challenge that remains is the identification and selection of the most 
suitable stem cell source to enhance regeneration. The ideal cell should be easily 
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harvested from the patient to allow autologous therapy and prevent rejection. However, 
allogeneic sources may also provide a good alternative if a detrimental immunological 
response can be avoided. It should be readily expandable in vitro (Bhangra et al., 2016), 
survive transplantation and engraft into the host tissues (Walsh and Midha, 2009). 
Further, it should exhibit similar phenotypic characteristics to Schwann cells and secrete 
factors required for peripheral nerve regeneration (Bhangra et al., 2016). Additionally, 
in order to facilitate further opportunities to improve efficacy, it should be amenable to 
genetic modification (Busuttil et al., 2017). 
 
2.3.3 Gene therapy 
 
Further to guiding axonal growth and providing support cells, nerve repair devices are 
also increasingly being used as a carrier for the delivery of substances which enhance 
the microenvironment following injury. Due to the short half-life of many of these 
substances as well as side effects when administered systemically, strategies for 
continuous local release have been developed. Acellular delivery systems include loaded 
crosslinked polymer scaffolds (Madduri et al., 2010), incorporation of loaded 
microspheres into the scaffold (Kokai et al., 2011) and mini osmotic pumps (Boyd and 
Gordon 2003). Neurotrophic factors may also be delivered naturally from cells seeded 
into the nerve conduits (Madduri and Gander, 2012). Further, genetically modified cells 
overexpressing neurotrophic factors have also been used to ensure a local and 
continuous release of substances required for peripheral nerve regeneration (Busuttil et 
al., 2017). Gene therapy has also been used to transduce resident cells to overexpress 
neurotrophic factors (Pfister et al., 2007).  
 
Gene therapy can be defined as the treatment of a medical disorder by the delivery of 
therapeutic nucleic acids into the relevant cellular targets. Gene therapy has been 
primarily associated with correcting the consequences of specific gene mutations in 
inherited diseases (Nayerossadat et al., 2012). However, it can also be utilised to 
reprogram cells in other contexts, one of which is peripheral nerve repair (Hoyng et al., 
2015a). Gene therapy is unique in its ability to correct the underlying pathological 
mechanism of a disease process with prolonged benefits (Mohan et al., 2013). Thus gene 
therapy could provide the damaged nerve with the prolonged regenerative support 
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necessary for repair. The success of gene therapy can be attested by a number high 
profile life-saving or life-changing clinical trials for haematological (Nathwani et al., 
2014; Negre et al., 2016), immunological (Aiuti et al., 2013; Castiello et al., 2015), 
ophthalmic (Bainbridge et al., 2015; Feuer et al., 2016) and neurological conditions 
(Cartier et al., 2009; Biffi et al., 2013). These advances may become pertinent to 
translational research to enhance peripheral nerve repair (Busuttil et al., 2017).  
 
2.3.3.1 Gene delivery vectors 
 
Eukaryotic cells have developed several mechanisms to prevent the entry of exogenous 
genetic material. These barriers include the hydrophobic plasma membrane, enzymes 
and the nuclear envelope. This presents a problem for efficient gene therapy, which is 
reliant on the delivery of genes to cells (figure 11).  
 
Figure 11. Issues relating to successful gene delivery. In addition to the choice of vector, 
successful gene delivery is influenced by the quantity of vector needed and any toxicity or 
immunity that will limit its use. The vector has to be introduced into cells, which may require 
targeting specificity. Once inside the target cells, the vector’s genetic payload needs to 
translocate to the nucleus where it is expressed. Gene expression may induce toxicity and may 
need to be controlled. Image taken from Worgall and Crystal (2014).  
 
 
 
 
 
 
 
 
 
 
 
In order to circumvent the problems associated with delivering genes, gene delivery 
systems have been developed, with viral vectors proving to be the most efficient (de 
Winter et al., 2013). Viral vectors result in a high rate of target cell transduction and 
transgene expression and recent advances have led to good safety profiles (Tannemaat 
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et al., 2008). Notably, around 70% of the gene therapy clinical trials for different 
conditions carried out so far have used viruses to deliver genes (Yin et al., 2014). Further, 
the first licensed gene therapy product in Europe (Glybera®) involves an adeno-
associated virus (AAV) vector for the treatment of lipoprotein lipase deficiency, 
indicating that viral vector-based gene therapy is becoming more relevant to 
translational research (Ylä-Herttuala, 2012). More recent developments in the field 
include the regulatory approval of StrimvelisTM, the first ex vivo autologous stem cell 
gene therapy to treat patients with severe combined immunodeficiency due to 
adenosine deaminase deficiency (Ylä-Herttuala, 2016), as well as FDA approval for 
Luxturna®, which involves an AAV vector for the treatment of inherited retinopathies.  
 
The efficiency of viral vectors can be attributed to the fact that viruses have developed 
mechanisms by which to infect cells and deliver their genetic cargo. In order to be used 
as a clinical tool, viral vectors have been genetically engineered to remove the 
pathogenic components as well as their ability to self-replicate. However, their ability to 
enter cells and deliver genes is preserved. Different viral vectors have been developed 
to target the diverse range of disease applications. These include adenovirus, adeno-
associated virus, lentivirus and retrovirus (table 4). Ideal characteristics of a viral vector 
include the abilities to be reproducibly and stably produced, to be purified to high titres 
and to mediate targeted delivery and transgene expression without inducing harmful 
side effects (Thomas et al., 2003).     
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Table 4. Characteristics of different viral vectors. Table taken from Chamcheu et al. (2015).  
 
Vector Packaging 
ability (kb) 
Genetic 
material 
Tropism Vector genome form Advantages Disadvantages 
Adeno-
associated 
virus 
<5 ssDNA Dividing/non-
dividing cells  
Non-integrated (90 
%), integrated (<10 
%) 
Non-inflammatory, non-
pathogenic 
Low production profile, low 
transduction efficiency, low 
packaging capacity 
Adenovirus 7.5 dsDNA Dividing/non-
dividing cells 
Non-integrated Excellent transduction 
efficiency 
High antigenicity, elicits immune 
response, transient gene expression 
Lentivirus 8 RNA Dividing/non-
dividing cells 
Integrated High transduction efficiency, 
long term gene expression 
Potential for random integration into 
host genome 
Retrovirus 8 RNA Dividing cells  Integrated High transduction efficiency, 
long term gene expression, 
Cannot transduce non-dividing cells, 
random integration into the host 
genome 
Abbreviations: ss – single stranded; ds – double stranded. 
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2.3.3.2 in vivo gene delivery to Schwann cells and nerves 
 
Successful in vivo gene delivery of various neurotrophic factors to the PNS in animal 
models has been reported with various vectors (Mason et al., 2011) (table 5). Schwann 
cells are the main target cells for gene therapy in the injured peripheral nerve itself (de 
Winter et al., 2013). As described in section 2.2.2.2, Schwann cells play a central role in 
peripheral nerve regeneration as they are responsible for secreting growth-promoting 
molecules, guiding the regenerating axons toward target organs and myelinating 
regenerated axons. However, the pro-regenerative properties of these cells can fade 
away after long periods of denervation (Jessen and Mirksy, 2016). Gene delivery to 
Schwann cells could be used to prevent down-regulation of genes associated with 
maintaining the repair phenotype and to keep the cells in their pro-regenerative state 
for a longer period of time. This makes gene therapy a potential adjuvant treatment in 
the reconstruction of peripheral nerves following injury.   
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Table 5. In vivo gene delivery targeting nerves and Schwann cells.  
 
Author Gene (s) Vector Mode of delivery Animal model (length of gap, 
mode of repair, duration of 
experiment) 
Outcome measures 
Nikolaev et al., 
2014 
FGF2, VEGF 
 
Double-cassette 
plasmid 
Direct injection of the 
vector into the sciatic 
nerve 
Rat sciatic nerve transection, 
5mm gap, poly( 
ε-caprolactone) conduit  
filled with  
fibrin hydrogel matrix, up to 
30 days  
Functional tests, number of myelinated 
fibres, immunochemistry 
Cheng et al., 2013 CDNF Lentivirus Direct injection of the 
vector into the sciatic 
nerve 
Rat sciatic nerve transection, 
3mm gap, silicone tube, up to 
8 weeks  
Gastrocnemius muscle weight, sciatic 
function index, immunohistochemistry, 
myelination 
Hu et al., 2010 NGF Adenovirus Direct injection of the 
vector into the femoral 
nerve 
Rat femoral transection, 0.5 – 
0.8 mm gap, silicone tube, up 
to 8 weeks 
Retrograde tract tracing 
Tsai et al., 2010 BMP7 Adenovirus Direct injection of the 
vector into the sciatic 
nerve 
Rat sciatic nerve transection, 
immediate resuturing, up to 4 
weeks 
Behavioural tests, histological analysis 
Tannemaat et al., 
2008 
NGF, GDNF Lentivirus Direct injection of the 
vector into the sciatic 
nerve 
Rat sciatic transection, 
immediate resuturing, up to 
12 weeks  
Behavioural tests, soleus and 
gastrocnemius muscle weight, number of 
neurites 
 
Abbreviations: FGF2 - fibroblast growth factor-2; VEGF - vascular endothelial growth factor; CDNF - conserved dopamine neurotrophic factor; NGF - 
nerve growth factor; BMP7 - bone morphogenetic protein-7 ; GDNF - glial cell-derived neurotrophic factor. 
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2.3.3.3 ex vivo gene delivery for peripheral nerve repair 
 
Hoyng et al. (2015b) compared the ability of AAV serotypes 1–9 and a lentivirus to 
transduce cultured rat and human Schwann cells and nerve segments. The AAV and 
lentiviral vectors were produced using an identical expression cassette that consisted 
of a cytomegalovirus promotor driving green fluorescent protein. The nine AAV 
serotypes tested showed differential transduction of dissociated primary rat and 
human Schwann cells and in rat and human nerve segments. AAV1 was the best 
serotype to transduce rat Schwann cells, while AAV2 and AAV6 were the best to 
transduce human Schwann cells. Rat nerve segments could be genetically modified 
equally well by AAV1, AAV5, AAV7, AAV9, whereas AAV2 was superior in human nerve 
segments. The lentiviral vector proved to be more effective than all the AAV serotypes 
tested in transducing cultured rat and human Schwann cells.  In rat nerve segments, 
AAV5, AAV7 and AAV9 were not significantly different from the lentiviral vector while 
in human nerve, the lentiviral vector was superior to all AAV serotypes. According to 
Hoyng et al. (2015b), lentiviral vectors (figure 12) are considered to be the current 
gold standard in experimental gene therapy for peripheral nerve repair. Verrier et al. 
(2010) and Yang et al. (2012) have also previously reported successful ex vivo 
transduction of rat Schwann cells using lentiviral vectors.  
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Figure 12. Gene transfer by a lentiviral vector. After the lentiviral vector has infected a cell, the 
vector RNA containing the therapeutic gene is transcribed into DNA. The DNA forms a 
preintegration complex with the accessory protein Vpr, the enzyme integrase, and the protein 
matrix. This complex then enters the nucleus and the DNA is inserted into the host genome by 
integrase. Image taken from Amado and Chen (1999).  
 
 
 
 
 
 
 
 
 
 
 
 
In addition to Schwann cells and nerve segments, lentiviruses have been used to 
successfully transduce human and rodent stem cells of various origin (Ye et al., 2008; Lin 
et al., 2012).  The use of therapeutic cells in the context of peripheral nerve injury may 
be enhanced by subjecting them to ex vivo genetic modification prior to seeding in nerve 
repair devices for transplantation (table 6). This involves obtaining cells from patients or 
donors followed by in vitro manipulation to enhance the therapeutic potential of the 
cell and subsequent transplantation into the patient. This approach has a number of 
advantages over in vivo gene therapy mentioned in section 2.3.3.2. The delivery of 
genetic material can be targeted to a specific cell type, i.e. the therapeutic cell, without 
affecting other cells in the body. Cells can be characterised in vitro for successful 
incorporation of the transgene and only those which show biological activity are then 
incorporated into nerve repair devices. Further, in the cases of autologous stem cell 
harvest, no apparent adverse immune response has been reported, as demonstrated by 
Gaspar et al. (2004) and Aiuti et al. (2013).    
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Table 6. Studies enhancing the regenerative potential of therapeutic cells by over expression of neurotrophic factors. 
 
Author Gene delivery 
method 
Gene(s) Cell type Mode of delivery Animal model 
(length of gap, 
duration of 
experiment) 
Outcome measures 
Ee et al., 2017  Lentivirus  GDNF  Rat primary 
Schwann cells  
Cells injected into a cellular 
nerve allograft 
Rat sciatic 
transection (14 
mm gap, 6 weeks) 
Myelinated axon count, 
neural tissue  
Hsu et al., 2017 Baculovirus GDNF Rat adipose 
derived stem cells 
Adipose derived stem cell 
sheets wrapped around the 
injury site 
Rat sciatic 
transection 
(direct repair, up 
to 8 weeks) 
Electrophysiology, walking 
track analysis, muscle 
mass, axon area, 
angiogenesis, myelination 
Man et al., 2016 Lentivirus VEGF Human bone 
marrow stem cells 
Cells in fibrin gel seeded in 
a poly-L-lactide acid conduit 
Mouse sciatic 
transection (4 mm 
gap, 2 weeks)  
Neurite extension,  
Schwann cell  
proliferation, VEGF  
expression, axon  
regeneration, stem  
cell tracking  
May et al., 2016 Retrovirus GDNF Rat Schwann cells Cells seeded in silicone 
tubes 
Rat cavernous 
nerve transection 
to (5 mm gap, 12 
weeks) 
Neurostimulation, and 
intracavernous pressure, 
measurement, histology, 
functional recovery 
Meyer et al., 2016 Nucleofection GDNF, FGF2 Rat Schwann cells  Cells in NVR gel seeded in a 
chitosan conduit 
Rat sciatic nerve 
transection (15 
mm gap, up to 17 
weeks) 
Functional recovery, 
electrophysiology, muscle 
weight, myelin thickness, 
g-ratio, total axon count, 
nerve fibre density, fibre 
diameter 
  65 
 
Marquardt et al. 
(2015)  
Lentivirus GDNF Rat Schwann cells Acellular nerve allografts 
and cells injected into the 
distal nerve stump 
Rat sciatic nerve 
transection (30 
mm gap, up to 8 
weeks) 
Total axon count, axon 
density,  
fibre width, myelination, 
percent neural tissue, live 
tracking of regenerating 
axons 
Tseng and Hsu 
(2014)  
Effectene®-based 
transfection 
BDNF Rat adipose 
derived stem cells 
Cell spheroids seeded in a 
poly(D,L-lactide) conduit 
Rat sciatic nerve 
transection (10 
mm gap, 31 days) 
Electrophysiology, cell 
tracking, cross-sectional 
area of regenerated axons, 
quantification of axonal 
growth 
Liu et al., 2014 Lentivirus CDNF Rat bone marrow 
stem cells 
Cells in a collagen conduit Rat sciatic nerve 
transection (5 mm 
gap, up to 12 
weeks) 
Protein expression, walking 
track analysis, muscle 
mass, horseradish 
peroxidase tracing, 
myelination thickness, 
axon diameter, G-ratio 
Allodi et al., 2014  
  
Lentivirus FGF2 Rat Schwann cells Cells in collagen matrix 
seeded in a silicone conduit 
Rat sciatic 
transection (6 mm 
gap, up to 2 
months)  
  
Protein expression, 
immunohistochemistry, 
electrophysiology, axon 
regeneration, myelination, 
functional recovery 
Godinho et al., 
2013  
  
Lentivirus  
  
BDNF, CNTF, NT3  
  
Rat Schwann cells Cells in culture media 
injected into an acellular 
nerve sheath  
Rat peroneal 
transection (10 
mm gap, 10 
weeks)  
  
Quantification of axonal 
numbers, functional 
recovery, axonal 
regeneration, myelination, 
immunohistochemistry  
Santosa et al., 
2013  
Lentivirus  
  
GDNF  
  
Rat Schwann cells Cells in culture media 
seeded in an acellular nerve 
allograft 
Rat sciatic 
transection (14 
Gene expression, 
electrophysiology, total 
myelinated fibre count and 
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mm gap, up to 12 
weeks)  
  
fibre width, percent neural 
tissue, muscle mass 
Shakhbazau et 
al., 2013 
  
Lentivirus  
  
GDNF Rat Schwann cells Silicone conduit and cells 
injected into the distal 
nerve stump 
Rat sciatic 
transection (5 mm 
gap, up to 11 
weeks) 
Electrophysiology, 
sensitivity testing, motor 
recovery, muscle mass 
Fu et al. (2011)  Polyfect®-based 
transfection  
BDNF, GDNF Mouse neural 
stem cells 
Cells in culture media 
seeded in a poly(D,L-
lactide) conduit 
Rat sciatic nerve 
transection (15 
mm gap, 8 weeks) 
Functional analysis, 
electrophysiology, cross-
sectional area of 
regenerated nerve, 
numbers of myelinated 
sheaths and blood vessels 
Shi et al. (2009)  Lentivirus GDNF Rat neural stem 
cells 
Cells in Matrigel seeded in a 
polyglycolic/polyglycolic   
acid conduit 
Rat facial nerve 
transection (8 mm 
gap, up to 12 
weeks) 
Electrophysiology, number 
of  regenerated  axons, 
myelin thickness 
  
Haastert et al. 
(2006)  
Metafectene®-
based 
transfection 
  
FGF2 Rat Schwann cells Cells in culture media 
seeded in a silicone conduit 
Rat sciatic nerve 
transection (15 
mm gap, up to 6 
months)  
  
Cell tracing, analysis of 
protein expression, 
functional recovery, 
electrophysiology, 
retrograde labelling of 
regenerated neurons, 
quantification of 
myelinated nerve fibres 
Abbreviations:  FGF2 - fibroblast growth factor-2; VEGF - vascular endothelial growth factor; CNTF - ciliary neurotrophic factor; NGF – nerve growth 
factor; GDNF - glial cell-derived neurotrophic factor; BDNF - brain-derived neurotrophic factor; CDNF - conserved dopamine neurotrophic factor; NT3 
-  neurotrophin-3. 
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Chapter 3. Materials and methods 
 
3.1 Introduction  
 
The overarching goal of this project was to combine cell-based tissue engineering and 
gene delivery to enhance peripheral nerve regeneration following injury. Cells were 
initially labelled using lentiviral vectors to deliver a bioluminescent gene to monitor and 
further our understanding of cell viability in the tissue engineered constructs in vitro and 
in vivo. It was also thought that improving vascularisation to the implanted tissue 
engineered constructs would enhance peripheral nerve tissue engineering strategies as 
perfusion and oxygen transport have direct effects on cell viability. Cells used to make 
the tissue engineered constructs were therefore genetically modified using lentiviral-
mediated gene delivery to overexpress VEGF-A165, an angiogenic factor which also 
exhibits neurotrophic effects. Owing to the neurotrophic effects of VEGF-A165, it was 
thought that its overexpression may further improve peripheral nerve regeneration by 
creating a microenvironment conducive to axonal regrowth. The experimental methods 
used in this project are outlined in figure 13. 
 
Figure 13. Schematic of the experimental methods used in the current project.  
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3.2 Cell culture 
 
3.2.1 SCL4.1/F7 rat Schwann cell culture  
 
Rat Schwann cell line SCL4.1/F7 (Health Protection Agency) cells were grown in 
Dulbecco's Modified Eagle's Medium (DMEM) with GlutaMax™ (GibcoTM, 
ThermoFisher), supplemented with 10 % (v/v) heat inactivated foetal bovine serum 
(FBS) (GibcoTM, ThermoFisher) and 1 % (v/v) penicillin/streptomycin solution (GibcoTM, 
ThermoFisher), in tissue cultured treated flasks with filters (Greiner CELLSTAR®, Sigma-
Aldrich). The cultures were maintained at sub-confluent levels at 37 oC with 5 % CO2/95 
% air and passaged when required. When passaging, cells were washed with phosphate 
buffered saline (PBS) (GibcoTM, ThermoFisher) and dissociated by the addition of 0.05 % 
Trypsin-EDTA (GibcoTM, ThermoFisher) for 5 minutes at 37 oC. Trypsin was inactivated 
by the addition of complete medium and the cell suspension was centrifuged at 1200 
rpm for 5 minutes at room temperature. The cell pellet was resuspended in complete 
medium and the total number of cells was determined using a haemocytometer. The 
appropriate volume of cell suspension was pipetted into new tissue culture flasks. 
SCL4.1/F7 cells were used up to passage 28 for in vitro experiments and up to passage 
14 for in vivo work.  
 
3.2.2 Rat adipose derived stem cells culture and differentiation  
 
Rat ADSCs (kindly provided by Dr Paul Kingham, Department of Integrative Medical 
Biology, Umeå University) were grown in Minimum Essential Medium - alpha 
Modification (α-MEM) (GibcoTM, ThermoFisher) containing 10 % (v/v) FBS and 1 % (v/v) 
penicillin/streptomycin solution. To differentiate the adipose stem cells into a Schwann 
cell-like phenotype, growth medium was supplemented with 1 mm β-mercaptoethanol 
(Sigma-Aldrich) for 24 hours. The cells were then washed with PBS and fresh medium 
supplemented with 35 ng/ml all-trans-retinoic acid (Sigma-Aldrich) was added. After 72 
hours, the cells were washed and the medium was replaced with differentiation medium 
containing cell growth medium supplemented with 14 μm forskolin (Sigma-Aldrich), 
10 ng/ml basic fibroblast growth factor (Pepro Tech Ltd.), 5 ng/ml platelet-derived 
growth factor (Pepro Tech Ltd.) and 252 ng/ml neuregulin-1 (R&D Systems). The cells 
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were incubated for a minimum of two weeks with the differentiation medium replaced 
every 72 hours. Cells were maintained at subconfluent levels at 37 °C with 5 % CO2/95 
% air and passaged as described in section 3.2.1 when required. ADSCs were used up to 
passage 15.  
 
3.2.3 Human foetal neural stem cell culture  
 
The human neural stem cell line CTX0E03 (supplied by ReNeuron Ltd.) was expanded 
using previously described methods (Pollock et al., 2006). CTX0E03 cells were cultured 
in DMEM:F12 medium (GibcoTM, ThermoFisher) supplemented with 0.03 %  human 
albumin solution (Grifols), 2 mM GlutaMAXTM (GibcoTM, ThermoFisher), 5 μg/ml human 
transferrin (Sigma-Aldrich), 16.2 μg/ml putrescine dihydrochloride (Sigma-Aldrich), 
5 μg/ml human insulin (Sigma-Aldrich), 60 ng/ml progesterone (Sigma-Aldrich), 40 
ng/ml sodium selenite (Sigma-Aldrich), 20 ng/ml epidermal growth factor (Sigma-
Aldrich), 10 ng/ml basic fibroblast growth factor (Invitrogen), and 100 nM 4-
hydroxytamoxifen (4-OHT) (Sigma-Aldrich) in 20 µg/ml laminin-coated (Amsbio) tissue 
culture treated flasks with filters. When passaging, cells were washed with Hanks' 
Balanced Salt Solution (HBSS) (GibcoTM, ThermoFisher), and dissociated by the addition 
of TrypZean® (Sigma-Aldrich) for 5 minutes at 37 oC. TrypZean® was inactivated by the 
addition of defined trypsin inhibitor (GibcoTM, ThermoFisher) and the cell suspension 
was centrifuged at 1500 rpm for 5 minutes at room temperature. The cell pellet was 
resuspended in growth media and the total number of cells was determined using a 
haemocytometer. The appropriate volume of cell suspension was pipetted into new 
laminin coated tissue culture flasks. Cells were used between passages 25 and 33.  
 
3.2.4 Human umbilical vein endothelial cells culture 
 
Human umbilical vein endothelial cells (HUVECs) (PromoCell) were grown in endothelial 
cell growth medium (EGM) (PromoCell), supplemented with 10 % FBS, 1 % 
penicillin/streptomycin and SupplementMix (PromoCell).  For conditions of serum 
starvation, HUVECs were grown in media containing 0.1 % FBS, 1 % 
penicillin/streptomycin and SupplementMix overnight. Cells were maintained at 
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subconfluent levels at 37 °C with 5 % CO2/95 % air and passaged as described in section 
3.2.1 when required. HUVECs were used up to passage 10.  
 
3.2.5 PC12 cell culture 
 
PC12 cells (Sigma-Aldrich) were grown in suspension in RPMI 1640 culture medium 
(GibcoTM, ThermoFisher), supplemented with 1 % (v/v) penicillin/streptomycin solution, 
2 mM l-glutamine (Sigma-Aldrich), 10 % (v/v) heat-inactivated horse serum (Sigma-
Aldrich) and 5 % (v/v) heat inactivated FBS in tissue culture treated flasks with filters. 
Cells were maintained at subconfluent levels at 37 oC with 5 % CO2/95 % air. When 
passaging, cells in culture media were centrifuged at 1200 rpm for 5 minutes. The cell 
pellet was resuspended in complete media and the total number of cells was 
determined using a haemocytometer. The appropriate volume of cell suspension was 
pipetted into new tissue culture flasks. Cells were used up to passage 35.  
 
3.2.6 HEK293T cell culture 
 
Human embryonic kidney cells (HEK293T) (ThermoFisher Scientific) were grown in 
DMEM GlutaMax™ supplemented with 10 % (v/v) heat inactivated FBS and 1 % (v/v) 
penicillin/streptomycin solution in tissue culture treated flasks with filters. Cells were 
maintained at sub-confluent levels at 37 oC with 5 % CO2/95 % air and passaged when 
required as described in section 3.2.1. Cells were used up to passage 15 for lentivirus 
production. 
 
3.3 Cloning of the VEGF-A165 gene 
 
VEGF-A165 cDNA was extracted from an adenoviral vector containing the human pro-
angiogenic VEGF-A165 gene cDNA sequence (Swanson et al., 2016) (kindly provided by 
Professor Anna David, UCL Institute for Women's Health). It was decided to clone the 
gene into the expression cassette of the pSFFV-IRES-eGFP lentiviral backbone plasmid 
using the polymerase chain reaction (PCR) (figure 14). Using this technique, polymerase 
chain reaction (PCR) primers that included restriction enzyme sites were designed for 
the amplification of the VEGF-A165 gene cDNA sequence. Following PCR amplification 
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and purification, the PCR product and lentiviral backbone plasmid pSFFV-IRES-eGFP 
were digested using restriction enzymes. The digested DNA was separated on an 
agarose gel and isolated. The VEGF-A165 gene cDNA sequence was then ligated into the 
pSFFV-IRES-eGFP backbone plasmid downstream of the SFFV promoter sequence and in 
front of the IRES sequence. The recombinant plasmid pSFFV-VEGF-IRES-eGFP was 
subsequently transformed into competent bacteria. Individual colonies were selected 
and the plasmid DNA was extracted. A diagnostic restriction digest was performed to 
confirm the presence of the VEGF-A165 gene in the backbone plasmid. The final 
recombinant plasmid was then verified by Sanger sequencing.  
 
Figure 14. Plasmid cloning by PCR. The VEGF-A165 gene was extracted from an adenoviral vector 
(blue) using PCR. BamHI and XhoI restriction enzyme sites were introduced on each end of the 
gene to allow insertion into the pSFFV-IRES-eGFP lentiviral backbone plasmid (red), forming the 
pSFFV-VEGF-IRES-eGFP recombinant plasmid (blue and red). Image taken and adapted from 
engineerbiology.org. Accessed on 10th October 2018.  
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3.3.1 Polymerase chain reaction 
 
High fidelity proof reading PFU DNA polymerase (Promega Corporation) was used to 
amplify the VEGF-A165 gene from the adenoviral vector. Primer pairs (Sigma-Aldrich) 
were designed to flank the sequence at the 5’ and 3’ ends and to introduce BamHI and 
XhoI restriction enzyme sites to allow cloning into the pSFFV-IRES-eGFP backbone 
plasmid. The primers used are shown in table 7.  
 
Table 7. Primers used to amplify the VEGF-A165 gene.  
 
 Sequence (5’  3’) Length 
(bp) 
% GC 
content 
Tm 
Forward 
primer 
CACAGGATCCGCCACCATGAACTTTCTGCTG 31 54.8 65.4 
Reverse 
primer 
ATATCTCGAGTCACCGCCTCGGCTTGTC 28 57.1 64.7 
 
A PCR nucleotide mix (VWR International) containing equimolar amounts of each of the 
four deoxyribonucleotide triphosphates (dATP, dCTP, dGTP, and dTTP) was used to 
generate amplified DNA. All PCR reaction mixtures were made up to a volume of 20 µl. 
The composition of the reaction mix is shown in table 8.  
 
Table 8. Components and volumes used in the PCR reaction.  
 
 
The PCR was carried out using the 96-well Veriti™ thermal cycler (Applied Biosystems) 
using the conditions shown in table 9.  
 
 
 
Component Volume (μl) 
10x enzyme buffer 2 
dNTPs (10 mM) 2 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
PFU DNA polymerase 0.5 
Adenovirus template 5 
dH2O to a final volume of  20 
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Table 9. Initial PCR conditions. Each reaction involved 25 cycles of denaturation, annealing and 
extension.  
 
Step Time (minutes) Temperature (oC) 
Initial denaturation 2 94 
Denaturation  0.25 94 
Annealing 1  60 
Extension 5 68 
Final extension 7 72 
Storage Indefinitely 4 
 
The PCR products obtained were subsequently purified using a silica-membrane-based 
purification column (QIAquick PCR Purification Kit, Qiagen) according to the 
manufacturer’s instructions. 
 
3.3.1.1 PCR optimisation 
 
The initial conditions described in table 8 resulted in poor PCR efficiency. In order to 
establish the optimum PCR conditions, the effects of changing the concentration of the 
template DNA and annealing temperature of the reaction were investigated. PCR 
efficiency was compared by running the reaction at annealing temperatures of 56 oC, 58 
oC and 61 oC using serial dilutions (10-1, 10-2, 10-3, 10-4, and 10-5) of the adenovirus 
template.  
 
3.3.2 Restriction enzyme digest 
 
The backbone plasmid and PCR products were digested with a restriction enzyme buffer 
system (New England Biolabs Inc.) for 1 hour at 37 oC.  The double digest reaction 
mixture consisted of the components in table 10. 
 
Table 10. Components and volumes used in a typical restriction enzyme digest.  
 
Component  Volume (µl) 
BamHI 0.5 
XhoI 0.5 
DNA/plasmid vector Equivalent to 1 µg 
Enzyme buffer 2.5 
dH2O to a final volume of  25 
 
  74 
 
3.3.3 Gel electrophoresis 
 
The digested PCR products and backbone plasmid were separated according to size on 
0.8 % agarose gel (Invitrogen) using 1x tris-acetate-EDTA (TAE) buffer. A 50x TAE buffer 
stock solution was prepared by dissolving 242 g Tris base (Sigma-Aldrich) in distilled 
water (dH2O) followed by the addition of 57.1 ml glacial acetic acid (Sigma-Aldrich) and 
100 ml of 500 mM EDTA (Sigma-Aldrich). The pH was adjusted to 8 by the addition of 1 
M sodium hydroxide (Sigma-Aldrich) and the final volume up was brought up to 1 litre. 
The nucleic acid stain SafeView™ (Applied Biological Materials Inc.) was added to the 
agarose gel at a dilution of 1:10 000 prior to setting.  
 
30 µl of each sample were loaded into the wells with 1x orange G gel loading buffer 
(Sigma-Aldrich) to allow visual tracking of DNA migration during electrophoresis. 10 µl 
of a 1 kbp plus and/or 100 bp molecular weight marker (ThermoFisher Scientific) were 
used to determine DNA fragment size. Gels were run at 100 V (PowerPac Basic, Biorad) 
for 45 minutes and visualised under an ultraviolet transilluminator at low setting and for 
minimal periods of time to avoid UV-mediated mutations in gene sequences.  
 
3.3.4 DNA extraction 
 
The DNA fragments were isolated from the agarose gel under UV light using a sterile 
scalpel to remove the desired bands. The DNA was subsequently purified using silica-
membrane-based purification (QIAquick Gel Extraction Kit, Qiagen) following the 
manufacturer’s instructions. DNA was eluted in a final volume of 30 µl of dH2O and the 
concentration and purity determined by spectrophotometry. The concentration was 
measured by absorbance at 260 nm while the ratio of absorbance at 260 nm and 280 
nm was used to assess the purity of the DNA. 
 
3.3.5 Ligation 
 
The purified VEGF-A165 gene was inserted into the pSFFV-IRES-eGFP lentiviral vector 
plasmid by cohesive-end ligation using the bacteriophage T4 DNA ligase (Promega 
Corporation) according to the manufacturer’s instructions. Several insert: vector ratios 
  75 
 
(3:1, 5:1 and 7:1) were tested in order to establish the optimal ratio for single insertion 
into the vector.  The mass of insert required at the different insert: vector ratios tested 
was calculated using the following equation: 
 
ng of vector × kb size of insert
kb size of vector
 × molar ratio of (
insert
vector
) = ng of insert         
 
Each 10µl ligation reaction mixture contained the components in table 11. 
 
Table 11: Components and volumes used in a typical ligation reaction.  
 
Component Volume (µl) 
Vector According to the ratio required 
Insert  According to the ratio required 
T4 DNA ligase 1 
Enzyme buffer 5 
dH2O to a final volume of  10 
 
3.3.6 Bacterial transformation 
 
In order to produce multiple copies of the recombinant plasmid formed in the ligation 
reaction described in section 2.2.5, the plasmid was transformed into chemically 
competent Escherichia coli (One Shot™ Stbl3™, ThermoFisher), following the 
manufacturer’s instructions. The transformation mix was streak-plated on Luria-Bertani 
(LB) agar (Fisher Scientific) containing 100 µg/ml of ampicillin (Sigma-Aldrich) in Petri 
dishes. The dishes were incubated at 37 °C overnight. The following morning, single 
colonies were isolated and used to inoculate 5 ml of LB broth containing 100 µg/ml 
ampicillin (starter cultures). The starter cultures were incubated overnight at 37 °C in a 
shaking incubator at 225 rpm.  
 
3.3.7 Plasmid purification and diagnostic digest 
 
The desired recombinant plasmid DNA was purified from the bacterial cultures in the 
starter cultures following a bind-wash-elute procedure (QIAprep Spin Miniprep Kit, 
Qiagen) according to the manufacturer’s instructions. The purified plasmid DNA was 
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eluted in 50 µl of distilled water and the concentration was determined by 
spectrophotometry as described in section 3.3.4. 
 
For larger scale plasmid DNA purification, a starter culture was grown in 500 ml of LB 
broth containing 100 µg/ml ampicillin overnight at 37 °C in a shaking incubator at 225 
rpm. The desired recombinant plasmid DNA was purified using a QIAprep Spin Maxiprep 
Kit (Qiagen) according to the manufacturer’s instructions. The purified plasmid DNA was 
eluted in 500 µl of distilled water and the concentration determined by 
spectrophotometry as described in section 3.3.4.  
 
The plasmid DNA obtained was purified and subjected to a diagnostic digest and gel 
electrophoresis (section 3.3.3) to confirm the presence of the inserted genes.  
 
3.3.8 Synthesised genes 
 
The VEGF-A165 gene was not successfully cloned into the pSFFV-IRES-eGFP backbone 
plasmid using the PCR method even after multiple cloning attempts. It was decided that 
instead of using PCR to attach restriction enzymes sites to the gene of interest, the gene 
together with the restriction enzyme sites would be synthesised by Life Technologies 
Limited to facilitate the cloning process.  
 
3.3.9 Sequencing  
 
The final recombinant plasmid DNA obtained using the synthesised genes, together with 
sequencing primers (table 12) were sent externally to Source BioScience for Sanger 
sequencing.  
 
Table 12. Sequencing primers.  
 
Primer location (region, locus 
in plasmid) 
Sequence (5’  3’) Length 
(bp) 
% GC 
content 
Tm 
SFFV promoter, 387 - 405 
 
TGCTTCTCGCTTCTGTTCG 19 52.6 58.2 
VEGF-A165 gene, 791 - 810 
 
CCACTGAGGAGTCCAACATC 20 55 57 
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The resulting DNA electropherograms were visualised and analysed using MacVector 
v15.0. 
 
3.4 Plasmid transfection 
 
Before the recombinant plasmid produced was used to manufacture the lentiviral 
vector, its functionality was tested by a transient transfection in HEK293T cells. 1.5 x 105 
cells/well were seeded onto 6-well plates and grown in complete media for 24 hours.  
The transfection mix per sample was the following: 500 μl of Opti-MEM (GibcoTM, 
ThermoFisher), 2 μg of DNA plasmid and 2.5 μl of polyethylenimine (PEI) (Polyscience). 
The solution was vortexed and left at room temperature for 20 minutes to allow the 
formation of DNA-PEI complexes. The transfection mix was then added to the cells. The 
cells were incubated at 37 oC with 5 % CO2/95 % air for 48 hours, after which proteins in 
the media and cell lysate were harvested and processed as described in section 3.7.1.  
 
3.5 Lentivirus production 
 
A second-generation lentiviral vector packaging system was used to produce the vectors 
described in this study. Standard lentiviral production (figure 15) typically relies on the 
transient transfection of HEK293T cells with a packaging plasmid, an envelope 
glycoprotein-encoding plasmid and a transfer plasmid. Following transfection, lentiviral 
particles are produced and released into the culture supernatant of the HEK293T cells 
(Vigna and Naldini, 2000). The particles are then harvested, purified by centrifugation 
and titred.  
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Figure 15. Lentiviral vector production. The transfer plasmid, packaging plasmid and envelope 
plasmid are triple transfected into HEK293T cells. After an incubation period of up to 48 hours, 
the media containing the viral particles is collected and centrifuged to concentrate virus. The 
virus is then titred and used to transduce the cells of interest. Image taken from 
http://www.cellbiolabs.com/pantropic-shrna-lentiviral-expression-systems. Accessed on 12th 
October 2018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.1 HEK293T cells triple transfection and virus harvest 
 
HEK293T cells were seeded in 15 cm dishes (Nunc) at a seeding density of 7 x 106 cells/ 
dish for a confluence of 70 - 80 % the following day. The following amounts of the three 
plasmids required for lentiviral production were added to 2.5 ml Opti-MEM® per dish:  
 
 40 μg of the transfer vector plasmid pSFFV.VEGF.IRES eGFP 
 10 μg of the envelope plasmid pMD2.G  
 30 μg of the packaging construct plasmid pCMV-dR8.74 
 
42 µl of 3.5 mg/ml PEI (Sigma-Aldrich) was added to the plasmid and Opti-MEM® 
mixture. PEI is a transfection agent that works by forming positively charged complexes 
with target DNA, which then interact with the negatively charged host cell membrane 
and release DNA into the cell (Kuroda et al., 2009). It has been shown to improve the 
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efficiency of lentiviral vector production (Tang et al., 2015). The mixture was gently 
vortexed and incubated at room temperature for 20 minutes to allow complexation. The 
cells were washed with PBS and 2.6 ml of the transfection mix was added to each dish. 
Cells were incubated overnight, after which the media was replaced with 15 ml complete 
DMEM. After 48 hours, the medium was removed for the first harvest and replaced with 
15 ml of fresh medium. The cells were then allowed to incubate for another 24 hours, 
after which the medium was collected again.  
 
3.5.2 Lentivirus concentration via centrifugation  
 
Media containing viral particles harvested 48 and 72 hours after transfection was 
centrifuged at 3000 g for 10 minutes at room temperature and filtered through a 0.22 
μm filter unit (Millipore® Stericup™, Sigma-Aldrich) to remove all cell debris. The viral 
particles were pelleted by centrifugation overnight at 3000 x g at 4 oC. The resulting 
pellet was resuspended in Opti-MEM®, aliquoted and stored at -80 oC. 
 
3.5.3 Lentivirus titration 
 
The physical lentiviral titre was obtained by the quantification of the viral envelope 
protein p24 using the ZeptoMetrix p24 antigen enzyme linked immunosorbent assay 
(Fischer Scientific) as per the manufacturer’s protocol. The assay measures the amount 
of p24 capsid protein present in the viral supernatant and this correlates directly with 
the virus titre. There are approximately 1 x 104 physical particles of lentivirus for every 
pg of p24 antigen. 
 
3.6 Transduction 
 
When the cells were growing exponentially, 1 x 105 - 1.5 x 105 cells in their respective 
medium were added to each well in a 6-well plate. The number varied according to cell 
type to accommodate a confluence of 70 - 80 % upon transduction. The cells were 
incubated at 37 oC with 5 % CO2/95 % air for 24 hours. The medium was then removed 
from the wells. 1.5 ml fresh medium was added to each well followed by the required 
volume of lentiviral particles. A range of multiplicities of infection (MOIs) (MOI of 1, 10 
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and 100) to determine the optimal number of lentiviral particles needed for efficient 
transduction was tested.    
 
The MOI was calculated using the following formula:  
 
Following addition of the viral particles, the plates were gently swirled and incubated at 
37 °C at 5 % CO2/95 % air. Lentiviral mediated eGFP expression was assessed over a 72 
hour period using a fluorescence microscope (Inverso-TC Trinocular Inverted 
Microscope with Epi-Fluorescence Module).  
 
3.6.1 Assessing transduction efficiency by flow cytometry 
 
Transduction efficiency was assessed 72 hours following transduction by flow cytometry 
(MACS Quant Flow Cytometer). The cells were detached and counted using a 
haemocytomer. Cells at a density of 7.5 x 105/ml were resuspended in sterile PBS and 
passed through a 40 μm nylon mesh filter (Falcon®) right before sorting to ensure that 
only single cells were present. Fluorescent cells were separated from non-fluorescent 
cells by setting a minimum fluorescence value (thresholding) on the histograms 
generated from the cell data provided by the cytometer. By setting the threshold just to 
the right of the dimmest peak, cells to the left of the threshold were excluded from those 
counted as fluorescent within the channel.  
 
3.7 Protein expression analysis 
 
To confirm successful overexpression of the transgene following transfection or 
transduction, Western blot and ELISA were used to measure protein expression.  
 
 
Total number of cells per well X desired MOI 
____________________________________       =       Total volume of lentiviral     
                                                                                                particles to add to each well (ml) 
       Lentiviral titre (viral particles/ml)                                       
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3.7.1 Sample preparation 
 
48-72 hours after transfection or transduction, cells and media were collected for 
protein extraction. The media was centrifuged at 1500 rpm for 10 min at 4 °C. The 
supernatant was transferred to clean 1.5 ml microcentrifuge tubes and used 
immediately or stored at -80 °C. After the media was collected, the cells were washed 
with ice-cold PBS. The PBS was discarded and 100 µl of cold radioimmunoprecipitation 
assay (RIPA) buffer (ThermoFisher) with 1x protease inhibitor cocktail (ThermoFisher) 
were added per well. The cells were incubated on ice for 5 minutes, swirling the plate 
every minute. The cells were then scraped using a cold plastic cell scraper and collected 
in 1.5 ml microcentrifuge tubes. The cell lysate was incubated for 30 minutes at 4 °C on 
a tube rotator and then centrifuged at 16 000 rpm for 20 minutes at 4 °C. The 
supernatant was collected and transferred into clean microcentrifuge tubes and used 
immediately or stored at -80 °C. 15 µl of the processed cell lysate and cell media were 
taken to estimate the total amount of protein per sample using a bicinchoninic acid 
(BCA) protein assay kit (ThermoFisher) according to the manufacturer’s instructions.  
 
3.7.2 Western blot 
 
Western blotting was used to provide semi-quantitative data on the presence and 
molecular weight of the VEGF-A165 protein produced by SCL4.1/F7 cells following 
lentiviral transduction. 1x lithium dodecyl sulfate sample buffer (NuPAGETM, 
ThermoFisher) and 1x sample reducing agent (NuPAGETM, ThermoFisher) were added 
the volume of cell lysate or media equivalent to 20 µg of total protein as determined by 
the BCA assay.  The sample buffer contains tracking dyes (Coomassie G250 and phenol 
red) which give a sharp dye front close to the moving ion front. The reducing agent 
completely reduces disulphide bonds present in the proteins. The solution was made up 
to a volume of 30 µl with RIPA buffer. The mixture was incubated at 70 oC for 10 minutes 
to denature the proteins. The samples were loaded into the wells of a pre-cast 8 cm x 8 
cm bis-tris 4 - 12 % polyacrylamide gel (NuPAGETM, ThermoFisher), which resolves 
proteins in the range of 1 - 200 kDa. 10 µl of sharp pre-stained protein standard 
(Novex™, ThermoFisher) was added to a separate well to confirm the molecular 
weight of the visualised bands. 500 µl of antioxidant (NuPAGETM, ThermoFisher) was 
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added was added to the upper buffer chamber of the XCell SureLock™ Mini-Cell gel 
running tank ((NuPAGETM, ThermoFisher)  to prevent sample reoxidation and maintain 
the proteins in a reduced state. Proteins were separated via polyacrylamide gel 
electrophoresis with 1x MES SDS running buffer (NuPAGETM, ThermoFisher) run at 90 V 
for 2 hours. 
 
Proteins were transferred on to a methanol activated polyvinyl difluoride membrane 
(Thermo Fisher Scientific) via semi dry transfer. The membrane was soaked in methanol 
for 1 minute and rinsed with transfer buffer (48 mM Tris, 39 mM glycine, 20 % methanol, 
0.04 % sodium dodecyl sulfate). Filter paper was also soaked in transfer buffer and 
placed in the semi dry transfer unit. A stack was formed by placing the membrane and 
gel on top of the filter paper and covering the gel with additional filter paper. Semi dry 
transferring was run at 400 mA for 1 hour. The membrane, now containing the 
transferred proteins, was blocked for 1 hour at room temperature using 3 % skimmed 
milk powder (Sigma-Aldrich) in TBST (Tris-buffered saline, 0.1 % Tween 20). The 
membrane was incubated with the appropriate dilutions of primary antibody (table 13) 
in TBST. After three 5 minute washes in 1x TBST, the membrane was incubated with 
horseradish peroxidase (HRP) conjugated secondary antibodies (table 14) in 3 % bovine 
serum albumin (BSA) (Sigma-Aldrich) in TBST at room temperature for one hour. After 
another three 5 minute washes in TBST, the signal was developed using an enhanced 
chemiluminescence system (ThermoFisher) following the manufacturer’s instructions. 
Bands were detected using a GeneGnome imager.  
 
Table 13. Primary antibodies used in western blotting.  
 
Primary antibody Host Reactivity Dilution Incubation 
conditions 
Anti-VEGFA (ab1316, 
Abcam) 
Mouse Mouse, rat, rabbit, dog, 
human 
1:1000 1 hour at room 
temperature 
Anti-tubulin 
(ab6161, Abcam) 
Rat  Mouse, rat, dog, human, 
Saccharomyces cerevisiae, 
Schizosaccharomyces 
pombe, alligator 
1:1000  Overnight at 4 
oC 
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Table 14. Secondary antibodies used in western blotting. 
 
Secondary antibody Host Reactivity Dilution Incubation 
conditions 
Goat anti-mouse IgG 
H&L (HRP) (ab6789, 
Abcam) 
Goat Mouse 1:2000 1 hour at room 
temperature 
Goat anti-rat IgG H&L 
(HRP) (ab97057, 
Abcam) 
Goat Rat 1:10000 1 hour at room 
temperature 
 
3.7.3 ELISA  
 
A solid-phase sandwich Enzyme-Linked Immunosorbent Assay (ELISA) (Invitrogen, 
ThermoFisher) was used to detect and quantify the level of human VEGF-A165 protein in 
cell lysate and cell culture medium. Following transfection and lentiviral transduction, 
sample preparation as described in section 3.7.1, the assay was performed according to 
the manufacturer’s instructions.   
 
3.8 Cell proliferation assay 
 
A colorimetric 5-bromo-2'-deoxyuridine (BrdU) cell proliferation ELISA kit (Abcam) was 
used used to evaluate whether the transduction or the expression of the transgenes had 
an effect on cell proliferation. 0.5 x 104 transduced and control untransduced SCL4.1/F7  
cells were seeded per well in a 96-well plate and allowed to attach overnight. The 
following day, 20 µl of 1x BrdU reagent was added to each well and incubated for 18 
hours. The assay protocol was followed as per manufacturer’s instructions.  
 
3.9 Cell morphology analysis 
 
Transduced and control untransduced SCL4.1/F7 cells were analysed morphologically by 
light microscopy and were also characterized by immunofluorescence staining.  A 0.01 
% solution of poly-l-lysine (Sigma-Aldrich) made in dH2O was used to coat the surface of 
circular coverslips (thickness # 1) (ThermoFisher) to ensure cell attachment.  5 x 104 
SCL4.1/F7 cells in 100 µl complete DMEM were seeded onto the coverslips and allowed 
to attach for 2 hours at 37 oC with 5 % CO2/95 % air before the addition of 2 ml of 
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complete media per well. After 24 hours, the cells were fixed by the addition of 4 % 
paraformaldehyde (PFA) for 10 minutes followed by two 5 minute washes in PBS. Cells 
were permeabilised using 0.3% Triton X-100 (Sigma) in PBS for 30 minutes at room 
temperature. Following two 5 minute washes in PBS, 5 % normal goat serum in PBS was 
added for 30 minutes at room temperature to block non-specific binding sites. The goat 
serum was then removed and after two 5 minute washes with PBS, primary antibodies 
diluted in PBS were added and incubated for 1 hour at room temperature. The cells were 
washed three times for 10 minutes in PBS and incubated with secondary antibodies 
diluted in PBS for 1 hour in the dark. After three final 5 minute washes in PBS, the 
coverslips containing the cells were mounted cell side down onto microscope slides 
using Vectashield mounting media with 4′,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories) and allowed to dry before viewing under a fluorescence microscope.  
Circularity, serving as a cell shape descriptor, was measured using ImageJ.  
 
3.10 Collection and processing of conditioned media 
 
Transduced and control untransduced SCL4.1/F7 cells were seeded at a density of 2 x 
104 cells/cm2 in complete DMEM in a T75 flask. After 24 hours, the cells were washed 
with PBS. 15 ml of DMEM containing 0.1 % FBS was added to the cells.  After 24 hours, 
the media was collected and filtered using a 0.2 µm syringe filer. The conditioned media 
was aliquoted and stored at -80 oC. The conditioned media was diluted with fresh EGM 
at a ratio of 2:3 for use in functional assays.  
 
3.11 Functional assays 
 
Functional assays were used to assess the angiogenic activity of the VEGFA produced by 
the transduced SCL4.1/F7 cells in conditioned media (CM). The following test groups 
were employed in the first three functional assays described in this section: 
 
 Group 1:  conditioned media from serum starved transduced SCL4.1/F7 cells 
overexpressing VEGF-A165 + endothelial cell media + 1 % FBS.  
 Group 2: conditioned media from serum starved control untransduced SCL4.1/F7 
cells + endothelial cell media + 1% FBS. 
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 Group 3: DMEM + 1 % FBS (negative control). 
 Group 4: EGM + 10 % FBS.   
 Group 5: EGM + 1 % FBS + recombinant VEGF-A165 protein (50 ng/ml) (positive 
control). 
 
3.11.1 Effect of VEGF-A165 on HUVEC viability 
 
HUVECs in complete EGM were seeded in a 96-well plate at a density of 2000 cells per 
well and allowed to attach overnight. The complete medium was removed and the cells 
were washed with PBS. Cells were then incubated with the test media described in 
section 3.11 for up to 72 hours. Cell viability was measured every 24 hours by the 
addition of 10% alamarBlue® 6 hours prior to readout as described in section 3.13.1. 
 
3.11.2 Endothelial tube formation assay 
 
An in vitro angiogenesis assay kit (Chemicon®, Merck), based on a solid gel of basement 
proteins prepared from the Engelbreth Holm-Swarm mouse tumour, was used to 
evaluate tube formation by HUVECs in response to the VEGF-A165 produced by the 
transduced SCL4.1/F7 cells (figure 16). The assay was carried out per manufacturer’s 
instructions using 0.5 x 103 HUVECs per well in a 96-well plate. After a 6 hour incubation 
period with the test media described in section 3.11, tube formation was visualised 
under an inverted light microscope with magnification of 10x. Five pre-determined view 
fields per well were photographed and following researcher blinding, the endothelial 
tube visual patterns were examined.  A numerical value associated with a degree of 
angiogenesis progression was assigned to each pattern.  
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Figure 16. HUVEC tube formation assay. The assay measures the ability of endothelial cells, 
seeded on basement proteins, to form capillary-like structures in the presence of angiogenic 
signals. Image taken and adapted from ibidi application note: Tube Formation Assays in the µ-
Plate Angiogenesis 96 Well. Available from: https://ibidi.com/content/92-tube-formation-
assays-in-the-plate-angiogenesis-96-well. Accessed on 12th October 2018.  
 
 
 
 
 
 
 
 
3.11.3 Scratch assay  
 
Serum starved HUVECs were detached from T175 tissue culture flasks and counted using 
a hemocytometer. HUVECs at a density of 2 x 105 cells/well were plated in a 6-well plate 
and allowed to adhere overnight.  This density was chosen to ensure a confluent 
monolayer the following morning. A scratch was made across the centre of the well 
using a P200 pipette tip (figure 17). A sterile razor blade was used as a straight edge to 
make the scratch as straight as possible. Cell debris was removed by washing with PBS.  
2 ml of test media described in section 3.11 was added to each well. Three equidistant 
positions in the scratch (top, middle and bottom) were marked with reference points on 
the outer bottom of the plate using an ultrafine tip marker.  These points were visualised 
using an inverted light microscope at 10x magnification and images were taken to 
measure the area of the scratch at time 0. The cells were then incubated at 37 % with 5 
% CO2/95 % air for 8 hours. The predetermined positions were located using the 
reference points, and images were taken to measure the area of the scratch after 8 
hours.  
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Figure 17. Scratch assay. A wound is introduced into a confluent monolayer of cells (A) by 
drawing a tip across the cell layer (B). The scratch is imaged to measure the area pre-
migration (C) and after cell migration (D). Image taken from Hulkower and Herber (2011).  
 
 
3.11.4 Transwell migration assay 
 
SCL4.1/F7 cells were detached from T175 tissue culture flasks and counted using a 
haemocytometer. 3 x 105 cells in 1.5 ml of serum free DMEM were pipetted into the top 
compartment of a transwell insert (Sigma-Aldrich) (8 μm pore size, placed in a 6-well 
plate). The contents of the lower compartments were varied across different 
experimental conditions. Cells were allowed to migrate for 12 hours (figure 18). At the 
end of the experiment, unmigrated cells on the apical side of the membrane were 
removed using a cotton bud soaked in PBS. Migrated cells on the basolateral side of the 
membrane were fixed with 4 % PFA for 10 minutes and washed three times with PBS. 
The membrane was cut out from the insert using a razor blade and placed onto a 
microscope slide, cell side facing up. Cells were stained with DAPI for 5 minutes and 
washed with PBS. The slides were cover slipped with Vectashield mounting media 
(Vector Laboratories) and allowed to dry. The number of nuclei (representing migrated 
cells) in 10 pre-determined view fields were counted using a fluorescent microscope. 
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Figure 18. Transwell migration assay. SCL4.1/F7 cells were placed in the upper compartment 
and their migration response to VEGF-A165 in the lower compartment was assessed. Image taken 
from https://www.corning.com/worldwide/en/products/life-sciences/products/permeable-
supports/permeable-support-systems.html. Accessed on 13th October 2018. 
 
 
3.12 Engineered neural tissue 
 
SCL4.1/F7 cells were used to create EngNT according to methods described previously 
(Georgiou et al., 2013). EngNT is produced through self-alignment of cells within a 
collagen gel followed by stabilisation using plastic compression, a process whereby a 
biocompatible absorbent material is placed upon the gel to absorb interstitial fluid. This 
generates a dense robust hydrogel with a 50-fold increase in cell and collagen density 
(Brown et al., 2005).  
 
3.12.1 Fabrication of engineered neural tissue  
 
100 µl 10x minimum essential medium (Sigma) was mixed with 800 µl type I rat tail 
collagen (2 mg/ml in 0.6 % acetic acid) (First Link, UK). The mixture was kept at  4 oC and 
was neutralised by the drop wise addition of 1 M sodium hydroxide (Sigma), indicated 
by a colour change from pale yellow to peach. The collagen solution was added to 100 
µl cell suspension to give a cell density of 4 × 106 cells/ml of gel.  Gels were allowed to 
set in tethering moulds (figure 19) at 37 °C for 15 minutes and then immersed in culture 
medium and incubated at 37 °C in a humidified incubator with 5 % CO2/ 95 % air for 
24 hours, during which time the cells contracted the tethered gels and become aligned. 
RAFTTM 24-well cell culture plate biocompatible absorbers (Lonza Bioscience) were then 
used to stabilise the aligned gels for 15 min (figure 20).  
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Figure 19. Cellular collagen gels in polyether ether ketone moulds. The tethering bars are 
supported at each end of the rectangular moulds. Gels adopt a characteristic shape as cells 
contract and align. 
 
 
 
 
 
 
 
 
 
 
Figure 20. Stabilising the EngNT to produce robust hydrogels. A RAFTTM absorber is used to 
stabilise the gel by drawing out the interstitial fluid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.12.2 Contraction assay 
 
75 µl of the collagen-cell mixture (4 × 106 cells/ml of gel) described in section 3.12.1 was 
added to individual wells of 96-well plates and allowed to set for 10 minutes at 37 oC. 
The gels were immersed in culture medium and incubated at 37 oC for a further 
15 minutes before detachment from well plates using a sterile needle. Gels were 
incubated at 37 oC in a humidified incubator with 5 % CO2/95 % air for 24 hours. The 
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media was removed from the wells and the plates were placed on a black surface and 
photographed. Percentage contraction was calculated by comparing the area of the well 
occupied by each gel to the area of the well using ImageJ.  
 
3.12.3 Distribution of cells in the EngNT 
 
A fluorescence stereomicroscope (Leica MZ16) was used to visualise the eGFP positive 
cells in the EngNT at a low magnification. This permitted the visualisation of the cells 
distributed throughout the construct. The 3D nature of the aligned SCL4.1/F7 cells 
within the collagen gels was captured by means of visualising lentivirus mediated 
expression of eGFP using scanning confocal microscopy (Zeiss LSM 710). DAPI was used 
as a nuclear and chromosome counterstain for identifying nuclei as it selectively binds 
to DNA and shows little to no background staining of the cytoplasm.   
 
3.13 Cell viability assays 
 
3.13.1 alamarBlue® assay 
 
alamarBlue® (Bio-Rad) was used to establish whether the transduction or the expression 
of the transgenes had an effect on cell viability. alamarBlue® is a cell viability assay 
reagent which contains the cell permeable and non-toxic indicator dye resazurin. 
Resazurin is used as an oxidation-reduction indicator that undergoes a colorimetric 
change from blue to pink in response to cellular metabolic reduction. The absorbance 
measured is is proportional to the number of living cells respiring. By detecting the level 
of oxidation during respiration, alamarBlue® can be used to quantitatively measure cell 
viability.   
 
alamarBlue® in complete DMEM at a final volume of 10 % (v/v) was added to SCL4.1/F7 
cells in a 96-well plate (2000 cells per well) as per manufacturer’s guidelines. Cells were 
allowed to incubate for 6 hours at 37 oC and the absorbance of the media was then read 
at 570 nm and 600 nm on a Synergy HT plate reader using Gen5 software. The 
percentage reduction of alamarBlue® was calculated using the equation: 
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Percentage reduction of alamarBlue® = (O2 x A1) – (O1 x A2) x 100 
                                                                          ------------------------------- 
                                                                              (R1 x N2) - (R2 x N1)  
 
Where:   
O1 = molar extinction coefficient of oxidized alamarBlue® at 570 nm (80 586)  
O2= molar extinction coefficient of oxidized alamarBlue® at 600 nm (117 216) 
R1 = molar extinction coefficient of reduced alamarBlue® at 570 nm (155 677) 
R2= molar extinction coefficient of reduced alamarBlue® at 600 nm (14 652) 
A1 = absorbance of test wells at 570 nm  
A2 = absorbance of test wells at 600 nm  
N1 = absorbance of negative control well (media plus alamarBlue® but no cells) at 570 
nm  
N2 = absorbance of negative control well (media plus alamarBlue® but no cells) at 600 
nm  
 
3.13.2 Live-dead stain 
 
Cellular gels prepared as described in section 3.12.2 were analysed by NUCLEAR-ID® 
Blue/Red cell viability reagent (GFP-CERTIFIED®) (Enzo Life Sciences), a mixture of a blue 
fluorescent cell-permeable nucleic acid dye and a red fluorescent cell-impermeable 
nucleic acid dye that is suited for staining dead nuclei. The staining pattern allows the 
determination of live and dead cell populations in GFP-expressing cell lines. The reagent 
was diluted in fresh cell culture media at a ratio of 1:1000 and incubated with the gels 
at 37 oC for 1 hour followed by three 5 minute washes in PBS. The stained gels were 
placed onto microscope slides and five predetermined fields were imaged using a 
magnification of 20x on a Zeiss Axiolab A1 Axiocam Cm1 microscope.  
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3.14 Bioluminescence imaging 
 
Luciferase gene expression in transduced cells and cellular gels was assessed using live 
bioluminescence imaging. A 15 mg/ml (100x) solution of d-luciferin potassium salt 
(GoldBio) was prepared in sterile normal saline. Luciferin was used at a final 
concentration of 150 μg/ml in all assays. Bioluminescence images were taken using an 
IVIS® Lumina Series III in vivo imaging system (Perkin Elmer). In order to establish a 
kinetic curve for luciferin uptake in the cells, cells and gels were imaged immediately 
after the addition of luciferin and every 5 minutes for 40 minutes.  
 
3.15 in vitro 3D co-cultures  
 
3.15.1 PC12 - SCL4.1/F7 co-cultures  
 
EngNT was made using SCL4.1/F7 cells as described in section 3.12.1. The EngNT was cut 
into 2 equal segments and each segment was transferred to a separate well in a 24-well 
plate. 1 x 105 PC12 cells suspended in 50 µl medium were seeded on top of each 
segment. The co-cultures were incubated for 1 hour at 37 oC to allow attachment of 
PC12 cells to the collagen gel. Following this, 1 ml complete DMEM was added to each 
well and the co-cultures were incubated at 37 oC in a humidified incubator with 5 % 
CO2/95 % air for 72 hours. The co-cultures were then fixed with 4% PFA overnight for 
relevant analysis. Fluorescence  microscopy  (Zeiss  Axiolab  A1  Axiocam  Cm1)  was   
used  to  observe neurites  in  five pre-determined  fields  of  each  gel segment.  
 
3.15.2 HUVEC - SCL4.1/F7 co-cultures  
 
EngNT was made using a mixture of SCL4.1/F7 and HUVECs. Muangsanit et al. 
(unpublished) tested different culture conditions in order to establish the optimal 
conditions for HUVECs to form tube-like structures in collagen gels. They tested different 
incubation times and cell densities and it was shown that an incubation time of 4 days 
and a ratio of 4 x 106 HUVECs: 1 x 106 SCL4.1/F7 cells /ml yielded optimal tube formation.  
Therefore, these optimised conditions were also used in the current study. Confocal 
microscopy was used to visualise the endothelial cell network.  Angiogenesis Analyzer, 
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a plugin in ImageJ (Carpentier, 2012), was used to measure the number of meshes, mesh 
area, number of junctions and total branching length of the tube-like structures per field 
of view formed by the HUVECs. 
 
3.16 Immunocytochemistry and imaging 
 
Cellular EngNT and 3D co-cultures were fixed in 4 % PFA in PBS overnight at 4 oC followed 
by two 10 minute washes in PBS. Gels were permeabilised using 0.5% Triton X-100 
(Sigma) in PBS for 30 minutes at room temperature with agitation. Gels were washed 
three times with PBS for 10 minutes each. 5 % normal goat serum in PBS was added for 
30 minutes at room temperature to block non-specific binding sites. The goat serum was 
then removed and after three 5 minute washes with PBS, primary antibodies (table 14) 
diluted in PBS were added and incubated at 4 oC overnight. The following day the gels 
were washed three times for 10 minutes in PBS and incubated with secondary 
antibodies (table 15) diluted in PBS. Gels were incubated for 90 minutes in a dark 
humidified chamber with agitation. Gels were then washed with PBS. Finally, gels were 
stained with DAPI with dilution factor of 1:1000 in PBS for 10 minutes and washed once 
more with PBS before viewing by confocal microscopy.  Per cellular gels, two z-stacks 
were acquired in 2 side regions, each containing 10 - 30 images (depending on the 
intensity of the signal at various depths) every 1 mm toward the centre of the gels.  
 
3.17 In vivo experiments 
 
3.17.1 Animals 
 
All surgical procedures were performed according to the Animals (Scientific Procedures) 
Act 1986 / the European Communities Council Directives (86/609/EEC) and approved by 
the UCL Animal Welfare and Ethics Review Board. Adult female Wistar rats (180 - 220 g) 
(Charles River Laboratories) were used for this study. Animals were housed in standard 
12-hour light/dark cycles at room temperature and had continuous access to food and 
water.  
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3.17.2 Device assembly 
 
Following stabilisation, the EngNT was thoroughly washed in PBS, cut to 15 mm in 
length, and rolled parallel to the axis of cellular alignment to form a tight rod (figure 21). 
Each rod was placed inside a sterile 17 mm silicone tube (Syndev; 1.57 mm inner 
diameter, 0.42 mm wall thickness). Assembled devices were stored in HibernateTM- A 
(GibcoTM; ThermoFisher) on ice until implantation in vivo. 
 
Figure 21. Assembly of the implantable device. The stabilised EngNT is rolled parallel to the axis 
of cellular alignment to produce a rod which is then placed into a silicone tube with a longitudinal 
slit. Image taken and adapted from Georgiou et al. (2013).  
 
 
3.17.3 Surgery  
 
The surgical procedure described in this section was carried out by Dr James Phillips (UCL 
School of Pharmacy). Anaesthesia was induced by inhalation of isoflurane and oxygen in 
an anaesthesia induction chamber and maintained using an anaesthesia gas mask 
throughout surgery. Surgery was carried out on a heated operating table set to 37 oC. 
The breathing of the animals was monitored closely and the anaesthetic dose was 
adjusted accordingly. Vitamin E eye ointment was applied to both eyes to prevent drying 
during the procedure.   
 
The thigh was shaved and a 3 cm lateral skin incision between the knee and hip joint 
was made (figure 22).  
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Figure 22. The position of the sciatic nerve in relation to the knee and hip. The sciatic nerve 
innervates the posterior aspect of the thigh and the entire lower limb below the knee except for 
a small patch of skin on the medial aspect of the leg and ankle, which is innervated by the 
saphenous nerve. Image taken and adapted from Nijhuis et al. (2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The intermuscular planes were separated using blunt dissection until the sciatic nerve 
was exposed (figure 23). 
 
Figure 23. Exposing the sciatic nerve. The sciatic nerve was exposed at the mid-thigh.  
 
 
 
 
 
 
 
 
 
 Common peroneal nerve 
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The nerve was freed from the surrounding tissue under a dissecting microscope and 
transected mid-way between the hip and knee. The repair device was secured to the 
proximal and distal stumps of the transected nerve using two epineurial 10-0 non-
absorbable nylon sutures (Ethicon) at each stump (figure 24).  
 
Figure 24. Positioning the implantable device. The implantable device was positioned between 
the stumps to produce an inter-stump distance of 15 mm. The device was kept in place using 
two 10/0 epineurial sutures at each stump. 
 
 
 
 
 
 
 
 
 
 
 
 
The muscle layer was closed with one 4-0 suture (figure 25) and the skin incision was 
closed using wound clips. 0.1 ml carprofen (5 % w/v) analgesic was administered 
subcutaneously to the injury site and wound powder was applied over the area to 
reduce the risk of infection.  
 
Figure 25. Closing the muscle layer. The muscle layer was closed with one 4-0 suture. 
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Immediately after surgery, the animals were placed in a post-operative warming 
chamber and monitored closely until they recovered from the anaesthesia. They were 
then returned to their previous social group. The wound clips were removed 7 days after 
surgery using a wound clip remover. The animals were monitored for signs of pain, 
distress and weight loss until culled at the time point being investigated.  
 
3.17.4 in vivo bioluminescence imaging 
 
Rats were anesthetised using an isoflurane vaporiser and 150 mg/kg of d-luciferin was 
injected intraperitoneally into the lower right quadrant of the abdominal region 10 
minutes before imaging. The rats were placed inside the camera box of the in vivo 
imaging system. Images were taken every 10 minutes for up to 40 minutes. An exposure 
time of 10 minutes, f-stop of 1 and binning value at medium were used.   
 
3.17.5 Functional tests 
 
3.17.5.1 Von Frey 
 
Rats were placed in acrylic chambers suspended above a wire mesh grid and allowed to 
acclimatise for 15 minutes prior to testing. There are different methods of measuring 
paw withdrawal with von Frey filaments. However, according to Bonin et al. (2014), the 
up-down method of Dixon (1965) as applied to rodents by Chaplan et al. (1994) is one 
of the most commonly used.  Using this approach, the von Frey filaments were pressed 
against the plantar surface of the paw (figure 26) until the filament buckled. A positive 
response was recorded if the paw was withdrawn on application of the filament. A lack 
of response to a filament required stimulation with the next higher filament, while a 
positive response necessitated the use of the next lower filament in order to establish 
the lowest stimulus required to elicit a response.  
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Figure 26. Application of the von Frey filament on the rat’s hind paw. The von Frey filaments 
were applied to the testing area shown. Image taken and adapted from Ferrier et al. (2016).  
   
 
 
 
 
 
 
 
 
 
 
3.17.5.2 Static sciatic index 
 
The animals were placed in an acrylic chamber and allowed to adopt a normal stance 
(supported by all four paws). Three images of the plantar surface of the hind paws were 
acquired per animal. The toe spread (distance between the tips of the first and fifth 
digits) and intermediate toe spread (distance between the tips of the second and fourth 
digits) of the injured and non-injured paws were measured using the digital images 
(figure 27). These values were averaged and incorporated into equations to used 
calculate the static sciatic index as described by Bervar (2000).  
 
Toe spread factor (TSF) = (ETS-NTS)/NTS 
Intermediary toe spread factor (ITF) = (EIT-NIT)/NIT  
Static sciatic function (SSF) = 108.44 TSF + 31.85 ITF – 5.49 
 
Where: 
E= experimental side 
N= normal side 
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Figure 27. Calculating the static sciatic index. The toe spread and intermediate toe spread were 
used to determine the static sciatic index.  
 
 
 
 
 
 
 
 
 
 
 
 
3.17.6 Electrophysiology 
 
After 8 weeks, animals were anesthetised and nerve function was assessed 
electrophysiologically (using a Sapphire 3ME system) by comparing the repaired nerve 
to the contralateral control nerve in each animal. A grounding electrode and a reference 
electrode (Ambu® Neuroline 710) were attached to the animal. A stimulating electrode 
(Neurosign Bipolar Probe 2 × 100 mm × 0.75 mm electrode) was placed proximal to the 
repair site on the surface of the nerve and a recording electrode (Ambu® Neuroline 
concentric) was placed into the gastrocnemius muscle (figure 28). The distance between 
the stimulating and recording monopolar electrodes was standardised. 
Electrophysiological stimulation of the nerve was performed in a bipolar stimulation 
constant voltage configuration and muscle response was recorded. The stimulation 
threshold was determined by increasing the stimulus amplitude in 0.1 V steps (200 µs 
pulse) up to 10 V, until a reproducible, stimulus-correlated muscle action potential was 
recorded. The latency was measured from the time of stimulus to the first deviation 
from the baseline, and the amplitude of the compound muscle action potential was 
measured from baseline to the greatest positive peak. Recordings were conducted in 
triplicate for the repaired nerve and contralateral control nerve in each animal.  
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Figure 28. Electrophysiology set up. Electrophysiological stimulation of the nerve was 
performed in a bipolar stimulation constant voltage configuration and the muscle response 
recorded. 
 
 
2.17.7 Tissue harvesting 
 
Immediately following electrophysiological analysis, animals were culled by cervical 
dislocation according to Schedule I in the Animals (Scientific Procedures) Act 1986. The 
sciatic nerve was cut above and below the repair device and mounted onto a cardboard 
frame, indicating the proximal and distal stumps, and immersion-fixed in 4 % PFA. The 
contralateral nerve was also harvested and processed in the same way. 
 
In order to evaluate the degree of muscle atrophy, the gastrocnemius muscle (figure 29) 
on each side were also harvested. An incision was made in the hind paw between the 
hip and the paw, exposing the gastrocnemius muscle which was then separated from 
the soleus muscle and collected. The wet muscle weight was measured immediately 
using a digital scale. 
 
 
 
 
 
 
Grounding 
electrode 
Recording 
electrode 
Stimulating 
electrode 
Reference 
electrode 
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Figure 29. The gastrocnemius muscle.  The gastrocnemius muscle undergoes significant atrophy 
in a rat sciatic nerve transection model. Thus, wet gastrocnemius muscle mass measurements 
may reflect the recovery of gastrocnemius muscle innervation and overall neuromuscular 
function recovery. Image taken from Nijhuis et al. (2013).  
 
 
3.17.8 Processing of tissue 
 
3.17.8.1 ex vivo bioluminescence imaging 
 
150 μg/ml luciferin substrate was added to the excised nerves which had been repaired 
by EngNT containing transduced SCL4.1/F7 cells expressing luciferase. Bioluminescence 
images were taken using the in vivo imaging system immediately after the addition of 
the substrate and every 5 minutes for 30 minutes.   
 
3.17.8.2 Tissue fixing and cryosectioning 
 
Excised nerves were immersion-fixed in 4 % PFA at 4 °C overnight after which they were 
washed with PBS and transferred to 30 % sucrose (Sigma-Aldrich) in PBS overnight. 
Nerves were embedded in a 50:50 solution of 30 % sucrose and optimal cutting 
temperature (OCT) compound (Leica Biosystems) in moulds and allowed to set at room 
temperature for 2 hours. The nerves were then snap frozen in liquid nitrogen and stored 
at -20 oC until required.  
 
Transverse cryostat sections (10 μm thick) were prepared from the middle of the device 
and the proximal and distal parts of the nerve stumps at a constant temperature of –20 
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oC. The transverse sections that were used for analysis were from positions 1 mm into 
the proximal and distal stumps, measured from the end of the nerve stump in each case, 
and from the middle of the device.  
 
3.17.9 Immunofluorescence staining of nerve sections 
 
3.17.9.1 Preparation of chrome-gelatine coated slides 
 
In order to increase tissue adhesion and allow downstream washes in 
immunofluorescent studies, all microscope slides (Superfrost, VWR) were double coated 
with a thin layer of gelatine. 2.5 g of gelatine powder (VWR) and 0.25 g of chromium (III) 
potassium sulfate 12-hydrate (VWR) were added to 500 ml dH2O. The mixture was 
warmed to 45 oC and constantly stirred until a uniform solution was obtained. Slides in 
slide racks were briefly immersed in the solution and allowed to dry at 56 oC overnight. 
The process was repeated a second time the following day.  
 
3.17.9.2 Immunofluorescence  
 
Nerve sections were washed in immunostaining buffer (PBS, 0.2 % Triton-X (Sigma-
Aldrich), 0.002 % sodium azide (Sigma-Aldrich) and 0.25 % BSA) before the addition of 
normal goat serum (Vector Laboratories) (1:20 in immunostaining buffer) for 45 min. 
The blocking serum was then removed and sections were incubated with the relevant 
primary antibodies (diluted in immunostaining buffer) (table 15) overnight at 4 oC. The 
sections were then washed with immunostaining buffer before addition of the 
fluorescence-tagged secondary antibody (table 16), and incubated at room temperature 
for 90 min. Sections underwent a final wash with immunostaining buffer before 
mounting with Vectashield. 
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Table 15. Primary antibodies used in immunofluorescence studies.  
 
Primary antibody Host Reactivity Dilution Incubation 
conditions 
Anti-VEGFA 
(ab1316, Abcam) 
Mouse Mouse, rat, 
rabbit, dog, 
human 
1:1000  
 
 
 
Overnight at 4 
oC 
Anti-CD31 
(M0823, Dako) 
Mouse Human 1:50 
Anti-S100 (Z0311, 
Dako) 
Rabbit Mouse, human, 
rat, zebrafish  
1:400 
Anti-RECA1 
(MCA970R, Bio-
Rad) 
Mouse Rat 1:200 
Anti-ΒIII-Tubulin 
(T8578, Sigma-
Aldrich) 
Mouse  Human, mouse 
rat  
1:400 
Anti-
Neurofilament 
(SMI-35P-050, 
Eurogentec) 
Mouse  Mammalian  1: 1000 
 
Table 16. Secondary antibodies used in immunofluorescence studies.  
 
Secondary 
antibody 
Host Reactivity Dilution Incubation 
conditions 
Alexa Fluor®488 
conjugated anti-
rabbit IgG (A-
11008, 
LifeTechnologies)  
Goat Rabbit 1:200  
 
 
90 minutes at 
room 
temperature  DyLight® 549 
conjugated anti-
mouse IgG 
(STAR117D549GA) 
Goat Mouse 1:200 
 
3.17.9.2 Quantitative analysis of immunofluorescence staining  
 
Tile scans were used to capture the entire nerve cross-section using a Zeiss LSM 710 
confocal microscope and images were analysed using Volocity™ 6.4 (PerkinElmer) 
running automated image analysis protocols to determine the number of 
neurofilament-immunoreactive neurites in each transverse nerve section. RECA-1 was 
used to visualise blood vessels, which were also counted. Blood vessel diameter was 
measured from images captured (Zeiss AxioCam) using ImageJ.  
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3.18 Statistical analysis  
 
All statistical analyses were carried out using GraphPad Prism software (version 5). A 
Shapiro-Wilk normality test was conducted on all data to determine appropriate 
statistical tests. For normally distributed data, two sample comparisons were performed 
using the student’s t-test and multiple comparisons were analysed by analysis of 
variance (ANOVA) followed by a Tukey’s post-test. Data which did not follow a normal 
distribution was analysed by a Kruskal-Wallis test followed by a Dunn’s post-test. For all 
tests, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 were considered to be 
significant. All graphs are plotted as individual data points with error bars representing 
the standard deviation unless otherwise stated.  
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Chapter 4. An evaluation of lentiviral-mediated gene 
delivery to Schwann cells for the purpose of peripheral 
nerve tissue engineering  
 
4.1 Introduction 
 
Nerve regeneration following injury can be enhanced by the implantation of tissue-
engineered constructs consisting of cells and biomaterials. It is thought that the 
presence of living cells is required for providing the signals necessary for optimal neurite 
extension and repair (de Luca et al., 2015). Therefore, tissue-engineering strategies 
focusing on biomaterials with aligned cells which can direct axon growth are favourable. 
These constructs can mimic the natural environment that consists of cell-cell 
interactions, ECM molecules and growth factors.  
 
Georgiou et al. (2013) developed aligned cellular biomaterials for the purpose of 
peripheral nerve repair. The technique involved cellular self-alignment in collagen gels 
with a stabilisation step involving removal of interstitial fluid. The engineered neural 
tissue (EngNT) produced consisted of aligned cells distributed evenly throughout a 
stable aligned matrix. Testing of this device for repair of a critical-sized 15 mm gap in a 
rat model of sciatic nerve injury showed that robust neuronal regeneration across the 
gap had occurred at eight weeks.  As promising results had already been obtained using 
this tissue engineering strategy, the overall aim of the current project was to retain the 
aligned cellular architecture achieved in the EngNT and to enhance the efficacy of the 
technology by gene delivery.  
 
Vascularisation of tissue-engineered constructs that are too thick to be sustained by 
diffusive nutrient transport alone (>100–200 µm) remains a major challenge in the 
field of tissue engineering (Chang and Niklason, 2017). An experimental approach for 
enhancing vascularisation to tissue engineered constructs following implantation is the 
use of genetically modified cells expressing angiogenic factors. Thus the genetic 
modification of cells used in EngNT in the current study may further aid peripheral nerve 
regeneration by providing the biological cues required to induce rapid vascularisation.  
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Prior to designing and producing a lentiviral vector delivering angiogenic factors, an 
initial proof-of-concept study was conducted. The aims of this initial study were to: 
 
 Use a lentiviral vector to deliver the reporter genes luciferase and eGFP to a rat 
Schwann cell line (SCL4.1/F7) previously used to construct EngNT (Georgiou et 
al., 2013).  
 Evaluate the transduction efficiency and assess whether transduction affected 
cell health.  
 Investigate the ability of the genetically modified cells to form EngNT.  
 
4.2 Lentiviral mediated gene delivery to SCL4.1/F7 cells 
 
4.2.1 The SFFV.Luc.2A.eGFP lentiviral vector 
 
A lentiviral vector delivering luciferase and eGFP (figure 30) was used for the initial 
proof-of-concept study. This vector was designed, produced and titred by Dr Michael 
Hughes from Dr Ahad Rahim’s research group at the UCL School of Pharmacy. Titration 
of the viral preparation by P24 assay revealed a high titre of 1x109 viral particles/ml. 
 
Figure 30.  A schematic of the lentiviral vector backbone delivering luciferase and eGFP 
reporter genes. LTR – long terminal repeats; RRE – Rev response element; SFFV - spleen focus 
forming virus promoter; Luc – luciferase; 2A – self cleaving element; eGFP enhanced green 
fluorescent protein; WPRE - woodchuck hepatitis virus post-transcriptional regulatory element. 
 
 
4.2.2 The SCL4.1/F7 cell line  
 
An important step in this project was the identification of a cell type which could be used 
to investigate whether gene therapy augmented tissue engineering can enhance 
peripheral nerve regeneration. Georgiou et al. (2013) showed that EngNT made from 
SCL4.1/F7 cells enhanced nerve regeneration when implanted into a rat model of sciatic 
nerve injury. Based on these promising results and the group’s experience with culturing 
SCL4.1/F7 cells, it was decided that this cell line would be a good starting point for the 
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current project. Additionally, it is a reliable, cost efficient and reproducible cell line 
which can be cultured to produce the large number of cells required for tissue 
engineering purposes. Further, it is a rat Schwann cell line and would avoid 
immunosuppression treatment in subsequent in vivo experiments.  
 
4.2.3 Lentiviral transduction resulted in eGFP expression 
 
SCL4.1/F7 cells were transduced with the lentiviral vector at a MOI of 1, 10 and 100 to 
determine the optimal ratio of viral particles to cells for efficient transduction. Research 
has shown that a MOI which is too low may result in insufficient gene transfer and 
transgene expression. On the other hand, a very high MOI may cause several copies of 
transgene to integrate into the chromosomes of the target cells, leading to 
chromosomal instability (Woods et al. 2003).  
 
Using fluorescence microscopy, eGFP expression was observed in the transduced cells 
48 hours post transduction and the number of eGFP positive cells continued to increase 
over the next 24 hours. No eGFP expression was seen in the control untransduced cells. 
As expected, the MOI of 100 resulted in the greatest proportion of eGFP positive cells 
(figure 31).  
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Figure 31. SCL4.1/F7 cells expressing eGFP 72 hours post transduction. Representative 
fluorescence micrographs of control untransduced SCL4.1/F7 cells and cells transduced with the 
lentiviral vector delivering luciferase and eGFP at MOIs of 1, 10 and 100. No fluorescence was 
observed in the control untransduced cells. A higher proportion of eGFP positive cells was 
observed with increasing MOI (n = 3 per group). Scale bar: 50 μm. 
 
            Control untransduced cells                          MOI 1 
 
          MOI 10                                                             MOI 100 
 
 
 
 
 
 
 
 
4.2.4 Establishing the transduction efficiency using flow cytometry 
 
After establishing that the SCL4.1/F7 cells were transduced using fluorescence 
microscopy, flow cytometry was used to determine the percentage of transduced cells, 
thus establishing the transduction efficiency for each MOI. To establish the background 
for fluorescence and to set gates for data acquisition, control untransduced cells were 
used. Two figures were generated for each MOI (figure 32). The first figure is a histogram 
which displays the relative fluorescence on the x-axis and cell count on the y-axis. The 
histogram shows the total number of cells in a sample which express the marker of 
interest, i.e., it shows the number of eGFP positive cells for each MOI. Fluorescent cells 
were identified by setting a minimum fluorescence value (thresholding) on the 
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histogram. By setting the threshold just to the right of the dimmest peak, cells to the left 
of the threshold were excluded from those counted as fluorescent. The second figure is 
a density plot or a plot of forward scatter. Each dot or point represents an individual cell 
that has passed through the instrument. Care was taken to analyse cells that were in the 
required gate as indicated by forward scatter characteristics. 
 
Figure 32. Flow cytometry analysis of eGFP expressing cells. Typical flow cytometry analysis 
data showing the proportion of eGFP positive and eGFP negative cells at the different MOIs. 
eGFP positive cells are shown in blue and eGFP negative cells are shown in red.   
 
Control untransduced cells 
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MOI 1  
 
 
MO1 10 
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MOI 100 
 
 
 
As expected from the fluorescence microscopy data (section 4.2.3), the percentage of 
eGFP positive cells increased with increasing MOI (figure 33). However, the increase in 
eGFP positive cells was not proportionate to the increase in MOI. A MOI of 1 resulted in 
an average of 4.57 % eGFP positive cells, while a MOI of 10 and 100 resulted in an 
average of 25.07 % and 82.17 % respectively.    
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Figure 33. Efficiency of lentiviral-mediated gene transfer to SCL4.1/F7 cells at increasing MOIs. 
a) The percentage of eGFP positive cells significantly increased with increasing MOI (one-way 
ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = <0.0001). b) A 
scatter plot of the mean value of the runs shown in a) with a line of best fit to represent the 
trend between MOI and percentage of eGFP positive cells. Each data point represents an 
individual flow cytometry run with 750 000 cells per sample (n = 3 per group). *p < 0.05, **p < 
0.01, ***p < 0.001 and ****p < 0.0001. 
 
   
 
4.2.5 Stability of eGFP expression 
 
To assess the stability of eGFP expression, cells transduced with a MOI of 100 were 
maintained in culture for 8 weeks (> 25 passages) and flow cytometry analysis was 
repeated. The mean number of eGFP positive cells decreased by around 1.3% (figure 
34). However, this change was not significant and indicated that eGFP expression 
remained stable during this period. Additionally, eGFP positive cells could be observed 
using a fluorescence microscope until the cells were discarded due to high passage 
number.  
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Figure 34. Stability of lentiviral mediated eGFP expression over an 8 week period. While slightly 
lower than at 72 hours after transduction, eGFP expression was not significantly lower at 8 
weeks post transduction (two-tailed unpaired T test, 95 % confidence interval, p value = 0.0108). 
Each data point represents an individual flow cytometry run with 750 000 cells per sample (n = 
3 per group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
4.2.6 Effect of transduction on cell viability, proliferation and 
morphology 
 
After establishing high-level gene expression in transduced SCL4.1/F7 cells, it was 
important to test whether lentiviral transduction resulted in cytotoxic effects as highly 
concentrated vesicular stomatitis virus G glycoprotein (VSG-V) pseudotyped lentiviral 
vectors have been previously reported to cause cytotoxicity (Castellani et al., 2010; 
Joglekar and Sandoval, 2017). In depth analysis was carried out by assessing cell viability, 
proliferation rate and morphology.  
 
Cell viability 
alamarBlue® was used to detect any changes in the metabolic activity of cells following 
transduction at MOIs of 1, 10 and 100.  Mitochondrial enzymes present in viable cells 
reduce resazurin (blue) present in alamarBlue® to resorufin (red). The extent of 
reduction is a reflection of cellular activity and can be quantified using absorbance 
(Rampersad et al., 2012). After 3 days, the percentage reduction of alamarBlue® in 
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control untransduced cells increased by an average of 36.73 %, whereas the percentage 
reduction of alamarBlue® in cells transduced with a MOI of 1, 10 and 100 increased by 
an average of 23.49, 24.95 and 27.98 % respectively (figure 35).   
 
Figure 35. Effect of transduction on cell viability. There was no significant difference between 
the groups on each day (two-way ANOVA, Tukey’s multiple comparison test, 95 % confidence 
interval, p value = >0.4111). However, the % reduction for all the groups was significantly higher 
on day 3 when compared to day 1 (p value = <0.0391).  Each point represents the percentage 
reduction by control cells and cells transduced with the different MOIs over 3 days, n = 6 per 
group. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
Proliferation 
BrdU is a synthetic thymidine analog that incorporates into the DNA of dividing cells 
during the S-phase of the cell cycle. The amount of BrdU incorporated into cultured cells 
can be quantified colorimetrically by ELISA and is a commonly employed method to 
assess cell proliferation (Vega-Avila and Pugsley, 2011). In the present study, a BrdU 
ELISA kit was used to assess whether lentiviral mediated gene delivery to SCL4.1/F7 cells 
had an effect on cell proliferation. Control untransduced cells had a mean absorbance 
of 0.84, while cells transduced with MOIs of 1, 10 and 100 had a mean absorbance of 
0.76, 0.75 and 0.74 respectively. This was equivalent to an approximately 1.12 fold 
difference in proliferation between the control untransduced cells and the transduced 
cells, irrespective of MOI. However, this difference did not prove to be significant (figure 
36).  
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Figure 36. Effect of lentiviral transduction on SCL4.1/F7 cell proliferation. Transduction with 
the lentiviral vector at different MOIs did not have a significant effect on proliferation (two-way 
ANOVA, Tukey’s multiple comparison test, 95 % confidence interval, p value = >0.9467). There 
was no significant difference between the transduced cells and the control untransduced cells 
(p value = >0.0939). Each data point represents the absorbance for control cells and cells 
transduced with different MOIs (n = 6 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Morphology  
Morphology is an important large-scale manifestation of the physiological state of cells, 
and is commonly used as a qualitative measure of toxicity (Pincus and Theriot, 2007). 
Morphology was observed using light microscopy and cell shape was analysed by 
measuring circularity with ImageJ (figure 37). Circularity is a normalised ratio of area to 
perimeter and was defined as 4π x (area/perimeter2). A circle has a circularity value of 1 
and lines have a circularity value of 0 (Hart et al., 2018). Control untransduced cells had 
a mean circularity factor of 0.36 while cells transduced with a MOI of 100 had a mean 
circularity factor of 0.38 (figure 37). 
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Figure 37. Effect of lentiviral transduction on SCL4.1/F7 morphology. a) Representative light 
microscopy images of SCL4.1/F7 control untransduced cells and SCL4.1/F7 cells transduced with 
a MOI of 100 at the same passage number (p 15). Scale bar: 150 µm. No gross changes in 
morphology were observed. b) The circularity factor was used to analyse morphology. No 
significant difference between the two groups was observed (two-tailed unpaired T test, 95 % 
confidence interval, p value = 0.8103). Each data point represents the mean circularity factor of 
40 cells from one image (n = 4 independent images for each group).  
                                                              
                    Control SCL4.1/F7 cells                                       Transduced SCL4.1/F7 cells 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 in vitro bioluminescence imaging 
 
In the field of tissue engineering, there is a need for methods that allow the monitoring 
of tissue engineered constructs noninvasively in vitro and in vivo. Bioluminescence 
imaging has been widely used for non-invasive and highly sensitive visualisation of 
implanted cell localisation, proliferation and migration in vivo (Hwang et al., 2014a). It is 
also a well-established method for monitoring cell viability (Peeters et al., 2015), using 
a luminometer or an in vivo imaging system (IVIS).  One of the aims of the current study 
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was to establish whether bioluminescence imaging can be used to monitor cell viability 
in EngNT used for peripheral nerve engineering. Prior to constructing EngNT, lentiviral-
mediated luciferase expression in 2D monolayers was studied to identify signal strength, 
luciferin kinetics, possible luciferin toxicity and stability of the luciferase signal over time 
and after cryopreservation.  
 
4.3.1 Lentiviral transduction resulted in luciferase expression 
 
The bioluminescence signal produced by SCL4.1/F7 cells in vitro was measured using an 
IVIS. The bioluminescence images were overlaid on black and white photographs of the 
well plates that were taken just before bioluminescence imaging, allowing the precise 
location of the light emission to be determined. The intensity of light emission was 
represented using a pseudo-colour scale, with red areas showing the highest amount of 
light emission and blue areas showing the least. A circular region of interest was drawn 
around each well on the well plates and the bioluminescence values were measured in 
absolute units of radiance (photons/sec/cm2/steradian). This unit refers to the photons 
per second of light that radiate in a unit area (1 cm2) and unit angle (1 steradian) and 
enables data comparison between different systems and experiments (Zinn et al., 2008).  
 
Control untransduced cells had a mean bioluminescence signal of 2.85 x 105 which was 
similar to the signal given by culture media only (1.36 x 105). As expected, the 
bioluminescence signal increased with increasing MOI. Compared to the control, cells 
transduced with MOIs of 1, 10 and 100 showed a 13.38, 114.48 and 547.18 fold increase 
in signal respectively. The signal emitted by the SCL4.1/F7 cells transduced with a MOI 
of 1 was not statistically different to the control untransduced cells (figure 38). Based on 
this data, together with the results generated from fluorescence microscopy, flow 
cytometry analysis and cell proliferation and viability assays described earlier, it was 
decided that a MOI of 100 will be used throughout the study.  
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Figure 38. Bioluminescence imaging of SCL4.1/F7 transduced with MOIs of 1, 10 and 100. a) 
Representative bioluminescence images of luciferase expressing SCL4.1/F7 transduced with 
different MOIs imaged 72 hours post transduction. A well containing media with no cells was 
used to determine the background bioluminescence. The rainbow pseudocolour scale was 
adjusted for all images. b) There was no statistical significance between the signal given off by 
the media only, the control untransduced cells and the cells transduced with a MOI of 1 (one-
way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = >0.9634). 
The bioluminescence signal increased with increasing MOI, with a MOI of 100 producing the 
strongest signal (p value = <0.0001). Each data point represents the average radiance measured 
in one well (n = 3 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 Adjusting the exposure time 
 
As exposure times using the IVIS  can range from 1 second to several minutes depending 
on signal stength, the cells were initially imaged for 5 minutes. However, the signal was 
extremely high and resulted in pixel saturation. The imaging time was reduced to 1 
minute and 10 seconds but this still resulted in saturation. The cells could only be imaged 
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for the minimal amount of time (1 second) to prevent saturation (figure 39). This was 
consistent with the high levels of transduction achieved as well as the strong viral 
promoter driving the expression of luciferase. 
 
Figure 39. Bioluminescence imaging of luciferase expressing SCL4.1/F7 cells to determine the 
optimal acquistion time. Bioluminescence images showing the signal emitted from SCL4.1/F7 
cells transduced with a MOI of 100 imaged for 1 second, 10 seconds, 1 minute and 5 minutes in 
triplicate. Saturated pixels were observed when the cells were imaged for more than 1 second. 
The rainbow pseudocolour scale was adjusted for all images (n = 3 wells for each group). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 Luciferin kinetics study 
 
In order to determine the kinetic curve and find the peak imaging time point for 
luciferase expressing SCL4.1/F7 cells in 2D monolayers in vitro, the cells were imaged for 
10 seconds every 5 minutes up to 40 minutes after the addition of luciferin.  The 
bioluminescence intensity was maximum immediately after luciferin addition and then 
decayed over time (figure 40). Five minutes after addition of luciferin, the signal had 
already decreased 1.8 fold. By 40 minutes, the signal had decreased 9.49 fold. Based on 
this data, it was decided that bioluminescence images would be acquired immediately 
after luciferin addition.  
Imaged for 5 minutes 
Imaged for 1 second 
Imaged for 10 seconds 
Imaged for 1 minute 
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Figure 40. Luciferin kinetic curve to determine peak signal time. The signal obtained 5 minutes 
after the addition of luciferin was significantly lower than the signal obtained immediately after 
luciferin addition (one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, 
p value = <0.0001). Each point represents the mean ± SD of three independent experiments (n 
= 3). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
                        
0 5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
0
2  1 0 0 8
4  1 0 0 8
6  1 0 0 8
T i m e  a f t e r  l u c i f e r i n  a d m i n i s t r a t i o n  ( m i n )
A
v
e
r
a
g
e
 r
a
d
i
a
n
c
e
 
(
p
/s
/
c
m
2
/
s
r
)
* * * *
 
 
4.3.4 Correlation between bioluminescence signal strength and cell 
number 
 
A suspension of cells was serially diluted into a 96-well plate and the bioluminescence 
intensity for a given volume of cell suspension was measured. The bioluminescence 
intensity increased proportionally with increasing cell numbers (figure 41). A strong 
linear correlation between number of cells and light emission was obtained (R2 = 
0.9972).  Bioluminescence imaging was able to detect at least 234 transduced SCL4.1/F7 
cells in vitro, illustrating the high sensitivity of bioluminescence imaging. This result was 
encouraging as it suggested that bioluminescence imaging would be suitable for 
monitoring luciferase expressing SCL4.1/F7 cells following implantation in vivo.  
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Figure 41. Quantitative correlation between signal strength and cell number.  a) Transduced 
SCL4.1/F7 cells were serially diluted in wells from 30000 to 234 cells/well and imaged. b) The 
correlation between mean radiance flux and cell numbers is indicated by the R2 values. Each 
point represents the mean ± SD of three independent experiments (n = 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5 Luciferin toxicity study 
 
Bioluminescence-mediated longitudinal monitoring requires the repeated 
administration of luciferin. It has been suggested that the build-up of oxyluciferin in long 
term imaging might cause oxidative damage to the cells. Further, as bioluminescence 
requires the presence of oxygen and ATP, repeated imaging may increase the energy 
requirements of the cells, leading to decreased growth (Tiffen et al., 2010). It was 
therefore decided to investigate the possible toxic effect of repeated luciferin 
administration on SCL4.1/F7 cells. Luciferase expressing SCL4.1/F7 cells in a 96-well 
plate were imaged daily over a 3 day period. Following imaging, the cells were washed 
with PBS and fresh media was added.  Additionally, the effect of repeated luciferin 
addition compared to a one off single administration was investigated.  For the latter 
Number of cells/ well 
30000       15000        7500         3750          1875           937            468            234           media only                                                                                                                                                                                                         
a) 
 
b) 
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experiment, luciferase expressing SCL4.1/F7 cells were plated in the same 96-well plate, 
but luciferin was only added on day 3.   
 
The bioluminescence signal increased over the three day period. By day 3, the signal had 
increased 1.81 fold, indicating that the cells were healthy and viable (figure 42). Further, 
the mean bioluminescence signal of these cells on day 3 was comparable to the signal 
observed in the cells which had received a single dose of luciferin on day 3, with means 
of 4.11 x 107 and 3.88 x 107 p/sec/cm2/sr respectively (figure 42). 
 
Figure 42. Investigating the effect of repeated and single luciferin addition on SCL4.1/F7 cells 
viability. a) The bioluminescence signal produced by cells subjected to repeated luciferin 
administration over a 3 day period was measured. The signal increased over the 3 days, with a 
significant increase observed between days 1 and 3 (one-way ANOVA, Tukey’s multiple 
comparisons test, 95 % confidence interval, p value = 0.0243). b) The bioluminescence signal of 
cells subjected to repeated luciferin addition was comparable to the signal observed in the cells 
which had received a single dose of luciferin on day 3 (two-tailed unpaired T test, 95 % 
confidence interval, p value = 0.6978). Each data point represents the bioluminescence signal 
obtained from one individual well (n = 4 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
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4.3.6 Monitoring the luciferase intensity over time  
 
In the current study, it was hypothesised that the inclusion of the luciferase gene in the 
lentiviral expression cassette will allow for longitudinal monitoring of the cells in the 
EngNT in vitro and in vivo. It was therefore essential to ensure that the bioluminescence 
observed reflects true luciferase expression and that luciferase activity does not 
diminish over time.  
 
Pseudotransduction has been described as a process that may lead to the expression of 
foreign proteins, without delivering integrating proviral DNA, and has been reported in 
several studies (Haas et al., 2000; Geering et al., 2011). Nash and Lever (2004) postulated 
that during the formation of a lentiviral vector particle, some protein is passively 
incorporated into the viral particle and transferred to the target cell, leading to an 
overestimation of transduction at early time points.  Gallardo et al. (1997) reported 
that VSG-S pseudotyped lentiviral vectors could result in pseudotransduction in the first 
5 days after infection. Similar results were also reported by Nash and Lever (2004). In 
order to investigate possible psuedotransduction in the current study, luciferase 
expressing SCL4.1/F7 cells were imaged 72 hours and 7 days after transduction. A similar 
bioluminescence signal was obtained at both time points, with means of 1.62 x 108 and 
1.65 x 108 p/sec/cm2/sr respectively (figure 43).  
 
In order to assess the stability of luciferase activity over an extended period of time, the 
transduced SCL4.1/F7 cells were cultured for 8 weeks (>25 passages) and imaged. While 
the signal after 8 weeks was 1.99 fold lower than at 72 hours after transduction, it was 
still approximately 275 fold higher than the control untransduced cells (figure 43). This 
indicated that although the signal had dropped, bioluminescence imaging could still be 
used to monitor cell viability.  
 
Transduced cells were frozen and used to replenish cell stocks when the passage 
number exceeded 25. Cells were frozen in 90% FBS and 10% dimethyl sulfoxide and 
stored in a cryogenic freezing container at -80 oC overnight and then transferred to -150 
oC for long term storage. Three months later, the cells were thawed and allowed to 
proliferate before imaging.  The signal produced by cells that had been cryopreserved 
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was similar to the signal produced 72 hours after transduction, with means of 1.45 x 108 
and 1.62 x 108 p/sec/cm2/sr respectively (figure 43). This indicated that cryopreservation 
did not have an effect on luciferase activity, eliminating the need to continually 
transduce new batches of cells.  
 
Figure 43. Evaluating the stability of luciferase activity over time and after cryopreservation. 
No significant difference in luciferase activity was observed 72 hours and 7 days after 
transduction (one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p 
value = 0.9979). While significantly lower at 8 weeks compared to 72 hours after transduction 
(p value = <0.0001), the signal was still significantly higher compared to control untransduced 
cells (p value = <0.0001). No statistical difference between the signal produced by cells which 
had been cryopreserved and the signal obtained 72 hours after transduction was observed (p 
value = 0.5090). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Engineered neural tissue 
 
Having established that SCL4.1/F7 cells could be transduced to high efficiency using a 
lentiviral vector and that robust gene delivery was possible without affecting cell 
viability, the transduced cells were used to construct EngNT used in peripheral nerve 
repair. Fluorescence stereoscopic microscopy was used to visualise the eGFP positive 
cells throughout the entire length and width of the EngNT (figure 44). Fluorescence was 
observed throughout the construct, indicating even distribution of the cells EngNT made 
from control untransduced cells did not display any fluorescence.  
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Figure 44. Stereoscopic fluorescence micrograph showing even distribution of eGFP positive 
cells throughout the entire length and width of the EngNT. EngNT constructed from a) 
transduced SCL4.1/F7 cells expressing eGFP and b) control untransduced SCL4.1/F7 cells. No 
fluorescence was seen in the EngNT made from control untransduced cells.  
 
 
 
 
 
 
 
 
 
 
Scanning confocal microscopy was used to observe the cellular architecture in the 
EngNT. SCL4.1/F7 cells in the EngNT were counterstained with DAPI and images were 
taken from a single plane through the constructs (figure 45). No eGFP signal was 
detected in the constructs containing control untransduced SCL4.1/F7 cells. This 
ensured that any eGFP signal that was detected in the transduced cells was not 
autofluorescence or background signal.  Colocalisation of cyan and green in the nucleus 
of many eGFP expressing SCL4.1/F7 cells was observed, indicating the presence of 
nuclear eGFP in addition to cytoplasmic eGFP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
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Figure 45. Lentiviral mediated eGFP expression in SCL4.1/F7 cells in EngNT. Representative 
confocal micrographs showing eGFP expression in transduced SCL4.1/F7 cells in EngNT. No eGFP 
expression was seen in control untransduced cells. eGFP expression is shown in green and DAPI 
as cyan (n = 3 for each group). Scale bar: 75 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to confirm that the eGFP distribution was uniform throughout the 3D 
constructs, a series of 20 images was taken through the depth of the constructs along 
the Z-axis (figure 46). The Z stack corroborated the images obtained from stereoscopic 
fluorescence microscopy, i.e. the cells were evenly distributed throughout the EngNT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
untransduced 
SCL4.1/F7 
cells 
 
Transduced 
SCL4.1/F7 
cells 
 
Merged eGFP DAPI 
Merged DAPI eGFP 
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Figure 46. Z- stack through EngNT containing SCL4.1/F7 cells expressing eGFP. eGFP expression 
was seen throughout the EngNT, indicating that the cells had distributed evenly trhuoght the 
construct.  eGFP  expression is shown in green and DAPI as cyan. Magnification, x20. Z-distance 
20 μm, step size 1 μm. 
 
 
4.5 Discussion 
 
This chapter described the results obtained from the lentiviral mediated gene delivery 
to SCL4.1/F7 cells. A lentiviral gene delivery mediated approach was used in this study 
for several reasons. Firstly and most importantly, a precedent for using lentiviral vectors 
has been set in clinical trials. Lentiviral vectors have been used in a range of successful 
gene therapy clinical trials for a number of conditions such as X-linked severe combined 
immunodeficiency (Hacein-Bey-Abina et al., 2010) and X-linked adrenoleukodystrophy 
(Cartier et al., 2009). Secondly, lentiviral vectors have broad species and cell tropism, 
allowing the transduction of different cell types with a potential application in peripheral 
nerve engineering.   Finally, lentiviral mediated delivery of therapeutic genes in animal 
models of peripheral nerve injury has been shown to improve regeneration (de Winter 
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et al., 2013). In fact, Hoyng et al. (2015b) suggested that lentiviral vectors are to be 
considered the current gold standard in experimental gene therapy for peripheral nerve 
injuries. Lentiviral vectors permit stable gene expression as transgenes integrate into 
the target cell genome (Nightingale et al., 2006). In the context of peripheral nerve 
regeneration, stable expression ensures a continuous provision of growth factors, thus 
maintaining the pro-regenerative environment needed for regeneration.  Additionally, 
this long-term expression may be beneficial when reporter genes have applications in 
longitudinal cell fate tracking in tissue engineering studies.   
 
Different generations of lentiviral vector systems have been produced due to the 
pathogenicity of the Human Immunodeficiency Virus-1, on which they are based. 
(Merten et al., 2016). A second generation lentiviral packaging system (Zufferey et al., 
1997) was used in this study. In this system, the lentiviral genome is modified and spread 
among three plasmids: the packaging plasmid, the transfer plasmid and the envelope 
plasmid (figure 47).  
 
Figure 47. Second generation lentiviral plasmids. Splitting the vector components into three 
plasmids means at least two recombination events are required to produce a replication-
competent lentivirus during vector production, which is highly unlikely. Additionally, this design 
has evolved to increase the transgene capacity size. Image taken from: Addgene – Lentiviral 
Guide. Available from: https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/. Accessed 
on 20th October 2018. 
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The envelope plasmid (pMD2.G) used in this study encodes the envelope protein VSV-
G.  This envelope protein is commonly used in many basic research applications as it 
permits very broad species and tissue tropism (Hastie et al., 2013). This is useful in the 
context of peripheral nerve engineering as cells of different origin have been used to 
improve regeneration in animal models of nerve injury (Bhangra and Busuttil, 2016). 
Additionally, VSV-G provides high stability, allowing for concentration of viral particles 
by centrifugation (Cronin et al., 2005).  
 
The packaging plasmid (pCMV-dR8.74) used in this study contains the structural Gag and 
Pol genes as well as the regulatory Rev and Tat genes (Dull et al., 1998). In order to 
create a safe and efficient vector system, viral genes that are not required for the 
production, transduction and integration of the vector were deleted in this plasmid (Kim 
et al., 1998). The Vif, Vpu, Vpr and Nef genes encode for proteins that are essential for 
efficient HIV-1 propagation/virulence in primary cells or in vivo (Rücker et al., 2004). 
Therefore, as these genes are only important for HIV as a pathogen, they are not present 
in second-generation lentiviruses to enhance safety (Schlimgen et al., 2016). 
 
The transfer plasmid contains the only genetic material transferred to the target cells 
and consists of the lentiviral backbone containing the transgene expression cassette 
flanked by elements necessary for reverse transcription and integration (Merten et al., 
2016).  Viral long terminal repeats facilitate integration of the transfer plasmid 
sequences into the host genome.  Second-generation transfer plasmids have a wildtype 
5'LTR, which requires the presence of the Tat gene on the packaging plasmid to work. 
The Psi packaging signal is placed immediately downstream of the 5’ LTR and is required 
for viral genomic RNA packaging as well as gene delivery efficiency (Kim et al., 2012).  In 
order to reduce safety concerns, Zufferey et al. (1998) proposed the use of self-
inactivating lentiviral vectors, which rely on a deletion in the U3 region of the 3′ LTR. This 
deletion prevents full-length viral RNA from being produced in target cells and minimises 
the risk of producing RCLs.  
 
The lentiviral vector used in the current study contained an expression cassette 
consisting of the ubiquitous spleen focus forming virus (SFFV) promoter driving the 
expression of the luciferase gene and the downstream eGFP gene. The luciferase and 
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eGFP reporters allow in vivo and in vitro monitoring of labelled cells as well as the 
analysis of transduction efficiency by flow cytometry. The woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE) was present after the genes since it has 
been shown to stabilise mRNA expression and enhance gene expression (Zufferey et al., 
1999). The bicistronic expression of two genes from the same promoter was provided 
by inclusion of the self-cleaving 2A element (figure 48) between the two genes.    This 
has been shown to allow for multigene products from the same vector (Szymczak et al., 
2004). The mechanism of 2A-mediated self-cleavage was described by Donnelly et al. 
(2001) and involves ribosome skipping from one codon to the next without the 
formation of a peptide bond. This is turn allows the synthesis of a discrete downstream 
translation product to proceed. 
 
Figure 48. Schematic representation of the mechanism of “self-cleaving” 2A peptides. 2A 
peptides are 18–22 amino acid - long viral oligopeptides that mediate “cleavage” of polypeptides 
during translation in eukaryotic cells. The term 2A refers to a specific region of the viral genome. 
Image taken from Liu et al. (2017).  
 
 
 
In the current study, lentiviral mediated gene delivery resulted in high level gene 
expression. Generally, the higher the MOI, the higher the efficiency of gene transfer and 
the level of gene expression. In the current study, the level of gene expression following 
lentiviral transduction increased with increasing MOI. However, this increase was not 
directly proportional (section 4.2.4).  in vitro experiments employing MOIs greater than 
1000 have still resulted in less than 100% of cells transduced (Hamaguchi et al., 2000), 
indicating the presence of unknown variables.  Theoretically, a MOI of 2 should result in 
every single cell experiencing two gene transfer events in a given transduction 
experiment. However, the efficiencies of transduction are lower than the theoretical 
outcomes and are thought to be influenced by factors such as target cell type, cell 
membrane composition and Brownian motion which allows the viral vector to reach the 
target cell (Zhang et al., 2004).   
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It was particularly important to establish the effect of transduction on cell viability and 
proliferation as a downstream application of the transduced cells was to use 
bioluminescence imaging to monitor the cells in EngNT. Therefore if transduction 
compromised viability and proliferation, the data generated by bioluminescence 
imaging would not be a true representation of the cell health in the EngNT. A reduction 
in cell viability following lentiviral transduction has been noted by some authors 
(Castellani et al., 2010). Maunder et al. (2017) suggested that the presence of the 
transgene may impact the metabolism and viability of the transduced cells.  Lee et al. 
(2004) reported that lentiviral vectors can cause a transient arrest at the S phase of the 
cell cycle in transduced cells, resulting in a marked decrease in proliferation of the cells. 
According to Millington et al. (2009), this effect is less likely to be observed if low MOIs 
are used. In the current study, lentiviral transduction did not have an effect on the 
viability or proliferation rate of SCL4.1/F7 cells irrespective of the MOI used (section 
4.2.6). This may be explained by the relatively low range of MOIs used, which is markedly 
lower than those reported in other studies (Mostoslavsky et al., 2005; Castellani et al., 
2010). Transduction of cells using lower MOIs may be preferable to decrease the risk of 
insertional mutagenesis and toxicity.  
 
As mentioned in section 2.1.2, Schwann cells are the principal mediators of nerve 
regeneration in the PNS. It is therefore desirable for nerve repair devices to contain a 
cellular component that can simulate the regenerative roles of Schwann cells (Johnson 
et al., 2013). While allogeneic or autologous Schwann cells may seem like an attractive 
choice, there are numerous disadvantages associated with their sourcing and culturing. 
Their harvesting requires invasive nerve biopsies (Gersey et al., 2017) while in vitro 
culture is laborious and time consuming due to their slow growth rate and potential 
overgrowth of fibroblasts over time (Jiang et al., 2012). Several models of immortalized 
Schwann cell lines, including JS‐1 (Kimura et al., 1990) and S16Y (Toda et al., 1994) have 
been used to study peripheral nerve regeneration (Geuna et al., 2016). However, it has 
been noted that Schwann cell lines tend to undergo rapid transformation and lose 
normal Schwann cell properties, such as myelination capacity at later passages (Porter 
et al., 1987) and the ability to downregulate their own growth (Eccleston et al., 1991).  
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The clonally derived diploid rat Schwann cell line SCL4.1/F7 developed by Haynes et al. 
(1994)  used in this study does not undergo rapid transformation and therefore retains 
some normal Schwann cell phenotypic properties. In order to prevent genetic instability 
and phenotypic drift, two frequently encountered problems with the use of cell lines 
(Geraghty et al., 2014), SCL4.1/F7 cells were frozen at the lowest passage number 
possible and used to replace stocks at regular intervals. However, while SCL4.1/F7 
cells are ideal for the current study, it must be noted that interpretation of results from 
these model cells cannot necessarily be extrapolated to represent Schwann cell 
behaviour more broadly. 
  
In vitro quantification of bioluminescence from luciferase expressing SCL4.1/F7 cells 
demonstrated a 547 fold increase in signal compared to the control untransduced cells 
(section 4.3.1).  According to Lim et al. (2009), a high expression level in vitro is required 
to ensure that the luciferase expressing cells can be imaged successfully in vivo. This was 
especially important in the current study as one of the aims was to demonstrate that 
luciferase expressing SCL4.1/F7 cells in EngNT implanted into a rat model of sciatic nerve 
injury can be monitored using an in vivo imaging system. Similar to eGFP expression, 
luciferase expression was demonstrated over an 8 week period in vitro, confirming long 
term gene expression (sections 4.2.5 and 4.3.6). A luciferin toxicity study (section 4.3.5) 
indicated that neither luciferin nor luciferase activity was detrimental to the health of 
transduced SCL4.1/F7 cells.  
 
The nerve autograft contains aligned Schwann cells which support and guide 
regenerating neurites from the proximal to the distal side of the repair site, and 
recreating this anisotropic 3D cellular architecture is the focus of much research in the 
area of peripheral nerve repair.  East et al. (2010) have shown that aligned astrocytes 
within a collagen gel can support and guide neuronal regeneration in vitro, and that 
aligned astrocyte gels can be stabilised through removal of interstitial fluid. Georgiou et 
al. (2013) applied this stabilisation technique to Schwann cell-populated collagen gels 
after cellular self-alignment, increasing cell and collagen density to a sufficient extent 
that tethering could be removed from the gels without subsequent loss of cell and 
matrix alignment. The resulting EngNT consisting of stable aligned cellular material 
guided regenerating neurons and was robust enough to withstand being rolled and 
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wrapped to form an implantable construct. In the current study, genetically modified 
SCL4.1/F7 cells were used to construct EngNT and stereoscopic fluorescence and 
confocal microscopy confirmed that cell distribution was uniform throughout the entire 
length and width of the EngNT. This suggests that EngNT can be constructed from 
genetically modified SCL4.1/F7 cells overexpressing factors required for nerve 
regeneration following injury. The presence of these factors may further increase the 
extent of regeneration currently supported by the cellular EngNT.   
 
4.6 Conclusion 
 
Fluorescence microscopy revealed that SCL4.1/F7 cells were successfully transduced by 
the lentiviral vector delivering luciferase and eGFP. Flow cytometry revealed that the 
greatest transduction efficiency (>80%) was obtained using a MOI of 100. Long term 
eGFP expression (8 weeks) was observed in vitro. No detrimental effects on cell viability, 
proliferation or morphology were noted following transduction. High luciferase 
expression was also observed in transduced cells and the cells could only be imaged for 
the minimum period of time to prevent signal saturation (1 second). Similar to eGFP 
expression, luciferase expression persisted over 8 week of in vitro culture. 
Cryopreservation was found to have no effect on luciferase expression. The genetically 
modified cells were used to construct EngNT used in peripheral nerve repair. 
Stereoscopic fluorescence and confocal microscopy confirmed that cell distribution was 
uniform throughout the entire length and width of the EngNT. No fluorescence was 
observed in EngNT made with control untransduced cells. This in vitro proof-of-concept 
study paves the way for a novel combination of tissue engineering and gene therapy. 
This is because the combination of nerve repair devices containing cells that overexpress 
neurotrophic of angiogenic factors could provide a microenvironment that enhances 
peripheral nerve regeneration after injury.  
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Chapter 5. Assessing cell viability in engineered neural 
tissue  
 
5.1 Introduction  
 
Results from the previous chapter showed that a lentiviral vector can be used to 
successfully deliver reporter genes to SCL4.1/F7 cells. One of the reporter genes 
delivered encoded firefly luciferase, an enzyme which catalyses the oxidation of luciferin 
in the presence of oxygen and ATP. This reaction produces oxyluciferin, a highly unstable 
compound that emits light upon relaxation to its ground state (Rowe et al., 2009). This 
emitted light peaks at 562 nm (Rice et al., 2001) and forms the basis of bioluminescence 
imaging, which detects visible light produced during the luciferase-mediated oxidation 
of luciferin by cells expressing luciferase (Sadikot and Blackwell, 2005). A major 
advantage of bioluminescence imaging is inherently low background, as mammalian 
cells and tissues do no emit endogenous light (Oudina et al., 2011). 
 
Although not directly translational to the clinic, bioluminescence imaging has become a 
popular method of imaging small animals in the research environment (Chen and 
Thorne, 2012). In fact, bioluminescence imaging has been applied in a range of 
preclinical studies including monitoring of transgene expression (Fan et al., 2011), 
progression of infection (Warawa and Lawrenz, 2014), tumor growth and metastasis 
(Giubellino et al., 2012), toxicology (Xu et al., 2013) and gene therapy (He et al., 2016).  
 
Another potential application of bioluminescence imaging is in tissue engineering (Bagó 
et al., 2013). Monitoring the distribution and viability of cells in tissue engineered 
constructs in vitro and in vivo is key to ensuring the success of tissue engineering 
strategies.  Most methods currently available to assess the number and distribution of 
viable cells within tissue engineered constructs have limited in vivo application as they 
require destruction of the sample and cannot be used for repeated monitoring. They 
may also not distinguish between implanted cells and host cells which can confound 
findings.  Additionally, the scaffold material may interfere with the assays used. 
Therefore, there is an increasing need for methods which can nondestructively and 
noninvasively assess the performance of tissue-engineered constructs (Close et al., 
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2011). This chapter describes the feasibility of bioluminescence imaging to monitor 
luciferase expressing SCL4.1/F7 cells in EngNT and to establish whether this technique 
is useful for studying cell survival and distribution in peripheral nerve engineering. This 
part of the study had the following aims: 
 
 To use bioluminescence imaging to monitor cell viability in EngNT in vitro. 
 To use bioluminescence imaging to monitor cell viability in EngNT following 
implantation in a rat model of sciatic nerve injury.  
 To determine how long the implanted cells survive in vivo.  
 
5.2 in vitro bioluminescence imaging 
 
Steady state imaging allows luciferase expressing cells to be imaged over time in order 
to determine if the signal increases or decreases, providing valuable information on cell 
survival and proliferation (Close et al., 2011). Longitudinal monitoring of lentiviral-
mediated luciferase expressing SCL4.1/F7 cells in EngNT in vitro was carried out non-
destructively using an IVIS bioluminescence imaging system. 
 
5.2.1 In vitro bioluminescence kinetics study 
 
The material of tissue-engineered constructs can influence the biodistribution kinetics 
of luciferin (Oudina et al., 2011). It is therefore important to carry out a kinetic study to 
determine the time at which light emission peaks. A series of imaging captures starting 
immediately after luciferin addition and then every 5 minutes for 30 minutes was taken 
using the IVIS and the signal emitted was quantified at each time point (figure 49). 
Similar to SCL4.1/F7 cells in monolayers, SCL4.1/F7 cells in the EngNT could only be 
imaged for 1 second to prevent signal saturation. The signal increased during the first 5 
minutes and then gradually declined over time. Although higher than immediately after 
the addition of luciferase, the signal after 5 minutes was not statistically different. 
However, based on this trend, it was decided that all subsequent readings would be 
taken 5 minutes after luciferin addition.  
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Figure 49. Kinetic profile of light emission following luciferin addition to EngNT. The graph 
shows a peak signal at 5 minutes which goes down steadily over the next 25 minutes. A statistical 
significance was seen between the signal obtained 5 minutes after addition and 25 minutes and 
30 minutes after addition (one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence 
interval, p value = <0.0201). No statistical significance was seen at any other time point (p value 
= >0.0515). Data presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2 Cell viability and proliferation assessment 
 
Bioluminescence imaging can be used to study cell viability, as the bioluminescence 
signal is dependent on the presence of ATP in metabolically active cells (Lomakina et 
al., 2015). In order to demonstrate the ability of bioluminescence imaging to measure 
cell viability in EngNT in vitro over time, changes in signal were evaluated by repeated 
imaging of EngNT over 10 days. Upon addition of luciferin, the light generated by the 
luciferase expressing SCL4.1/F7 cells was transmitted through the collagen hydrogel and 
was monitored externally using the IVIS. The imaging revealed signal throughout the 
entire EngNT, supporting previous observations about cell distribution obtained through 
stereoscopic fluorescence and confocal microscopy (section 4.4). As expected, no 
bioluminescence was emitted from EngNT made with control untransduced SCL4.1/F7 
cells.  When regions of interest were measured, a 1.69 fold increase in the 
bioluminescence signal was observed between days 0 and 1. However, this did not prove 
to be significant (figure 50). After this increase, the signal began to decrease and by day 
5 there was no significant difference between the signals obtained and the control. The 
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bioluminescence signal decreased from a mean of 1.01 x 109 p/s/cm2/sr on day 0 to a 
mean of 1.18 x 108 p/s/cm2/sr on day 10, equivalent to a 8.57 fold difference. 
 
Figure 50. Time-course of the in vitro cell viability of luciferase expressing SCL4.1/F7 cells in 
EngNT during 10 days of culture. a) Representative bioluminescent images of luciferase 
expressing and control SCL4.1/F7 cells in EngNT using the IVIS. The rainbow pseudocolour scale 
was adjusted for all images.  b)  The bioluminescence signals (p/s/cm²/sr) from luciferase 
expressing SCL4.1/F7 cells in EngNT. An increase in signal was observed on day 1, however, this 
was not statistically significant (Kruskal-Wallis test, Dunn’s multiple comparisons test, p value = 
>0.9999). Only the bioluminescence signals on days 0, 1 and 3 were significantly higher than the 
control (p value = >0.0008). The signal dropped to control level by day 5 (p value = >0.9999). 
Each data point represents the signal emitted from an individual EngNT (n = 4). *p < 0.05, **p < 
0.01, ***p < 0.001 and ****p < 0.0001. 
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5.3 Comparing bioluminescence imaging with cell viability 
assays 
 
Two cell viability assays, namely live-dead staining and the alamarBlue® assay, were 
compared to bioluminescence imaging in terms of their sensitivity in assessing cell 
viability in the EngNT. The assays used measured the integrity of three different cellular 
compartments, namely the cell membrane (live-dead staining), mitochondrial reducing 
agents (the alamarBlue® test) and the presence of ATP (bioluminescence imaging). Live-
dead staining is an endpoint approach and unlike the alamarBlue® assay and 
bioluminescence imaging, cannot be used for monitoring cell viability over time. 
 
The NUCLEAR-ID® blue/red cell viability reagent, which consists of a mixture of a blue 
fluorescent cell-permeable nucleic acid dye and a red fluorescent cell-impermeable 
nucleic acid dye, was used to determine the percentage of dead cells in the collagen gels 
by fluorescence microscopy (figure 51).  The percentage of dead cells on days 0 and 1 
was similar (≤20%). By days 3 and 5, the percentage of dead cells increased from a mean 
of 16.38% on day 0 to 27.191 and 41.15% respectively.  This was equivalent to a 1.7 and 
2.5 fold difference respectively. However, the percentage of dead cells on day 5 was still 
significantly lower than that observed in the collagen gels soaked in ethanol. Collagen 
gels were soaked in ethanol for 10 minutes to serve as a positive control, with a cell 
death of ≥80%.  
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Figure 51. Determination of the percentage cell death in collagen gels over a 5 day period. The 
percentage cell death was similar on days 0 and 1 (one-way ANOVA, Tukey’s multiple 
comparisons test, 95 % confidence interval, p value = 0.8438). Compared to day 0, the 
percentage cell death was significantly higher on day 3 (p value = 0.0055) and 5 (p value = 
<0.0001). The percentage cell death on day 5 was significantly lower than the positive control of 
ethanol soaked collagen gels (p value = <0.0001).  Each data point represents the percentage 
cell death in an individual collagen gel (n = 4 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The alamarBlue® assay was also used to assess the viability of the cells in the EngNT over 
a 5 day period. When incubated with viable cells, the reagent undergoes a colorimetric 
change from blue to pink in response to cellular metabolic reduction. The absorbance 
measured is proportional to the number of living cells respiring. Similar to the data 
obtained from bioluminescence imaging, there was an increase in cell viability between 
days 0 and 1. However, this increase was significant.  After day 1, the percentage 
reduction of alamarBlue® decreased steadily, indicating a decline in cell viability (figure 
52). Similar to the live-dead staining results, the cell viability on day 5 was still 
significantly higher than that observed in the EngNT soaked in ethanol. EngNT soaked in 
ethanol for 10 minutes served as a negative control.  A solution of 100% reduced 
alamarBlue® in DMEM (prepared by autoclaving for 15 minutes) was used as a positive 
control.  
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Figure 52. alamarBlue®  assay to assess cell viability in EngNT over a 5 day period. a) 
Representative images of alamarBlue® colour changes. Viable cells result in the reduction of 
alamarBlue®, which is accompanied by a colour change from blue to red. b)  alamarBlue®  
percentage reduction.  There was a significant increase in cell viability between days 0 and 1 
(one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = 
0.0008). The percentage reduction was significantly lower on day 5 compared to day 0 (p value 
= 0.0187), however it was still significantly higher than the percentage reduction seen in ethanol 
soaked EngNT (p value = <0.0001). Each data point represents the percentage reduction in 
alamarBlue® produced by the cells in an individual EngNT (n = 4). *p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001. 
 
                                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 in vivo bioluminescence imaging 
 
Physical defects caused by injury can result in the loss of specialised cells within tissues, 
compromising repair and impairing function. Cell-based therapies are being developed 
to promote repair and regeneration of damaged tissues. However, several obstacles, 
including low retention of transplanted cells, have been encountered and are a major 
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focus for improving cell-based therapy (Yang et al., 2013). Before moving onto clinical 
trials, the behaviour and mechanism of action of transplanted cells must be understood 
in vivo. Bioluminescence imaging can be used to provide repetitive, non-invasive and 
quantitative measurements of transplanted cells, providing information on cell survival, 
proliferation and migration over time in the same living subject (Close et al., 2011). 
Additionally, because of its high sensitivity, bioluminescence imaging has been recently 
applied to tracking cells in cellular constructs transplanted in live animals for tissue 
engineering purposes (Leferink et al., 2016). Having established that bioluminescence 
could be used to monitor cell viability in EngNT in vitro, it was decided to determine 
whether similar results would be obtained in vivo. 
 
5.4.1 In vivo kinetics study  
 
EngNT made from luciferase expressing SCL4.1/F7 cells was rolled and inserted into a 
silicone tube to form an implantable device which was used to repair a 10 mm gap in 
the rat sciatic nerve. A sequence of images was taken starting 10 minutes after 
intraperitoneal administration of luciferin and then every 10 minutes for 30 minutes in 
order to establish the optimal timing of imaging.  Badr et al. (2014) suggested that an 
incubation step of 5-15 minutes following intraperitoneal luciferin administration would 
allow its absorption through the peritoneum and result in a better tissue distribution. 
Data acquisition was also continued until 30 minutes after injection on days 3, 5 and 7 
post surgery.  Unexpectedly, a signal was not obtained on any of the days the animal 
was imaged (figure 53). The exposure time was increased from 5 to 10 minutes, but this 
did not have an effect on the signal produced.  
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Figure 53. No bioluminescence signal was obtained in the in vivo imaging study. 
Representative images showing that no signal was obtained throughout the course of the kinetic 
study following intraperitoneal injection of luciferin on a) day 1, b) day 3, c) day 6 and d) day 7. 
The rainbow pseudocolour scale was adjusted for all images (n = 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.2 Route of luciferin administration 
 
The optimal route of administration of luciferin should be determined for every in vivo 
bioluminescence imaging experiment as this can influence the bioluminescence signal 
(Badr et al., 2014). Intraperitoneal administration of luciferin is a popular choice for 
many researchers. However, following this route of injection, luciferin must be absorbed 
through the peritoneum and reach the luciferase expressing cells via the bloodstream. 
Variations in the rate of absorption can influence the signal and confound results 
(Keyaerts et al., 2008).  Further, luciferin may be inadvertently injected into the bowel, 
resulting in a weak or non-existent signal that may be misinterpreted as a negative result 
(Baba et al., 2007).  
 
a) 
b) 
a) b) 
c) d) 
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Subcutaneous injection of luciferin has been proposed as an alternative to 
intraperitoneal injection (Inoue et al., 2009; Khalil et al., 2013).  Khalil et al. (2013) 
suggested that subcutaneous injection may be preferable to intraperitoneal 
administration when weak signals are obtained or when greater precision is required.  
 
In the current study, luciferin was initially administered via intraperitoneal injection. 
However, no signal was obtained following this route of administration. It was then 
decided to inject luciferin subcutaneously in the thigh, close to the implantation site. 
Luciferin (15 mg/ml) in sterile saline solution was administered at a dose of 150 mg/kg 
for both routes. It was thought that a local injection would result in greater availability 
of the luciferin to the luciferase expressing cells. However, a signal was still not obtained 
(figure 54).  
 
Figure 54. Subcutaneous administration of luciferin did not result in a bioluminescence signal. 
Representative images showing that no signal was obtained throughout the course of the kinetic 
study following subcutaneous injection of luciferin on a) day 1, b) day 3, c) day 6 and d) day 7. 
The rainbow pseudocolour scale was adjusted for all images (n = 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
a) 
a) 
c) 
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c) d) 
  144 
 
5.4.3 Animal position 
 
Bioluminescence measurements can be affected by rotation of the sample as the 
detected photon emission depends on the angle the surface makes with the optical axis 
of the camera. Virostko et al. (2004) investigated the effect of subject positioning on 
bioluminescence measurements by imaging a constant emission bioluminescent bead 
implanted at a renal and hepatic site. Supine orientation was used as normal placement 
for hepatic bead imaging, whereas lateral orientation was used for renal imaging. At 
rotations of 50o from normal, the signal decreased to approximately a quarter compared 
to the normal measurement for renal beads. For hepatic beads, a 50o rotation resulted 
in intensity less than half of the normal measurement. This implies that the exact 
position of the subject relative to the camera must be carefully controlled and can result 
in signal variations that are not representative of the biological processes for which 
bioluminescence is being measured. As no signal was obtained when the animal was in 
the prone position, it was decided to image the rat in a lateral orientation. However, a 
signal was still not obtained (figure 55).  
 
Figure 55. Investigating the effect of animal positioning on bioluminescence imaging. A 
representative image showing that a bioluminescence signal was still not obtained when the rat 
was imaged in a lateral orientation.  
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5.5 ex vivo bioluminescence imaging  
 
It was thought bioluminescence imaging would be useful to monitor the survival of 
luciferase expressing SCL4.1/F7 cells in the nerve repair device in a rat model of sciatic 
nerve injury. However, a signal was not obtained throughout the in vivo imaging study, 
even after parameters such as the route of administration of luciferin and animal 
positioning were adjusted. This could be due to a number of biologic variables and 
imaging parameters which influence bioluminescence, such as the size and composition 
of the device, the thickness and optical properties of overlying tissue, perfusion and 
luciferin availability (Virostko et al., 2004).  
 
On day 8 of the in vivo imaging study, it was decided to cull the animal and explant the 
EngNT in the silicone tube. The explant was placed in PBS and imaged in a 6-well plate 
following the addition of luciferin. Even though confounding factors, such as the 
overlying tissue and luciferin availability, were removed a signal was not obtained (figure 
56). This indicated that the majority of the cells in the nerve repair device had not 
survived 8 days post implantation.  
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Figure 56. Ex vivo imaging of the nerve repair device 8 days post implantation. The nerve repair 
device was explanted and imaged ex vivo in a 6-well plate. Following the addition of luciferin, 
the device was imaged every 5 minutes for 30 minutes. A representative image showing that a 
signal was not obtained at any time point (n = 1).    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to establish whether cells survived at earlier time points, and to eliminate 
confounding factors, it was decided to repeat the experiment and explant and image the 
nerve repair device 1, 3 and 5 days post implantation. To ensure that the cells in the 
EngNT were viable on the day of implantation, a 2mm segment was cut from the EngNT 
prior to assembling the device and imaged. A high signal was obtained for all the 
segments (figure 57), indicating that the cells in the EngNT were healthy prior to 
implantation.  
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Figure 57. Segments cut from the EngNT prior to assembling the nerve repair devices. Groups 
1, 2 and 3 refer to segments removed from EngNT implanted to the animals and explanted and 
imaged ex vivo on days 1, 3 and 5 respectively. The cells in each segment emitted a high 
bioluminescence signal and no statistical difference between any of the groups was obtained 
(one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = 
>0.9235). Each data point represents the signal obtained from one segment in the different 
groups (n = 3 for each group).  
 
 
 
 
 
 
 
 
 
 
On day 1, bioluminescence imaging revealed that the signal obtained from the nerve 
repair devices explanted from the three rats varied greatly (figure 58). The highest signal 
was obtained 30 minutes after the addition of luciferase and ranged from 6.19 x 107 
p/s/cm2/sr in the EngNT explanted from rat 3, to 7.47 x 107 and 2.78 x 108 p/s/cm2/sr in 
the EngNT explanted from rat 1 and 2 respectively. This was equivalent to a 4.49 fold 
difference in bioluminescence intensity.  
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Figure 58. Ex vivo imaging of the explanted nerve repair devices and a representative control 
contralateral nerve one day post implantation. a) Bioluminescence images showing the emitted 
light immediately after the addition of luciferin up to 30 minutes after addition. The rainbow 
pseudocolour scale was adjusted for all images.  b)  The bioluminescent signals (p/s/cm²/sr) 
were plotted for each explant (n = 3). 
 
          Time after luciferin addition 
          Immediately  5 min       10 min        15 min       20 min        25 min       30 min 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
On day 3, the bioluminescence signal obtained from the EngNT explanted from the three 
rats varied greatly again (figure 59). The signal obtained 30 minutes after the addition 
of luciferase ranged from 1.63 x 107 p/s/cm2/sr in the EngNT explanted from rat 5, to 
2.83 x 107 p/s/cm2/sr and 4.03 x 107 p/s/cm2/sr in the EngNT explanted from rat 6 and 
4 respectively. This was equivalent to a 2.47 fold difference in bioluminescence intensity.   
 
Animal 1  
Animal 2  
Animal 3  
Contralateral 
a) 
b) 
  149 
 
Figure 59. Ex vivo imaging of the explanted nerve repair devices and a representative control 
contralateral nerve three days post implantation. a) Bioluminescence images showing the 
emitted light immediately after the addition of luciferin up to 30 minutes after addition. The 
rainbow pseudocolour scale was adjusted for all images.   b) The bioluminescent signals 
(p/s/cm²/sr) plotted for each explant (n = 3). 
 
             Time after luciferin addition 
             Immediately  5 min        10 min        15 min      20 min        25 min       30 min 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
On day 5, the signal obtained 30 minutes after the addition of luciferase ranged from 1 
x 106 p/s/cm2/sr in the EngNT explanted from rats 7 and 9, to 2.18 x 105 p/s/cm2/sr in 
the EngNT explanted from rat 8 (figure 60). This was equivalent to a 5.32 fold difference 
in bioluminescence intensity.  
 
 
 
 
Animal 4  
Animal 5  
Animal 6  
Contralateral 
a) 
b) 
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Figure 60. Ex vivo imaging of the explanted nerve repair devices and a representative control 
contralateral nerve five days post implantation. a) Bioluminescence images showing the 
emitted light immediately after the addition of luciferin up to 30 minutes after addition. The 
rainbow pseudocolour scale was adjusted for all images.   b)  The bioluminescent signals 
(p/s/cm²/sr) plotted for each explant (n = 3). 
 
     Time after luciferin addition                     
     Immediately  5 min       10 min         15 min        20 min       25 min        30 min  
 
 
 
   
  
 
 
 
 
 
 
 
The highest bioluminescence signal obtained 30 minutes after the addition of luciferin 
on day 1 was 2.78 x 108 p/s/cm2/sr. By day 5, the highest signal obtained had decreased 
to 2.18 x 105 p/s/cm2/sr, equivalent to a 1000 fold difference. As the kinetic study 
revealed that the highest signal was obtained 30 minutes after the addition of luciferin, 
the bioluminescence signal at 30 minutes obtained for each explanted nerve repair 
device and control contralateral nerve on different days post implantation was plotted 
(figure 61). Only the bioluminescence signal obtained from the nerve repair devices 
explanted on day 1 was significantly higher than the control nerves.  
 
Animal 7  
Animal 8  
Animal 9  
Contralateral 
a) 
b) 
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Figure 61.  The bioluminescence signals obtained 30 minutes after the addition of luciferin up 
to 5 days post implantation. Only the bioluminescence signal obtained from the nerve repair 
devices explanted on day 1 was significantly higher than the control nerve (two-way ANOVA, 
Tukey’s multiple comparisons test, 95 % confidence interval, p value = 0.0465). Each data point 
represents the signal obtained from each individual nerve repair device and contralateral nerve 
1, 3 and 5 days post implantation (n = 3 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
 
 
5.6 Fluorescence imaging  
 
As described in the previous chapter, the lentiviral expression cassette consisted of a 
gene encoding eGFP in addition to one encoding luciferase. As ex vivo bioluminescence 
imaging gave highly variable results, it was decided to investigate whether eGFP cells 
were present in the explanted nerve devices and to establish whether fluorescence 
microscopy data would reflect bioluminescence data.  
 
Following ex vivo bioluminescence imaging, the nerve repair devices were fixed and 
cryoprotected. The silicone tube was removed and the EngNT was subsequently placed 
in OCT compound. Transverse cryostat sections were cut from the proximal, middle and 
distal parts of the EngNT. Following mounting onto microscope slides, a Zeiss Axio Lab 
A1 fluorescence microscope at 20x magnification was used to directly visualise eGFP 
positive cells in predetermined areas in the sections.  A qualitative analysis revealed that 
eGFP positive cells were still visible on day 5 (figure 62), indicating the presence of live 
cells.  Sections through contralateral nerves were used a negative control, as no eGFP 
positive cells should be present. 
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Figure 62. Explanted EngNT contained eGFP positive cells. Representative images showing 
eGFP expressing cells at different positions in the explanted EngNT, 1, 3 and 5 days post 
implantation. A section from a control contralateral nerve is also shown, no eGFP expressing 
cells are seen (n = 3 for each day). Scale bar: 50 µm.  
 
                         Proximal EngNT                              Mid EngNT                             Distal EngNT 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7 Monitoring cell viability in the nerve repair device 
 
Following the results obtained in the ex vivo imaging study, it was decided to investigate 
the effect of the silicone tube on bioluminescence imaging. The first step was to 
determine whether the silicone tube attenuated the emitted light. EngNT was imaged 
immediately after the addition of luciferin, then rolled and inserted into a silicone tube 
and imaged again. In the absence of light attenuation, it was expected that the 
bioluminescence will continue to increase in the first 5 minutes after luciferin addition 
(section 5.2.1). Both measurements were taken within 2 minutes of each other and as 
Day 1  
Day 3 
Day 5 
Control contralateral nerve 
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can be seen in figure 63, the presence of the silicone tube did not attenuate the emitted 
light.   
 
Figure 63. The silicone tube in the nerve repair device did not attenuate the emitted light.  
While the signal emitted from the EngNT in the silicone tube appeared to be slightly, no 
statistical difference was observed between the two groups (two-tailed unpaired T test, 95 % 
confidence interval, p value = 0.6655). Each data point represents the signal emitted from an 
individual EngNT with and without a silicone tube (n = 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Having established that the silicone tube does not attenuate the emitted light, it was 
then decided to investigate whether the silicone tube influenced luciferin kinetics and 
impeded contact of luciferin with the cells in the EngNT (figure 64).  The highest signal 
(a mean of 8.73 x 108 p/s/cm2/sr) was obtained 30 minutes after the addition of luciferin. 
When imaging EngNT without a silicone tube, the highest signal was obtained 5 minutes 
after the addition of luciferin and had a mean value of 4.16 x 109 p/s/cm2/sr (section 
4.2.1). This was equivalent to a 4.77 fold difference in bioluminescence intensity. In 
addition to a lower bioluminescence intensity, another difference was observed 
between EngNT in a silicone tube and EngNT without a silicone tube. At the early time 
points, a bioluminescence signal was only seen at the ends of the EngNT in silicone 
tubes.  The bioluminescence signal in EngNT without a silicone tube was evenly 
distributed throughout the entire construct at all time points (image 50). The silicone 
tube has two open ends and this data indicated that the luciferin could only penetrate 
the EngNT though the ends, suggesting that the silicone tube does influence the 
penetration of luciferin.  
N
o
 s
i l
i c
o
n
e
 t
u
b
e
S
i l
i c
o
n
e
 t
u
b
e
0
2  1 0 0 9
4  1 0 0 9
6  1 0 0 9
8  1 0 0 9
A
v
e
r
a
g
e
 r
a
d
ia
n
c
e
 (
p
/s
/c
m
2
/
s
r
)
n s
  154 
 
Figure 64. Assessing the impact of the silicone tube on luciferin kinetics. a) Bioluminescent 
images showing the emitted light in 3 individual EngNT in silicone tubes up to 30 minutes after 
luciferin addition. The rainbow pseudocolour scale was adjusted for all images.  b)  The 
bioluminescent signals plotted for the EngNT in silicone tubes. The signal at 30 minutes was 
significantly higher than the signal obtained immediately after the addition of luciferin (Kruskal-
Wallis test, Dunn’s multiple comparisons test, p value = 0.0148). No other significant differences 
were observed (p value = >0.0510).  Data presented as the mean ± SD (n = 3). *p < 0.05, **p < 
0.01, ***p < 0.001 and ****p < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
EngNT 1                 EngNT 2               EngNT 3 a) 
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5.8 Discussion  
 
A major parameter of interest following implantation of tissue engineered constructs is 
tracking cell fate. Bioluminescence imaging has emerged as a valuable tool for 
monitoring cell populations in vivo and has been used to assess cell survival and 
proliferation in tissue engineered constructs (Logeart-Avramoglou et al., 20010; Hwang 
et al., 2014b). In the current study, the efficacy of bioluminescence imaging to monitor 
luciferase expressing SCL4.1/F7 cells in EngNT in vitro and in vivo was assessed.  
 
The survival of cells in 3D constructs may present a challenge when compared to culture 
in 2D monolayers (Ren et al., 2015). This is because the presence of the scaffold may 
influence oxygen and nutrient availability. Further, the size, thickness, and complexity 
of these models can complicate the monitoring of cell viability of cells inside the 
constructs (Goliwas et al., 2017). In the current study, cell viability in the EngNT in vitro 
was monitored by bioluminescence imaging, live-dead staining and the alamarBlue® 
assay. A decrease in cell viability in the EngNT over time was observed regardless of the 
method used.  However, some differences in the sensitivity of the methods was noticed. 
When bioluminescence imaging was used, the signal emitted by the cells in the EngNT 
was similar to the signal emitted by the negative control by day 5, suggesting that the 
majority of the cells were no longer viable. However, when live-dead staining and the 
alamarBlue® assay were used, a significantly higher number of viable cells compared to 
the negative control was observed on day 5. Further, while an increase in cell viability 
between day 0 and day 1 was noted in both bioluminescence imaging and the 
alamarBlue® assay, the increase was only significant in the latter. The reduced sensitivity 
of bioluminescence imaging was possibly attributed to the fact that only around 80% of 
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the cells in the EngNT expressed luciferase (section 4.2.4). As bioluminescence imaging 
depends on the emission of light by luciferase expressing cells, viable cells which did not 
express luciferase were not detected by the imaging system.   
 
It was thought that the relationship between emitted light intensity and the number of 
luciferase expressing cells would be useful for monitoring the survival of cells in the 
EngNT in vivo, as cell survival may be critical for achieving satisfactory regenerative 
outcomes. Further, a comprehensive literature review carried out in June 2018 revealed 
that a number of studies had reported the use of bioluminescence imaging to monitor 
cell survival in tissue engineered constructs implanted in live animals (table 16).  
 
As can be seen in table 16, limited persistence of the bioluminescence signal has been 
observed extensively, with several studies reporting signal attenuation within the first 
two weeks (Kutschka et al., 2006; Manassero et al., 2016; Speidel et al., 2017). However, 
this trend is unclear as Hwang et al. (2014b) reported an increase in signal in the first 3 
weeks period and Schmitt et al. (2013) reported that the signal persisted for 4 weeks.  
Interestingly, Takaku et al. (2014) reported that a bioluminescence signal was still 
obtained at 21 months.  It is important to note that simply quantifying the emitted light 
may not provide a true representation of cell viability in vivo. This is because the 
intensity of the bioluminescence signal is influenced by the number of metabolically 
active luciferase expressing cells, the concentration of luciferin, ATP and oxygen levels 
and the depth and optical properties of the tissue (Rice et al., 2001).  
 
Allen et al. (2014) found that lower cell doses (0.25 x 106 cells) survived better than high 
cell doses (2 x 106 cells) after 1 week. They suggest that following implantation, cells 
compete for nutrients and in the absence of an integrated vasculature, only a fraction 
of the implanted cells can be supported in vivo. Similar findings were described by 
Becquart et al. (2012). However, both authors reported that the signal decreased rapidly 
after 6-7 days irrespective of the cell number. Becquart et al. (2012) proposed that 
ischaemia in the core of the constructs resulted in cell death, leading to a reduced 
bioluminescence signal. However, they also suggested that other factors, such as cell 
migration, could have contributed to the reduced signal.  The likelihood of ischaemia 
increases in larger tissue engineered constructs (Gholipourmalekabadi et al., 2016).  
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However, while the authors cited in table 17 used constructs of varying sizes, it is not 
possible to compare the effect of construct size on the bioluminescence signal as 
different cell types, construct materials and implantation sites were used.   
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Table 17. Use of bioluminescence imaging to monitor cell survival in tissue engineered constructs implanted in live animals. 
 
Author Animal 
model 
Cell type and 
seeding 
density 
Scaffold 
material and 
size 
Implantatio
n site 
Dose of 
luciferin 
injected, 
route of 
injection 
and timing 
of imaging 
Exposure 
time and 
imaging 
protocol 
Imaging 
time points 
Vascularisati
on 
In vivo 
bioluminescence 
results 
Speidel et 
al., 2017 
Healthy mice Adult mouse 
cardiac stem 
cells; 3.5 x 
105 cells  
Poly(ethylen
e glycol) 
network 
cross-linked 
with 
heparin-
binding 
peptide; no 
information 
on size 
Myocardium 
 
10 μl per g of 
body weight; 
IP; 20 min 
before 
imaging 
No 
information 
given 
Days 0, 1, 3, 
7 and 14 
 
No 
information 
given 
Signal increased 
up to day 3 and 
decreased on days 
7 and 14. 
Manassero 
et al., 2016 
Immunodefi
cient NMRI 
mice 
Human 
BMSCs; 1 x 
106 cells 
Coral 
exoskeleton; 
3.5 x 2 mm 
cylinders 
Subcutaneou
s pocket in 
back and in a 
defect in the 
left femoral 
bone 
 
75 mg/kg, 
IM; no 
information 
given 
No 
information 
given; 
images were 
taken every 
3 min during 
a 40 min 
period 
Day 1, then 
twice a week 
for 5 weeks 
and then 
once a week 
for another 5 
weeks  
No 
information 
given 
85% signal 
decrease over the 
first 2 weeks in 
both locations. 
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Prins et al., 
2016 
Immunodefi
cient Balb/c 
mice 
Human and 
goat BMSCs; 
0.2 x 106 cells 
Hydroxyapat
ite or β-
tricalcium 
phosphate 
ceramics; 2-3 
mm 
Subcutaneou
s pocket in 
back 
 
2.5 mg; IP; 5 
min before 
imaging 
10 min Day 2 then 
weekly for 6 
weeks  
No 
information 
given 
Goat BMSCS – 
signal doubled 
after 1 week, 
declined to 60% of 
input after 3 
weeks and 
remained constant 
until week 6. 
Human BMSCs - 
constant signal 
decrease to 25% of 
input.  
Allen et al., 
2014 
Athymic 
nude rats 
Human 
BMSCs; 0.25, 
0.5, 1 or 2 x 
106 cells 
Alginate or 
agarose 
hydrogels in 
a PCL tube; 
12 x 5 x 1 mm  
Subcutaneou
s pocket in 
back 
300 µl; SC (2 
– 4mm from 
the implant 
site); 10 min 
before 
imaging  
10 sec; 
animals 
were imaged 
10, 20 and 30 
min post 
luciferin 
injection 
Days 0 and 7  Vascularisati
on was 
observed 
Decrease in signal 
on day 7. The 
survival efficiency 
of the cells was 
highest for the 
lower cell doses 
embedded within 
alginate matrix. 
Hwang et 
al., 2014a 
Sprague-
Dawley rats, 
immunosup
pressed with 
cyclosporine  
HB1.F3 
human 
neural stem 
cells 
transduced 
with a 
retroviral 
vector; 2 x 
106 cells 
Poly-L-lactic 
acid; no 
information 
on size 
Cavity in the 
corticectomi
zed rat brain 
0.6 mg, 
injected  
into the 
brain; no 
information 
given 
5 min; no 
information 
given 
Days 0, 1, 3, 
5, 8, 11 and 
14 
No 
information 
given 
Gradual increase 
in signal up to day 
8 followed by a 
dramatic decline 
after day 11.  
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Hwang et 
al., 2014b 
BALB/c nude 
mice 
HB1.F3 
human 
neural stem 
cells 
transduced 
with a 
retroviral 
vector; 0.5 x 
106 cells 
Gelatin-
polyethylene 
glycol-
tyramine 
hydrogel; no 
information 
on size 
Subcutaneou
s region in 
thigh 
150 mg/kg;   
IP; no 
information 
given 
5 min; 
animals 
were imaged 
for 90 min at 
5 min 
intervals 
Days 0, 8 and 
21 
No 
information 
given No 
information 
given 
Signal increased 
over the 21 day 
period. 
Takaku et 
al., 2014 
Wildtype 
Lewis rats 
Luciferase 
expressing 
synovial cells 
and 
chondrocyte
s from 
transgenic 
Lewis rats 
Chondrocyte 
and synovial 
cell sheets; 
no 
information 
on size  
Defect in the 
patellar 
groove of the 
femur 
150 mg/kg; 
SC; no 
information 
given 
No 
information 
given; 
animals 
were imaged 
at 1 min 
intervals for 
40 min 
Days 0 and 4, 
and at 3, 6, 
12, 18 and 21 
months 
No 
information 
given 
Signal peaked on 
day 4 then 
decreased over 
the first month, 
after which it 
stabilised at 
approximately 
1/10 of the 
intensity on day 0 
and persisted for 
21 months.  
Schmitt et 
al., 2013 
Rowett nude 
rats 
Human 
ADSCs; 1-2 x 
106 cells 
Decellularize
d cadaveric 
human 
flexor 
tendon 
grafts; 2 cm 
Subcutaneou
s pocket in 
back 
150 mg/kg;  
IP; 15 min 
before 
imaging 
 
No 
information 
given 
Days 7, 14, 
21 and 28 
Vascularisati
on of the 
construct 
observed 
after 4 
weeks in vivo 
Signal persisted for 
4 weeks. 
Yang et al., 
2013 
Sprague 
Dawley rats 
Rat ADSCs; 5 
x 106 cells 
Fibrin; no 
information 
on size 
Border of 
infarcted 
myocardium 
400 mg/kg 
luciferin; IP; 
no 
No 
information 
given; 
animals 
Days 1, 3, 7, 
14 and 28 
Vascularisati
on in the 
implanted 
Signal decreased 
during the first 
week. A plateau 
phase was 
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information 
given 
 
were imaged 
at 2 min 
intervals 
until peak 
signal 
occurred 
areas was 
observed 
observed between 
days 7-14. Further 
decline in signal on 
day 28, but still 
present.  
Becquart et 
al., 2012 
Nude mice Human 
immortalize
d 
multipotent 
stromal line; 
5 x 106, 1 x 
106, 1 x 105 
or 1 x 104 
cells 
Coral 
particles; 
600 – 900 
µm diameter  
Subcutaneou
s pocket in 
back 
50 µl; SC at 
the implant 
site; 
10 min 
before 
imaging 
No 
information 
given 
Days 1, 2, 6, 
9, 12 ,15, 21 
and 30  
Vascularisati
on was 
observed in 
the outer 
cells located 
in the outer 
regions of 
the 
constructs 
<1% of the initial 
cell numbers  
remained at 30 
days. 
Geuze et al., 
2010 
Immunodefi
cient BALB/c 
mice and 
nude 
Sprague 
Dawley rats 
Goat BMSCs; 
0.5 x 106, 1 x 
106 or 3 x 106 
cells 
Biphasic 
calcium 
phosphate 
porous 
particles; 2-3 
mm 
diameter 
Subcutaneou
s pocket in 
back (mice) 
and the 
spine (rats)  
125 mg/kg; 
IP; no 
information 
given 
10 min Day 1 and 
then weekly 
for 6-7 
weeks 
No 
information 
given 
Mice - From day 7 
to 21, signal 
increased 5.3-fold. 
After day 21, signal 
gradually 
decreased to a 
level 1.2-fold 
higher at day 42 
than at day 7.  
Rats - signal 
increased from 
day 1 to 7, after 
which it 
decreased. Signal 
decreased to 
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baseline on day 
21.  
Logeart-
Avramoglou 
et al., 2010 
Nude mice C3H10T1/2 
mouse 
embryonic 
stem cells 
transduced 
with a 
retroviral 
vector; 0.1 x 
106 cells 
AN69 
hydrogels 
(acrylonitrile 
and sodium 
methallyl 
sulfonate 
copolymer); 
diameter 6 
mm height  2 
mm or coral 
scaffolds; 
(3x3x3 mm3) 
Subcutaneou
s pocket in 
back 
50 µl; SC in 
the implant 
site; 10 min 
before 
imaging 
10 min Day 0 and 
then twice 
weekly for 8 
weeks 
No 
information 
given 
Signal during days 
3-6 decreased by 
approximately 
70% (AN69 
scaffold) and 80% 
(coral scaffold). 
Signal increased 
during the first 
week. The average 
final (at day 59) 
cell population 
was 2.5-fold 
higher than the 
initial seeding 
number for AN69 
scaffold. For coral 
scaffolds, a 12-fold 
increase at day 59 
was observed.  
Dégano et 
al., 2008 
Nude BALB/c 
mice  
Human 
ADSCs and 
human 
BMSCs; 2.5 x 
106 cells 
Arginine–
glycine–
aspartate 
crosslinked 
PEG 
hydrogel; no 
information 
on size 
Calvarial 
bone defect 
50 µl; SC in 
the implant 
site;  5 min 
before 
imaging 
5 min; 
animals 
were imaged 
at 5 min 
intervals for 
20 min 
Days 0, 7, 14, 
30, 45 and 90 
No 
information 
given 
A 63% drop in the 
number of the 
implanted BMSCs 
was observed and 
only 5% of the 
implanted ADSCs 
survived.   
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Olivo et al., 
2008 
Immunodefi
cient mice 
Goat BMSCs 
transduced 
by a 
retroviral 
vector; 0.05 
x 106, 0.125 x 
106, 0.25 x 
106, 0.5 x 106 
or 1 x 106 
cells 
Biphasic 
calcium 
phosphate; 4 
x 4 x 4 mm 
Subcutaneou
s pocket in 
back  
125 mg/kg; 
IP; no 
information 
given 
5 min; 
animals 
were imaged 
over a 20 
min period 
Day 1, 4, 11, 
18, 25, 32, 39 
and  46 
Blood 
vessels were 
present in 
and around 
the scaffold 
at day 46 
Until day 46, the 
signal continued to 
increase  
in the scaffolds 
seeded with 1, 0.5, 
0.25, and 
0.125 x 106 cells. In 
scaffolds seeded 
with 
0.05 x 106 cells, the 
signal 
progressively 
dropped to a 
background value. 
Kutschka et 
al., 2006 
Lewis rats, 
immunosup
pressed with 
cyclosporine  
Rat 
cardiomyobl
asts; 1 x 106 
cells  
Collagen or 
collagen with 
Matrigel; 
3×3×1 mm 
Infarcted 
myocardium 
400 mg/kg; 
IP; no 
information 
given 
5 min; 
animals 
were imaged 
8 times 
Days 1, 5 ,8, 
14 and 28 
Capillary in-
growth into 
the scaffold 
was 
observed 
Signal decreased 
during the first 8 
days. Signal in 
collagen graft 
reached 
background level 
on day 14. Signal in 
the collagen with 
Matrigel graft was 
detectable on day 
28.  
Abbreviations: ADSCs – adipose derived stem cells; BMSCs – bone marrow stem cells; IP – intraperitoneal; SC - subcutaneous 
 
All cells used in these studies expressed luciferase after transduction with lentiviral vectors unless stated otherwise. 
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As mentioned earlier, the efficacy of bioluminescence imaging can be influenced by 
several factors. This was particularly evident in the current study, as no bioluminescence 
signal was obtained in vivo, despite a very strong bioluminescence being obtained in 
vitro (section 5.2.1). It was thought that bioluminescence imaging was compromised by 
the exogenous and endogenous factors that will be discussed in this section. The impact 
of confounding factors in 2D monolayer systems is relatively limited and the 
bioluminescence signal tends to show a linear relationship with viable cell number. This 
has been reported by others (Kim et al., 2010) and was also observed in the current 
study (section 4.3.4).  However, in 3D tissue engineered constructs, bioluminescence 
imaging may be affected by luciferin transport kinetics and light scattering properties of 
the construct (Allen et al., 2014).  Further, following implantation, insufficient 
vascularisation of the newly implanted tissue engineered constructs may further 
confound bioluminescence imaging. These factors will be discussed below. 
 
The strength of the promoter driving the expression of luciferase in the transduced cells 
is an important consideration in bioluminescence imaging, as weak promoters may not 
produce sufficient luciferase. This is especially important for in vivo studies tracking cell 
fate since low levels of bioluminescence may not be detected (Chen and Thorne, 2012). 
The strength of the promotor can be predicted based on in vitro quantification of cell 
signal. The SFFV promoter used in the study has been shown to confer a strong 
transcriptional ability in a variety of cell types following lentiviral transduction (Gautam 
et al., 2016; Winiarska et al., 2017). In vitro, the transduced SCL4.1/F7 cells in 
monolayers and in the EngNT could only be imaged for the minimal amount of time (1 
second) to prevent saturation, indicating the production of a high level of luciferase. 
Despite the high levels of luciferase expression, bioluminescence imaging could not be 
used to monitor the cells following implantation as no signal was obtained. In addition 
to luciferase expression, efficient boluminescence imaging also depends on the 
availability of the luciferase substrate luciferin as well as oxygen.  
 
Cells implanted within tissue-engineered constructs may experience physiologically 
abnormal oxygen tension due to insufficient vascularisation following implantation 
(Muschler et al., 2004). As well as affecting oxygen availability, a lack of vascularisation 
may also affect the amount of luciferin reaching the luciferase expressing cells. Allen et 
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al. (2014) investigated the association between development of vasculature and 
bioluminescence signal 7 days following subcutaneous implantation of luciferase 
expressing human bone marrow stem cells in alginate constructs in athymic nude rats.   
They found that construct vasculature was significantly correlated to the 
bioluminescence signal obtained and suggested that a lack of vasculature may reduce 
the bioluminescence signal obtained by limiting luciferin and oxygen availability to the 
luciferase expressing cells. A significant association between vasculature and 
bioluminescence signal in 3D tissues has also been reported by Olivo et al. (2008) and 
Sekine et al. (2013). Further evidence supporting the importance of vascularisation in 
bioluminescence imaging came from a study by Levenberg et al. (2005), who compared 
the bioluminescence signal in pre-vascularised skeletal muscle grafts to muscle grafts 
without endothelial cells. They observed an increased bioluminescence signal in the pre-
vascularised samples that they suggested was due to increased perfusion, resulting in a 
higher amount of luciferin and oxygen reaching the luciferase expressing cells.  
 
A lack of vasculature has been implicated in the availability of luciferin, but the luciferin 
molecule itself is associated with a number of shortcomings in vivo, primarily relating to 
its low cell permeability (Shinde et al., 2006) and its heterogeneous tissue distribution 
(Berger et al., 2008).  Limited luciferin uptake in several tissues, including the brain (Lee 
et al., 2003, Berger et al., 2008), has been reported. Is it thought that the presence of 
the blood brain barrier prevented the entry of luciferin to the brain and limited the use 
of bioluminescence imaging (Mofford and Miller, 2015; Iwano et al., 2018). The blood 
brain barrier is a neurovascular unit essential for preserving CNS homeostasis. It is 
formed by highly specialised endothelial cells that interact directly with astrocytes, 
neurons and pericytes to regulate the movement of molecules, ions and cells between 
the blood and the CNS (Abbott, 2013). 
 
The presence of physical barriers preventing access of luciferin to the luciferase 
expressing cells is especially relevant in the current study. In the PNS, endoneurial 
microvessels are in direct contact with circulating blood, and form the blood-nerve 
barrier. The endoneurial microvessels share their basement membrane with pericytes 
and limit the diffusion of substances in and out of the endoneurium (Palladino et al., 
2017). A comprehensive literature search revealed that no researchers have yet 
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reported that the blood nerve barrier impeded the entry of luciferin. However, the 
blood nerve barrier is widely regarded as the second most restrictive microvascular 
barrier after the blood-brain barrier in mammals (Palladino et al., 2017), and 
therefore such an effect cannot be excluded. 
 
It was also decided to investigate whether the collagen hydrogel and the silicone tube 
used in the nerve repair device served as barriers to the entry of luciferin. Hwang et al. 
(2014b) suggested the mechanical strength of hydrogels used as cell scaffolds in tissue 
engineering applications may influence luciferin kinetics due to reduced permeability. 
The current study determined that the collagen hydrogel used did not affect 
bioluminescence imaging, as EngNT made from luciferase expressing SCL4.1/F7 cells 
could only be imaged for 1 second to prevent signal saturation, similar to luciferase 
expressing SCL4.1/F7 cells in monolayers. Further in vitro investigation revealed that the 
silicone tube influenced luciferin kinetics, resulting in an uneven distribution of luciferin 
in the EngNT leading to an inconsistent signal. Based on the pattern of bioluminescence 
signals obtained from the in vitro imaging of EngNT in silicone tubes (section 4.6), the 
luciferin entered the EngNT through the open ends of the silicone tube. This is an 
important consideration as small arteries and veins from neighbouring tissue space and 
muscular blood vessels run parallel along peripheral nerves in vivo (Gao et al., 2013a).  
A nerve repair device will consequently interrupt the vasculature and this can only be 
restored by angiogenesis. A lack of vasculature may therefore impede the entry of 
luciferin through the open ends of the silicone tube. It was therefore thought that a 
combination of the lack of vasculature and the impermeable nature of the silicone tube 
resulted in an insufficient amount of luciferin reaching the luciferase expressing cells in 
the EngNT.  
 
While Tögel et al. (2008) suggests that bioluminescence imaging has the distinct 
advantage of detecting only viable cells, a lack of bioluminescence signal is not 
necessarily indicative of cell death as photon emission is dependent on the availability 
of luciferin and oxygen. In the current study, a qualitative immunofluorescence analysis 
revealed that eGFP positive cells in the EngNT were still visible 5 days post implantation 
(figure 61). Therefore a correlation between bioluminescence imaging and fluorescence 
was not established in the current study. This is contrary to the results reported by 
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Dégano et al. (2008), who implanted 2.5×106 luciferase and eGFP expressing human 
bone marrow stem cells and adipose derived stem cells seeded in an arginine–glycine–
aspartate (RGD) crosslinked hydrogel scaffold in a mouse calvarial bone defect.  While 
no information on the vascularisation of the constructs was given, fluorescence 
microscopy revealed that eGFP positive cells were present throughout the light emitting 
implants, while few fluorescent cells were detected in implants that produced little or 
no light, in correlation with the in vivo BLI results.  
 
While the biomaterials used in tissue engineered constructs can affect the 
bioluminescence signal emitted by cells (Logeart-Avramoglou et al., 2010), Hwang et al. 
(2014a) used bioluminescence imaging to select the optimal biomaterials for tissue 
engineering purposes. They implanted 2x106 luciferase expressing human neural stem 
cells encapsulated within a poly-L-lactic acid scaffold and unencapsulated cells in a 
corticectomized rat model. Following implantation, the bioluminescence signal 
increased gradually up to 5 days without the scaffold, and up to 8 days with the scaffold. 
This was followed by a decline in the signal after 5 days without the scaffold, and after 
11 days with the scaffold. They related the increase in signal to cell proliferation and the 
decline in signal to cell death. They suggested that the decline in survival was because 
of the environment around the cortical lesion, where the implanted cells are subjected 
to immunological insults and a necrotic environment.  They postulated that the 
encapsulated cells survived longer as the scaffold protected them from the hostile 
environment.  
 
The final aim of this chapter was to determine how long the implanted cells survive in 
vivo. This was because a major goal of this study was to investigate whether EngNT 
made of SCL4.1/F7 cells overexpressing VEGF-A165 improved regeneration in a rat model 
of sciatic nerve injury. Cell survival is essential to ensure that the genetically modified 
cells are able to produce VEGF-A165 and potentially enhance regeneration. Although the 
data obtained from bioluminescence imaging suggested that cell death was prevalent 
from 3 days post implantation, fluorescence imaging revealed the presence of eGFP 
positive cells throughout the nerve repair device up to at least 5 days post implantation. 
Nishida et al. (2018) investigated the expression of VEGF-A following an inferior alveolar 
nerve transection in mice. They found that compared to an intact nerve, the level of 
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VEGF-A in the injured nerve started to increase one day post injury and reached its 
highest level on day 2.  VEGF-A levels began to decrease after day 3 and became 
undetectable by day 7. The authors suggest that VEGF-A is therefore crucial in the early 
stages of nerve regeneration and vascularisation. Based on the results obtained in this 
chapter and the observations made by Nishida et al. (2018), SCL4.1/F7 cells 
overexpressing VEGF-A165 should persist long enough to bring about a therapeutic 
effect.  
 
5.9 Conclusion  
 
A peripheral nerve injury often requires interventions to augment normal healing. Tissue 
engineered constructs containing therapeutic cells may offer an alternative to 
autologous nerve grafts for enhancing repair. However, the behaviour of implanted cells 
is still not fully understood. Such information is crucial for the optimal application of 
tissue engineering. To this end, gene-reporter technologies (involving, e.g., the labeling 
of cells with a bioluminescent reporter gene) are promising because they permit the 
noninvasive detection of cells in tissue engineered constructs. As seen from the results 
obtained in this chapter, bioluminescence imaging was not a suitable imaging 
modality for the current study and further work needs to be done to establish 
whether bioluminescence imaging is applicable to peripheral nerve tissue 
engineering. Specifically, work should be directed on enhancing vascularisation 
following implantation of nerve repair devices as well as selecting conduits with 
properties that mimic the natural epineurium.  Additionally, increasing vascularisation 
may lead to enhanced peripheral nerve regeneration and this will be the focus of the 
next chapters.  
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Chapter 6.  Lentivirus-mediated expression of VEGF-A165 
in SCL4.1/F7 cells: assessing in vitro effects 
 
6.1 Introduction  
 
An in vitro proof-of-concept study determined that SCL4.1/F7 cells were amenable to 
lentiviral transduction and that the transduced cells were still viable for the construction 
of   EngNT that can be used to enhance nerve repair (chapter 4). Transduction did not 
affect cell morphology, viability or proliferation and long term transgene expression was 
observed in the transduced cells.  It was initially thought the presence of the luciferase 
gene in the expression cassette would allow real-time and sustained imaging of the cells 
in the EngNT. Bioluminescence imaging provided an indication of the viability of the cells 
in EngNT in vitro but proved to be ineffective for in vivo imaging and yielded inconsistent 
data for ex vivo imaging. Further, a qualitative fluorescence study revealed the presence 
of the eGFP positive cells in explanted EngNT up to 5 days after implantation, revealing 
that bioluminescence imaging is not a suitable means of tracking cell fate in EngNT 
following implantation. 
 
In addition to tracking cell fate, another challenge in tissue engineering is the inability 
to adequately vascularise implants due to nutrient perfusion and mass transport 
limitations (Lovett et al., 2009). After implantation of tissue-engineered constructs, a 
spontaneous vascularisation of the implant is usually seen. However, this induced vessel 
ingrowth is often too slow to provide adequate nutrient transport to the cells in the 
interior of the transplanted tissue. Therefore, additional strategies for enhancing 
vascularisation are essential to ensure the survival of large tissue-engineered grafts as 
insufficient vascularisation can lead to improper cell integration or cell death 
(Rouwkema et al., 2008).  VEGF is a potent angiogenic factor that stimulates 
proliferation and migration of endothelial cells, formation of new blood vessels and 
enhances vascular permeability (Brockington et al., 2004). Additionally, VEGF increases 
axonal outgrowth, Schwann cell proliferation and Schwann cell invasion following injury 
(Sondell et al., 1999a; Haninec et al., 2012). As VEGF exhibits both angiogenic and 
neurotrophic properties, there has been an interest in the development of strategies for 
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delivering VEGF in peripheral nerve tissue engineering (Ma et al., 2014; Gnavi et al., 
2017).   
 
Based on the results obtained in the current study, it was hypothesised that a lentiviral 
vector could be used to deliver the VEGF-A165 gene to SCL4.1/F7 cells, which would then 
overexpress the protein. Once seeded in the EngNT, the VEGF-A165 overexpression could 
potentially encourage quicker vascularisation of the implant. Prior to implanting the 
EngNT containing the transduced cells into a rat model of sciatic nerve injury and 
assessing the effects on peripheral nerve regeneration, it was important to establish the 
functionality of the lentiviral vector expressing the VEGF protein produced in vitro as 
described in this chapter. The aims of this chapter were as follows:  
 
 To produce a lentiviral vector delivering the VEGF-A165 gene.  
 To transduce SCL4.1/F7 cells with the lentiviral vector and to confirm that the 
cells overexpress the VEGF-A165 protein.  
 To confirm the functionality of the VEGF-A165 protein produced by assessing its 
angiogenic and neurotrophic effects. 
 
6.2 Choice of the therapeutic gene  
 
The VEGF family consists of seven members, namely VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, VEGF-F and placental growth factor (Hoeben et al., 2004). VEGF-A is the single 
most important regulator of blood vessel formation (Holmes and Zachary, 2005) and will 
be discussed in greater detail. VEGF-A is a dimeric glycoprotein and is approximately 34-
42kDa in size (Hoeben et al., 2004). As shown in figure 65, alternative splicing of the 
human VEGF-A gene gives rise to at least six different transcripts, with monomers 
consisting of 121, 145, 148, 165, 183, 189 or 206 amino acids. A common VEGF 
homology domain consisting of a cysteine knot motif, participating in the formation of 
the disulfide bridges between the VEGF monomers can be observed in all VEGF family 
members (Hoeben et al., 2004).  
 
The VEGF-A gene encodes eight exons, of which the amino acids determined by exons 
1-5 and 8 are conserved in all VEGF-A isoforms. Exons 6 and 7 undergo alternative 
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splicing encoding two discrete heparin-binding domains (Hoeben et al., 2004). The 
presence or absence of the heparin-binding domains influences the solubility and 
receptor affinity of the proteins. VEGF-A121 is an acidic polypeptide that does not bind 
heparin and is thus freely diffusible. VEGF-A189 and VEGF-A206 are basic and bind to 
heparin with high affinity. As a result, they are almost completely bound in the ECM and 
do not diffuse (Houck et al., 1992). VEGF-A165 has intermediate properties, being both 
diffusible as well as having the ability to bind loosely to the heparin-containing 
proteoglycan receptors in the ECM (Park et al., 1993). Ferrara et al. (2003) suggested 
that VEGF-A165 is the isoform which exhibits the optimal bioavailability and biological 
potency and was therefore taken forward in this study. 
 
Figure 65. A schematic representing the structure of the VEGF-A gene. The VEGF-A gene 
contains 8 exons of which, through differential splicing, give rise to seven isoforms named after 
their amino acid lengths (VEGF-A 121, 145, 148, 165, 183, 189 and 206). An additional isoform, 
VEGF-A110, is produced by proteolytic cleavage by plasmin.  Taken from Hoeben et al. (2004).  
 
 
6.3 Cloning of the VEGF-A165 gene 
 
Having established that SCL4.1/F7 cells were successfully transduced using a lentiviral 
vector delivering marker genes, it was decided to insert the gene of interest, VEGF-A165, 
into a lentiviral transfer plasmid. The pro-angiogenic VEGF-A165 gene was supplied in an 
adenovirus, kindly provided by Professor Anna David (UCL Institute for Women’s 
Health). Professor David’s group has previously shown increased angiogenesis in a 
guinea pig model of foetal growth restriction following delivery of the adenovirus into 
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the uterine circulation (Swanson et al., 2016). The sequence of the VEGF-A165 gene used 
in this study is 576 base pairs (bp) in length and is as follows:  
 
5’ - ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTATGCCAAGTGGT 
CCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTGGTGAAGTTCAT
GGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGACATCTTCCAGGAGTA
CCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCCTGATGCGATGCGGGGGCTG
CTGCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTA
TGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCCTACAGCACAACAAA
TGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGCTCAGA
GCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCCTGCAAAAACACAGA
CTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGCAGATGTGACAAGCCGA
GGCGGTGA - 3’ 
 
6.3.1 The polymerase chain reaction 
 
PCR based cloning was used to amplify the VEGF-A165 gene in the adenovirus and to add 
restriction sites to each end to allow cloning into the transfer plasmid. Gel 
electrophoresis was used to detect the purified PCR product. Initial PCR conditions 
employing an annealing temperature of 60°C and using the neat concentration of the 
adenovirus resulted in a large and bright band in the 600 base pair region of the DNA 
ladder (figure 66).  
 
Figure 66. Gel electrophoresis image suggesting the presence of the VEGF-A165 gene. A 100 bp 
ladder was used with the 600 bp region highlighted in the image.  
 
  
 
 
 
 
 
 
 
100 bp ladder Potential 
VEGF-A165 
band 
600 bp 
region 
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However, this data was not reproduced during subsequent PCR runs. PCR optimisation, 
whereby the annealing temperature and the concentration of the template DNA were 
changed, was carried out. It is commonly suggested to use an annealing temperature of 
around 5-10oC below the melting temperatures of the primers as this increases the 
probability of primer binding. The forward and reverse primers had a melting 
temperature of 65.4 oC and 64.7 oC respectively. It was therefore decided to run the PCR 
reaction using an annealing temperature of 56 oC, 58 oC and 61 oC. Optimisation of 
template DNA concentration is required as high concentrations may increase the risk of 
nonspecific amplification whereas low concentrations result in poor yield. The 
adenovirus was serially diluted to generate 5 dilutions (10-1, 10-2, 10-3, 10-4, and 10-5) of 
the original template DNA. 
 
Using these conditions, no bands were observed for the annealing temperature of 61°C 
and for the 10-3, 10-4, and 10-5 dilutions of the original template DNA. A reproducible 
band was obtained when an annealing temperature of 56°C and a dilution of 10-1 was 
used (figure 67).  
 
Figure 67. Gel electrophoresis image deducing the optimum PCR conditions. The far left and 
right hand lanes were 100bp and 1Kb ladders, respectively, with the 600bp band highlighted. 
Lanes 1, 2 and 3 were PCR products ran at an annealing temperature of 58°C and using the 
original template DNA concentration, 10-1 and 10-2 dilutions, respectively. Lanes 4, 5 and 6 were 
PCR products ran at an annealing temperature of 56°C and using the original template DNA 
concentration, 10-1 and 10-3 dilutions respectively. The clearest band was seen in lane 5 
(annealing temperature of 56°C, 10-1 dilution) and hence the optimum condition. The bands 
towards the bottom of the gel were assumed to be primer dimers.   
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6.3.2 Inserting the VEGF-A165 gene into the pSFFV.IRES.eGFP transfer 
plasmid  
 
As the PCR reaction had introduced the BamHI and XhoI restriction enzyme sites on 
either end of the VEGF-A165 gene, the next step was to subclone the gene into the 
pSFFV.IRES.eGFP transfer plasmid, which also contained the same restriction enzyme 
sites. A double digest was set up both for the VEGF-A165 gene and pSFFV.IRES.eGFP 
transfer plasmid. This was followed by a ligation reaction to fuse the VEGF-A165 gene to 
the transfer plasmid, creating a recombinant plasmid.  
 
The ligation product was transformed into One Shot® Stbl3™ Chemically Competent E. 
coli cells. However, this did not result in the formation of colonies.  A positive control 
plasmid which was also transformed into the bacterial cells indicated that the 
transformation procedure had worked. This suggested that the ligation reaction had not 
resulted in a functional recombinant plasmid. The initial insert: vector ratio used for the 
ligation reaction was 5:1. As the insert:vector ratio can be modified to maximise the 
yield of the recombinant plasmid,  the ligation reaction was repeated using ratios of 1:1, 
3:1 and 7:1. However, these still proved to be unsuccessful.  
 
The initial subcloning approach did not result in the formation of a functional 
recombinant plasmid. It was therefore decided that VEGF-A165 gene together with the 
restriction enzyme sites on each end would be synthesised by Life Technologies Limited 
to facilitate the cloning process. The sequence generated for the synthesised gene is as 
follows:   
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TACGTAGGTACCGGATCCGCCACCATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCT
TGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGG
CAGAATCATCACGAAGTGGTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATC
GAGACCCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAGCCATCC
TGTGTGCCCCTGATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTGGAGTGTGTGCCCAC
TGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCAGCACATAGG
AGAGATGAGCTTCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGAC
AGAAAATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGAC
GTGTAAATGTTCCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACG
AACGTACTTGCAGATGTGACAAGCCGAGGCGGTGACTCGAGGTCGACAAGCTTTACGT 
 
6.3.3 Formation of the pSFFV.VEGF.IRES.eGFP transfer plasmid  
 
A double digest was set up for the synthesised VEGF-A165 gene and the pSFFV.IRES.eGFP 
transfer plasmid to produce a gene fragment and a linearised plasmid. This was followed 
by a ligation reaction that allowed the sticky ends of the insert and plasmid to stick 
together. An insert: vector ratio of 3:1 was used. The ligation mixture was transformed 
into competent bacteria and a single colony was isolated and used to generate a liquid 
bacterial culture. A diagnostic digest was carried out on purified plasmid DNA extracted 
from the bacterial culture.  The resulting fragments were then analysed by gel 
electrophoresis. Digestion with both BamHI and XhoI resulted in two bands: the 577 
base pair VEGF-A165 insert and the 10427 base pair plasmid (figure 68). 
 
Figure 68. Restriction digest analysis of the pSFFV.VEGF.IRES.eGFP plasmid using BamHI and 
XhoI. Lane 1 shows the 1kb ladder. Lane 2 shows the undigested pSFFV.IRES.eGFP plasmid. Lane 
3 shows the pSFFV.IRES.eGFP plasmid cut with BamHI. Lanes 4-6 show the digested 
pSFFV.VEGF.IRES.eGFP plasmid and the VEGF-A165 insert at roughly the 600bp mark. 
 
 
 
 
 
 
 
The 
VEGF-
A165 
insert 
1 kb 
ladder 1 2 3 4 5 
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Restriction digest analysis produced bands of the predicted sizes. Before proceeding 
with functional experiments, it was important to sequence the plasmid by automated 
Sanger sequencing in order to fully confirm the successful construction of the 
pSFFV.VEGF.IRES.eGFP plasmid. Sanger sequencing confirmed that the VEGF-A165 gene 
had been successfully cloned into the plasmid, creating a transfer plasmid which could 
be used to construct a lentiviral vector. A schematic of this plasmid is shown in figure 
69.  
 
Figure 69. Schematic of the pSFFV.VEGF.IRES.eGFP transfer plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VEGF-A165 
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6.3.4 Functionality of the pSFFV.VEGF.IRES.eGFP transfer plasmid 
 
Following sequencing of the pSFFV.VEGF.IRES.eGFP transfer plasmid, it was important 
to confirm that the plasmid was capable of expressing its transgenes and respectively 
encoded proteins. The plasmid was transfected into HEK293T cells, which are highly 
amenable to transient transfection by PEI (Aydin et al., 2012). Using fluorescence 
microscopy, eGFP expression was observed in the cells 48 hours post transfection (figure 
70). Cells transfected with the plasmid exhibited positive whole cell eGFP fluorescence, 
indicating functional transgene and downstream protein expression. No background 
eGFP expression was observed in untransfected control cells.  
 
Figure 70. eGFP expression in HEK293T cells following transfection with the 
pSFFV.VEGF.IRES.eGFP transfer plasmid. Representative fluorescence micrographs of control 
mock transfected HEK293T cells (left) and cells transfected with the pSFFV.VEGF.IRES.eGFP 
plasmid (right) resulting in eGFP expression 48 hours after transfection (n = 3 per group). Scale 
bar: 400 μm. 
 
                  Control mock transfected cells                                  Transfected cells  
         
                                      
 
 
 
 
 
 
After establishing that delivery of the plasmid resulted in eGFP expression, it was 
decided to transfect SCL4.1/F7 cells and quantify the VEGF-A165 produced using a 
commercially available ELISA kit. A significant fraction of VEGF-A165 produced by cells 
remains bound to the cell surface and the ECM, however, some is also secreted. (Ferrara 
et al., 1997).  In fact, cells transfected with cDNA encoding VEGF-A165 secrete bioactive 
VEGF-A165 into the medium (Park et al., 1993). It was therefore decided to measure the 
VEGF-A165 concentration in both the cell lysate and the cell media (figure 70).  
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The VEGF-A165 concentration was over 500 fold higher in the transfected cell lysate than 
in the control cell lysate. The VEGF-A165 concentration was almost 20 fold higher in the 
transfected cell media compared to the control cell media (figure 71).  The VEGF-A165 
concentration was normalised to total protein concentration, determined by a BCA 
assay (figure 71).  A higher percentage of VEGF-A165 protein was found in the transfected 
cell lysate compared to the control cell lysate and transfected cell media compared to 
the control cell media.  
 
Figure 71.  Quantifying the amount of VEGF-A165 produced by transfected HEK293Tcells. a) The 
VEGF-A165 concentration in the lysate and media of control and transfected cells as determined 
by ELISA. A statistical significance was found between the transfected and control cell lysate 
(Kruskal-Wallis test, Dunn’s multiple comparisons test, p value = 0.0087) as well as the 
transfected and control cell media (p value = 0.0087). b) VEGF-A165 concentration normalised to 
total protein concentration.  A statistical significant was found between the transfected and 
control cell lysate (Kruskal-Wallis test, Dunn’s multiple comparisons test, p value = 0.0003) as 
well as the transfected and control cell media (p value = 0.0005). Each data point represents the 
mean of duplicate wells evaluated for VEGF-A165 concentration and VEGF-A165: total protein 
concentration (n = 7 per group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
 
 
6.4 The lentiviral vector delivering the VEGF-A165 gene 
 
As a result of in vitro confirmation of the pSFFV.VEGF.IRES.eGFP transgene expression 
capability, the plasmid was used to produce a bicistronic second generation lentiviral 
vector for subsequent testing. The lentiviral vector contained an expression cassette 
consisting of the SFFV promoter driving the expression of the VEGF-A165 gene and the 
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downstream eGFP gene (figure 72). Similar to the lentiviral vector described in chapter 
4, this vector also had a WPRE present after the genes to enhance gene expression 
(Zufferey et al., 1999). The bicistronic expression of two genes from the same promoter 
was provided by inclusion of an internal ribosomal entry site (IRES) element between 
the two genes. The IRES sequence mediates protein synthesis of the second gene 
product from an internal translational starting site within a single mRNA transgene (Yu 
et al., 2003). The lentiviral vector was found to have a high titre of 1.9x 109 vp/ml using 
a P24 ELISA.  
 
Figure 72. Schematic of the lentiviral vector delivering the VEGF-A165 gene. LTR – long terminal 
repeats; RRE – Rev response element; SFFV - spleen focus forming virus; Luc – luciferase; 2A – 
self cleaving element; eGFP enhanced green fluorescent protein; WPRE - woodchuck hepatitis 
virus post-transcriptional regulatory element. 
 
To confirm the production of a functional lentiviral vector, SCL4.1/F7 cells were 
transduced at a MOI of 100. Using fluorescence microscopy, eGFP expression was 
observed in the transduced cells 48-post transduction and the percentage of eGFP 
positive cells continued to increase over the next 24 hours. No eGFP expression was 
seen in the control untransduced cells (figure 73). While an IRES sequence has the 
capacity to specify translation of the second gene from a bicistronic transcript, Sugimoto 
et al. (1995) reported that in several cases, only the gene transcribed upstream of the 
IRES element is expressed strongly. This was not observed in the current study, as whole 
cell eGFP fluorescence was observed following both plasmid transfection and lentiviral 
transduction.  
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Figure 73.  eGFP expression following lentiviral transduction. Representative fluorescence 
micrographs of control untransduced SCL4.1/F7 cells (left) and cells transduced with the 
lentiviral vector delivering VEGF-A165 and eGFP (right) resulting in eGFP expression 72 hours after 
transduction (n = 3 per group). Scale bar: 400 μm. 
 
          Control untransduced cells                                                 Transduced cells 
 
 
 
 
 
 
 
 
 
6.4.1 Transduction efficiency  
 
After establishing that the SCL4.1/F7 cells were transduced using fluorescence 
microscopy, flow cytometry was used to determine the transduction efficiency as 
described in section 3.6.1. This showed that over 80% of the transduced cells were eGFP 
positive. An insignificant number of eGFP positive cells was observed in the control 
samples (figure 74). 
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Figure 74. Efficiency of lentiviral-mediated gene transfer to SCL4.1/F7 cells. There was a 
significantly higher percentage of eGFP positive cells in the transduced cell population 
than in the control cells (two-tailed unpaired T test, 95 % confidence interval, p value = 
<0.0001).  Each data point represents an individual flow cytometry run with 750 000 
cells per sample (n = 4 for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001. 
 
  
 
 
 
 
 
 
 
 
 
 
6.4.2 VEGF-A165 overexpression following transduction  
 
The protein expression of VEGF-A165 following lentiviral transduction was examined by 
Western blot analysis (figure 75). Densitometry analysis using ImageJ software was used 
to quantify the size of the bands. A very low constitutive production of VEGF-A165 was 
observed in the control untransduced cells. This was expected as VEGF-A165 is expressed 
and secreted at low physiological levels by most normal cells (Shellman et al., 2003). The 
expression of VEGF-A165 was increased over 9 fold in the transduced cells compared to 
the control cells (figure 75).  
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Figure 75. Western blot analysis of VEGF-A165 levels in SCL4.1/F7 cells following transduction 
compared to endogenous VEGF-A165 in untransduced cells. a) Densitometric quantification of 
VEGF-A165 bands normalised against the β-tubulin loading control and expressed as signal 
intensity. A significantly higher signal intensity was detected in the transduced cells compared 
to the control cells (two-tailed unpaired T test, 95 % confidence interval, p value = <0.0031).  b) 
The 45 kDa band represents VEGF-A165 protein and the 50 kDa band represents the β-tubulin 
loading control (n = 1 blot with 4 samples per group). *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
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After establishing that VEGF-A165 was overexpressed in transduced cells, the 
concentration of the protein was measured using an ELISA kit. The VEGF-A165 
concentration was over 100 fold higher in the transduced cell lysate than in the control 
cell lysate. The VEGF-A165 concentration was over 4000 fold higher in the transduced cell 
media compared to the control cell media. Furthermore, it was noted that the VEGF-
A165 concentration in the transduced cell media was 2.5 fold higher than in the 
transduced cell lysate (figure 76).   The VEGF-A165 concentration was normalised to total 
a) 
Transduced cells  Control cells 
b) 
VEGF-A165 (45 kDa) 
β-tubulin (50 kDa) 
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protein concentration, determined by a BCA assay (figure 76).  A higher percentage of 
VEGF-A165 protein was found in the transduced cell lysate of compared to the control 
cell lysate and transduced cell media compared to the control cell media.  
 
Figure 76. Quantifying the amount of VEGF-A165 produced by SCL4.1/F7 cells transduced by the 
lentiviral vector delivering VEGF-A165. a) The VEGF-A165 concentration in the lysate and media of 
control and transduced cells as determined by ELISA. A statistical significance was found 
between the transduced and control cell lysate as well as the transduced and control cell media 
(one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = 
<0.0001). The amount of VEGF-A165 in the transduced cell media was significantly higher than 
that in the transduced cell lysate (p value = <0.0001). b) VEGF-A165 concentration normalised to 
total protein concentration.  A statistical significance was found between the transduced and 
control cell lysate (one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence 
interval, p value = 0.0420) as well as the transduced and control cell media (p value = <0.0002). 
Each data point represents the mean of duplicate wells evaluated for VEGF-A165 concentration 
and VEGF-A165: total protein concentration (n = 3 for each group). *p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001. 
 
 
 
 
6.4.3 Effect of transduction on proliferation and morphology  
 
After establishing high-level gene expression in transduced SCL4.1/F7 cells, it was 
important to test whether the overexpression of VEGF-A165 resulted in cytotoxic effects. 
Previous experiments in section 4.2.6 showed that transduction with the lentiviral 
vector delivering luciferase and eGFP did not have any adverse effects on the cells and 
therefore cells transduced by this lentiviral vector were used as a control.  
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Proliferation  
A BrdU ELISA kit was used to assess whether lentiviral mediated VEGF-A165 delivery to 
SCL4.1/F7 cells had an effect on their proliferation. BrdU is a pyrimidine analog which is 
incorporated into the newly synthesized DNA of proliferating cells in place of thymidine. 
The incorporated BrdU can be detected by anti-BrdU antibody. A horseradish 
peroxidase-conjugated secondary antibody is then used to detect the anti-BrdU 
antibody bound to BrdU, followed by the addition of a horseradish peroxisade substrate. 
The extent of colour development is proportional to the quantity of BrdU incorporated 
into the cells and can be used directly as an indicator of cell proliferation (Vega-Avila and 
Pugsley, 2011). SCL4.1/F7 cells overexpressing VEGF-A165 proliferated 1.5 fold more than 
untransduced cells and cells expressing luciferase and eGFP (figure 77). This suggested 
that the increase in proliferation was not due to the transduction process, but rather 
due to the effect of VEGF-A165 overexpression.  
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Figure 77. VEGF-A165 overexpression resulted in a significant increase in SCL4.1/F7 cell 
proliferation. Cell proliferation in untransduced cells and cells transduced by a lentiviral vector 
delivering VEGF-A165 was measured using a BrdU ELISA. Cells transduced by a lentiviral vector 
delivering luciferase and eGFP were used as a control to ensure that the increased cell 
proliferation was not due to the transduction process.  A significant difference in proliferation 
rate was observed between the cells overexpressing VEGF-A165 and the untransduced cells (one-
way ANOVA, Tukey’s multiple comparison test, 95 % confidence interval, P value = 0.0002) as 
well as between the cells overexpressing VEGF-A165 and cells expressing luciferase and eGFP  (p 
value = <0.0001). No significant difference was observed between the untransduced cells and 
the cells expressing luciferase and eGFP (P value = 0.3770). Each data point represents the mean 
of duplicate wells evaluated for absorbance at 450 nm (n = 6 for each group). *p < 0.05, **p < 
0.01, ***p < 0.001 and ****p < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphology 
Morphology was observed using fluorescence microscopy and cell shape was analysed 
by measuring circularity with ImageJ (figure 78). Control untranduced SCL4.1/F7 cells 
and SCL4.1/F7 cells overexpressing VEGF-A165 were immunolabelled with S100 
antibodies to delineate the cell shape. Circularity was defined as 4π x (area/perimeter2). 
Transduction with a lentiviral vector delivering luciferase and eGFP did not have an 
effect on cell morphology (chapter 4) and so any differences in cell morphology could 
be attributed to VEGF-A165 overexpression. While the transduced SCL4.1/F7 cells 
appeared to be less rounded than the control cells, statistical analysis revealed that 
overexpression of VEGF-A165 did not influence the morphology of SCL4.1/F7 cells.  
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Figure 78. Effect of VEGF-A165 overexpression on SCL4.1/F7 morphology. Immunofluorecence 
staining revealed that the majority of the cells were S100-positive. However, a percentage of 
the cells did not express the protein, suggesting the presence of a potentially mixed population 
of cells. a) Control untransduced cells and cells overexpressing VEGF-A165 were immunostained 
to detect S100 (red) to allow visualisation of the cells. Cells were also counterstained with DAPI 
(blue). No gross changes in morphology were observed. Scale bar = 50 µm. b) The circularity 
factor was used to analyse morphology. No significant difference between the two groups was 
observed (two-tailed unpaired T test, 95 % confidence interval, p value = 0.4702). Each data 
point represents the mean circularity factor of 10 cells from one image (n = 10 cells from 4 
independent images for each group).  
 
             Control SCL4.1/F7 cells                            SCL4.1/F7 cells overexpressing VEGF-A165                                                                                                   
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6.5 Testing the functionality of the lentiviral expressed VEGF-
A165 protein  
 
6.5.1 Angiogenesis assays  
 
Angiogenesis is the process by which new vessels are made from existing vessels. During 
angiogenesis, endothelial cells begin to proliferate, migrate and undergo tubulogenesis 
to form functional vessels. Numerous in vitro assays have been developed to help 
understand the individual steps in this complex process. Despite significant progress in 
the field, none of the assays successfully recapitulates the complexity of angiogenesis 
and researchers must rely on the selection of multiple assays (Irvin et al., 2014). 
Therefore, in order to investigate the angiogenic behaviour of the VEGF-A165 produced 
in this study, a number of assays which mimic different steps in angiogenesis were 
chosen and will be discussed in this section. 
 
6.5.1.1 Endothelial cell viability assay  
 
In adults, endothelial cells in blood vessels tend to exist in a quiescent state. However, 
they are able to respond to pro-angiogenic cues and begin to proliferate and migrate. 
This angiogenic switch is accompanied by an increased metabolic state (Zecchin et al., 
2017). In order to establish whether the VEGF-A165 produced had an effect on 
endothelial cell viability, alamarBlue® was used to detect changes in the metabolic 
activity of HUVECs following a 72 hour incubation period with the test media described 
in section 3.11.  
 
While a 1.4 fold increase in cell viability was observed in cells incubated with  diluted 
conditioned media from transduced SCL4.1/F7 cells compared to diluted conditioned 
media from untransduced SCL4.1/F7 cells, this difference did not prove to be significant 
(figure 79).  No difference in cell viability was observed between diluted conditioned 
media from transduced SCL4.1/F7 cells compared to media containing recombinant 
VEGF-A165 protein or EGM used as positive controls.  
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Figure 79. Effect of VEGF-A165 on endothelial cell viability. No significant increase in 
alamarBlue® reduction was observed between HUVECs  incubated with  diluted conditioned 
media from transduced SCL4.1/F7 cells and those incubated with conditioned media from 
untransduced SCL4.1/F7 cells (Kruskal-Wallis test, Dunn’s multiple comparisons test, p value = 
>0.9999). No difference in cell viability was observed between diluted conditioned media from 
transduced SCL4.1/F7 cells compared to media containing recombinant VEGF-A165 protein or 
EGM (p value = >0.7114). The only statistical difference observed was between the DMEM 
negative control and the diluted conditioned media from transduced SCL4.1/F7 cells and media 
containing recombinant VEGF-A165 protein (p value = <0.0094). Each data point represents the 
percentage reduction by HUVECs in wells (n = 5 wells for each group). *p < 0.05, **p < 0.01, ***p 
< 0.001 and ****p < 0.0001. 
 
 
 
 
 
 
 
 
  
 
 
 
 
6.5.1.2 Scratch wound assay  
 
Since cell migration is one of the major processes underlying angiogenesis, it was 
decided to assess the effect of the VEGF-A165 produced on the migration of HUVECs, as 
measured by the scratch wound assay. HUVECs were grown to confluence and a scratch 
was introduced using a pipet tip followed by incubation with the test media described 
in section 3.11. Cell filling of the cleared space initially occurs by migration, although the 
cells will eventually start to proliferate. In order to minimise cell proliferation, HUVECs 
were serum starved overnight and the assay was carried out over a period of 8 hours. 
The diluted conditioned media from untransduced SCL4.1/F7 cells resulted in around 
50% wound closure while the diluted conditioned media from SCL4.1/F7 cells 
overexpressing VEGF-A165 protein and media containing the recombinant VEGF-A165 
protein resulted in around 70% wound closure, a roughly 1.4 fold increase (figure 80).  
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Figure 80. Effect of VEGF-A165 on endothelial cell migration. a) Representative images of a 
scratch assay performed using HUVECs incubated with the test media. The red box represents 
the scratch area immediately after scratching and after 8 hours.  b) % closure was calculated 
using the area of the scratch at time 0 hours and at 8 hours. A significant difference in wound 
closure was observed compared with the diluted conditioned media from untransduced 
SCL4.1/F7 cells (one-way ANOVA, Tukey’s multiple comparison test, 95 % confidence interval, p 
value = 0.0116). No difference in wound closure was observed between diluted conditioned 
media from transduced SCL4.1/F7 cells compared to media containing recombinant VEGF-A165 
protein (p value = 0.7145).  Each data point represents the percentage closure in one well, n = 3 
per group.  *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
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6.5.1.3 Tube formation assay 
 
Having established that the lentiviral-mediated VEGF-A165 produced had positive effects 
on both HUVEC viability and migration, it was decided to carry out a tube formation 
assay, as endothelial cells form capillary like structures in response to angiogenic signals. 
Tube formation involves several steps, including cell adhesion, migration, differentiation 
and growth.   HUVECs were plated on a basement membrane matrix and incubated with 
the test media described in section 3.11 for 8 hours. HUVECs began to align themselves 
within 1 hour and tubules appeared after 2 hours. HUVECs incubated with diluted 
conditioned media from transduced SCL4.1/F7 cells formed several capillary-like tubes 
which were indistinguishable from the HUVECs incubated with positive control VEGF-
A165 recombinant protein (figure 81). HUVECs incubated with diluted media from 
untransduced SCL4.1/F7 cells formed significantly fewer tube-like structures. 
 
 
 
 
 
b) 
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Figure 81. Effect of VEGF-A165 on endothelial tube formation. a) Representative images of 
HUVECs showing the degree of angiogenesis progression together with the associated 
angiogenesis score. b)  Quantification of tube formation assay. HUVECs incubated with diluted 
conditioned media from transduced SCL4.1/F7 cells formed several capillary-like tubes which 
were indistinguishable from the HUVECs incubated with positive control VEGF-A165 recombinant 
protein (one-way ANOVA, Tukey’s multiple comparison test, 95 % confidence interval, p value = 
0.9994). HUVECs incubated with diluted media from untransduced SCL4.1/F7 cells formed 
significantly fewer tube-like structures p value = <0.0001). Each point represents the tube 
formation score in one well, n = 7 wells for each group.  *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
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6.5.2 Effect of VEGF-A165 on Schwann cell migration 
 
Following peripheral nerve injury, Schwann cells migrate to the site of injury to provide 
a supportive environment for axonal regeneration (Han et al., 2007). To determine 
whether the VEGF-A165 produced from lentiviral transduction increased migration of 
Schwann cells, a transwell assay was performed. Untransduced SCL4.1/F7 cells were 
pipetted into the upper compartment of a transwell insert. The contents of the lower 
compartments were varied across different experimental conditions. After 12 hours of 
incubation, SCL4.1/F7 cells incubated with conditioned media from transduced 
SCL4.1/F7 cells overexpressing VEGF-A165 showed a migration rate 1.6 fold higher 
compared to SCL4.1/F7 cells incubated with conditioned media from untransduced 
SCL4.1/F7 cells (figure 82). Similar migration rates (around 12 migrated cells per field of 
view) were observed with SCL4.1/F7 cells incubated with positive control recombinant 
VEGF-A165 protein. 
 
 
b) 
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Figure 82. Analysis of the effect of VEGF-A165 on the migration of SCL4.1/F7 cells. A transwell 
assay with SCL4.1/F7 cells seeded in the upper chamber and different media in the lower 
chamber. After 12 hours, SCL4.1/F7 cells incubated with conditioned media from transduced 
SCL4.1/F7 cells overexpressing VEGF-A165 showed a significantly higher migration rate compared 
to SCL4.1/F7 cells incubated with conditioned media from untransduced SCL4.1/F7 cells (one-
way ANOVA, Tukey’s multiple comparison test, 95 % confidence interval, p value = 0.0287). 
Similar migration rates were observed with SCL4.1/F7 cells incubated with positive control 
recombinant VEGF-A165 protein (p value = 0.9120). Each point represents the mean of 10 
predetermined fields of view per transwell, n = 3 for each group. *p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Constructing EngNT from SCL4.1/F7 cells overexpressing 
VEGF-A165 
 
Having established that VEGF-A165 produced by the transduced SCL4.1/F7 cells had 
angiogenic effects and increased Schwann cell migration and proliferation (sections 6.5 
and 6.4.3) in vitro, it was decided to construct EngNT using the SCL4.1/F7 cells 
overexpressing VEGF-A165 for subsequent in vivo use. Prior to constructing the EngNT, it 
was important to ensure that the overexpression of VEGF-A165 did not influence the 
contraction profile of the cellular collagen gel. Cellular self-alignment in the EngNT 
involves cells exerting forces that contract and deform the surrounding matrix and 
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different cell types vary in their ability to contract collagen gels (Bellows et al., 1981).  
O’Rourke et al. (2015) developed an assay based on contraction of free-floating cellular 
gels in 96-well plates to investigate cell–matrix interactions. This assay was used to 
quantify contraction in the current study. As can be seen in figure 83, over 60% 
contraction was obtained for both control untransduced and transduced SCL4.1/F7 cells. 
O’Rourke et al. (2015) found that 60–80% contraction in the 96-well plate assay 
corresponded to alignment throughout tethered gels made using the same parameters. 
Gels made from control SCL4.1/F7 cells and SCL4.1/F7 cells overexpressing VEGF-A165 
had a mean percentage contraction of 62 and 64% respectively.  
 
Figure 83. Contraction assay for control SCL4.1/F7 cells and SCL4.1/F7 cells overexpressing 
VEGF-A165. The percentage contraction of free-floating gels was calculated. No significant 
difference in contraction was observed between the control and transduced cells (two-tailed 
unpaired T test, 95 % confidence interval, p value = 0.4784).  Each point represents the 
percentage contraction of one individual free-floating gel, n = 6 for each group.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Transduced SCL4.1/F7 cells were then used to construct EngNT. Scanning confocal 
microscopy was used to observe the cellular architecture in the EngNT. eGFP expressing 
SCL4.1/F7 cells in the EngNT were counterstained with DAPI and images were taken 
from a single plane through the constructs (figure 84). No eGFP signal was detected in 
the constructs containing control untransduced SCL4.1/F7 cells. This ensured that any 
eGFP signal that was detected in the transduced cells was not autofluorescence or 
C
o
n
t r
o
l  
u
n
t r
a
n
s
d
u
c
e
d
 c
e
l l
s
T
r a
n
s
d
u
c
e
d
 c
e
l l
s
4 0
5 0
6 0
7 0
8 0
%
 c
o
n
t
r
a
c
t
io
n
n s
   195 
 
background signal.  Colocalisation of blue channel (DAPI) and green channel (eGFP) in 
the nucleus of many eGFP expressing SCL4.1/F7 cells was observed. This indicated the 
presence of nuclear eGFP in addition to cytoplasmic eGFP.  
 
Figure 84. Laser scanning confocal microscopy for imaging of lentiviral mediated gene 
expression in SCL4.1/F7 cell constructs. Representative images of the nuclear stain DAPI (blue 
channel) and eGFP (green channel) were taken from stabilised constructs and from control 
constructs containing untransduced SCL4.1/F7 cells. eGFP is shown in green and DAPI in blue. N 
= 3 individual EngNT for each group. Scale bar = 100 µm. Z-distance = 20 μm, step size = 1 μm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, VEGF-A165 distribution in the EngNT was visualised by immunofluorescence 
staining using a monoclonal anti-VEGF-A antibody.  Diffuse VEGF staining was observed 
in and around the cells in the EngNT (figure 85).  
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Figure 85. Laser scanning confocal microscopy for imaging of lentiviral mediated VEGF-A165 
expression in SCL4.1/F7 cell constructs. Representative images of the nuclear stain DAPI and 
eGFP were taken from stabilised constructs and from control constructs containing 
untransduced SCL4.1/F7 cells. eGFP is shown in green, DAPI in blue and VEGF-A165 in red. N = 3 
individual EngNT for each group. Magnification, x20. Z-distance = 20 μm, step size = 1 μm.  
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6.6.1 VEGF-A165 production by transduced cells in EngNT  
 
Immunofluorescence staining in the previous section revealed the presence of VEGF-
A165 throughout the EngNT constructed from transduced SCL4.1/F7 cells. The next step 
was to quantify the amount of the protein produced by the cells in the EngNT using an 
ELISA kit. Similar to cells in monolayer, the VEGF-A165 concentration in both the EngNT 
cell lysate and media was measured. The concentration of VEGF-A165 in the transduced 
cell lysate was around 700 fold higher than in the control cell lysate while the 
concentration in the transduced cell media was around 4000 fold higher than in the 
control cell media (figure 86). It was also noted that the VEGF-A165 concentration in the 
transduced cell media was 5.5 fold higher than the in the transduced cell lysate. The 
VEGF-A165 concentration was normalised to total protein concentration, determined by 
a BCA assay. As expected, the percentage of VEGF-A165 to total protein in transduced 
cell lysate and media was higher compared to a negligible amount in the control cell 
lysate and media (figure 86).  
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Figure 86. Quantifying the amount of VEGF-A165 produced by SCL4.1/F7 cells incorporated into 
EngNT. a) The VEGF-A165 concentration in the lysate and media of control and transduced cells 
as determined by ELISA. A statistical significance was found between the transduced and control 
cell lysate as well as the transduced and control cell media (one-way ANOVA, Tukey’s multiple 
comparisons test, 95 % confidence interval, p value = <0.0001). The amount of VEGF-A165 in the 
transduced cell media was significantly higher than that in the transduced cell lysate (p value = 
<0.0001). Each data point represents the mean of duplicate wells evaluated for VEGF-A165 
concentration (n = 4 individual EngNT per group).   b) VEGF concentration normalised to total 
protein concentration.  A statistical significant was found between the transduced and control 
cell lysate (one-way ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p 
value = <0.0001) as well as the transduced and control cell media (p value = <0.0001). No 
statistical difference was found between the transduced cell media and transduced cell lysate 
(p value =0.1108). Each data point represents the mean of duplicate wells evaluated for VEGF-
A165 concentration and VEGF-A165: total protein concentration (n = 4 individual EngNT for each 
group).  *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
  
As the implantable device consisted of EngNT in a silicone tube, it was decided to also 
measure the VEGF-A165 concentration in such a device (figure 86). The concentration of 
VEGF-A165 in the transduced cell lysate was around 2200 fold higher than in the control 
cell lysate while the concentration in the transduced cell media was around 1700 fold 
higher than in the control cell media (figure 87). It was also noted that unlike the EngNT 
without the silicone tube, the VEGF-A165 concentration in the transduced cell lysate was 
1.3 fold higher than in the transduced cell media.  Once again, the VEGF-A165 
concentration was normalised to total protein concentration, determined by a BCA 
assay. The percentage of VEGF-A165 to total protein in transduced cell lysate and media 
was around 0.0016 and 0.0003% respectively and compared to a negligible amount in 
the control cell lysate and media (figure 87). The percentage of VEGF-A165 to total 
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protein in the transduced cell lysate was around 4.9 fold higher than in the transduced 
cell media. 
 
Figure 87. Quantifying the amount of VEGF-A165 produced by transduced SCL4.1/F7 cells in 
EngNT in a silicone tube. a) The VEGF-A165 concentration in the lysate and media of control and 
transduced cells as determined by ELISA. A statistical significance was found between the 
transduced and control cell lysate as well as the transduced and control cell media (one-way 
ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = <0.0001). The 
amount of VEGF-A165 in the transduced cell lysate was significantly higher than that in the 
transduced cell media (p value = <0.0332). Each data point represents the mean of duplicate 
wells evaluated for VEGF-A165 concentration (n = 4 individual EngNT for each group).   b) VEGF 
concentration normalised to total protein concentration.  A statistical significance was found 
between the transduced and control cell lysate (one-way ANOVA, Tukey’s multiple comparisons 
test, 95 % confidence interval, p value = <0.0001) as well as the transduced and control cell 
media (p value = 0.0096). A statistical difference was found between the transduced cell media 
and transduced cell lysate (p value = <0.0001). Each data point represents the mean of duplicate 
wells evaluated for VEGF-A165 concentration and VEGF-A165: total protein concentration (n = 4 
individual EngNT for each group).  *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
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It was observed that compared to EngNT without a silicone tube, the VEGF-A165 protein 
concentration in the EngNT in the silicone tube contributed to a larger percentage of the 
total protein in the cell lysate. This difference (an average of 0.0016% in the EngNT in 
the silicone tube and 0.0004% in the EngNT without the silicone tube) proved to be 
significant (two-tailed unpaired T test, 95 % confidence interval, p value = <0.0001, n = 
4).  The opposite was observed in the media, where a higher percentage of VEGF-A165 
protein was observed in the EngNT without the silicone tube (p value = 0.0004).   
 
6.7 Co-cultures   
 
With the functionality of the VEGF-A165 protein proven in monolayer SCL4.1/F7 cell 
culture models, it was decided to test its efficacy in 3D cell culture models. This was 
especially important as the ELISA assay revealed that in EngNT in a silicone tube, a large 
proportion of the VEGF-A165 produced is found in the cells in the collagen gel. Further, 
despite their ease of use, monolayer cell culture models generally do not represent the 
complex 3D characteristics of living tissues (Ko and Frampton, 2016). It is generally 
agreed that the development of 3D cell models could potentially allow researchers to 
bridge between results obtained in in vitro models and in vivo studies more effectively. 
Additionally, in vitro monolayer studies tend to incorporate single cell types without 
considering the effect of other cells present in living tissue. It was therefore decided to 
test the effect of the neurotrophic and angiogenic effects of transduced SCL4.1/F7 cells 
overexpressing VEGF-A165 on PC12 cells and HUVECs in 3D co-culture models.  
 
6.7.1 Neurotrophic effects  
 
Neuron-EngNT co-cultures have been previously used as a means of testing potential 
drug compounds that could increase regeneration following peripheral nerve injury 
(Rayner et al., 2018). This is because when neurons are co-cultured with EngNT, neurite 
growth is supported and guided by the aligned Schwann cells in a 3D ECM environment, 
mimicking the key features of the peripheral nerve environment in the distal nerve 
segment. In order to establish whether the overexpression of VEGF-A165 would increase 
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neurite length in vitro, it was decided to construct EngNT made from SCL4.1/F7 cells 
overexpressing VEGF-A165 and culture PC12 cells on top of the EngNT (figure 88).  
 
Figure 88. Representation of the 3D engineered co-culture. EngNT containing aligned Schwann 
cells (green) and neurons seeding on the gel surface (red). Image taken from Rayner et al. (2018).  
 
 
 
 
 
 
 
 
Compared to EngNT made from control untransduced SCL4.1/F7 cells, EngNT made from 
SCL4.1/F7 cells overexpressing VEGF-A165 resulted in a 1.39 fold increase in PC12 neurite 
length (figure 89).  
 
Figure 89. Effect of VEGF-A165 on neurite length in vitro. Representative fluorescence 
micrographs of PC12 neuronal cells seeded on EngNT made with a) transduced SCL4.1/F7 cells 
and b) control untransduced cells. Cultures were immunostained to detect β-III tubulin (red). 
Scale bar =  c) VEGF-A165  significantly  increases PC12 neurite growth in the 3D EngNT co-culture 
model after 72 hour exposure (two-tailed unpaired T test, 95 % confidence interval, P value = 
<0.0404). Each data point represents the mean neurite length from 5 predetermined fields of 
view in one individual co-culture, n = 3 co-cultures for each group. Scale bar = 200 µm. *p < 0.05, 
**p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
 
  
 
 
 
a) b) 
   202 
 
 
C
o
n
t r
o
l  
S
C
L
4
. 1
/ F
7
 c
e
l l
s
T
r a
n
s
d
u
c
e
d
 S
C
L
4
. 1
/ F
7
 c
e
l l
s
0
2 0
4 0
6 0
A
v
e
r
a
g
e
 
n
e
u
r
i
t
e
 l
e
n
g
t
h
 (

m
)
*
 
6.7.2 Angiogenic effects  
 
Muangsanit et al. (unpublished) constructed EngNT from a mixture of HUVECs and 
SCL4.1/F7 and found that HUVECs formed tube-like structures within the 3D matrix.  A 
co-culture of HUVECs and SCL4.1/F7 cells was set up to investigate whether transduced 
SCL4.1/F7 cells overexpressing VEGF-A165 would increase the extent of HUVEC tube 
formation in the collagen gel.  Previous experiments by Muangsanit et al. (unpublished) 
have shown that an incubation time of 4 days and a ratio of 4 x 106 HUVECs: 1 x 106 
SCL4.1/F7 cells /ml yielded optimal tube formation and so these conditions were used 
in the current study (figure 90).  
 
 
 
 
 
 
 
 
 
 
 
c) 
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Figure 90. Evaluation of endothelial tube formation in the 3D co-culture system after 4 days. 
The co-culture consisted of a ratio of 4 x 106 HUVECs: 1 x 106 SCL4.1/F7 cells /ml Representative 
immunofluorescence images show HUVECs forming tube-like structures and Schwann cell 
alignment. HUVECs were immunolabelled with CD31 (red) and control untransduced Schwann 
cells were immunofluorescently stained to detect S100 (green) to allow visualisation of the cells. 
The cells were counterstained with DAPI (blue). N = 3 individual 3D co-cultures per groups. 
Magnification, x20.  Z-distance = 20 μm, step size 1 = μm. 
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Angiogenesis Analyzer, a plugin in ImageJ (Carpentier, 2012), was used to visualise 
endothelial network formation in the co-cultures. The parameters evaluated were 
number of junctions, number of meshes, total mesh area and total branching length 
(figure 91).  The number of meshes was similar in the co-cultures made with control 
SCL4.1/F7 cells and transduced SCL4.1/F7 cells, with means of 9.6 and 10.3 meshes per 
group. However, the total mesh area was 1.78 fold higher in the co-cultures with 
SCL4.1/F7 cells overexpressing VEGF-A165. Similarly, the number of junctions was 1.32 
fold higher in the co-cultures with SCL4.1/F7 cells overexpressing VEGF-A165. The total 
branching length of the HUVECs was 1.05 fold higher in the co-cultures with SCL4.1/F7 
cells overexpressing VEGF-A165 compared to the co-cultures with the untransduced cells, 
however, this was not a significant increase.   
 
Figure 91. Endothelial cell network characteristics in the HUVEC - SCL4.1/F7 cell 3D co-
cultures. The number of meshes was similar in the co-cultures made with control SCL4.1/F7 cells 
and transduced SCL4.1/F7 cells (two-tailed unpaired T test, 95 % confidence interval, p value = 
0.6213). However, the total mesh area was significantly higher in the co-cultures with SCL4.1/F7 
cells overexpressing VEGF-A165 (p value = 0.0037). Similarly, the number of junctions was 
significantly higher in the co-cultures with SCL4.1/F7 cells overexpressing VEGF-A165 (p value = 
0.0452). The total branching length of the HUVECs the co-cultures with SCL4.1/F7 cells 
overexpressing VEGF-A165 was similar to the co-cultures with the untransduced cells (p value = 
0.4197). Each data point represents a value from an individual co-culture (n = 3 individual co-
cultures for each group). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
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6.8 Discussion  
 
Having established that SCL4.1/F7 cells can be successfully transduced by a lentiviral 
vector delivering marker genes (chapter 4), it was decided to design and produce a 
lentiviral vector delivering the VEGF-A165 gene. The first step involved subcloning the 
VEGF-A165 gene into a lentiviral transfer plasmid. However, this proved to be 
unsuccessful. Due to the nature of cloning and recombinant DNA technology, it could 
take multiple attempts before successfully cloning a candidate gene into a transfer 
plasmid. While it is unclear why the initial cloning attempts were unsuccessful, several 
factors could have contributed to the failed attempts, including inefficient 
transformation, incompatible DNA ends and poor DNA quality.  
 
No colonies were observed after the ligation mixture was transformed into the One 
Shot® Stbl3™ Chemically Competent E. coli. However, the transformation efficiency of 
the bacteria was confirmed as a pUC19 control plasmid yielded several colonies. This 
excluded the possibility of low transformation efficiency of the bacteria. A cloned 
sequence which is not tolerated by E.coli can lead to toxicity, resulting in no colonies 
being produced.  However, this possibility was eliminated as the VEGF-A165 gene has 
been subcloned several times in literature (Ellison et al., 2013; Luo et al., 2017). Further, 
this proved not to be the case when the synthesised genes were used as colonies were 
formed.  
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Incomplete cleavage of the VEGF-A165 gene and pSFFV-IRES-eGFP backbone plasmid 
during the double digest could have also contributed to the cloning failure. However, 
new high quality restriction enzymes were used for the double digest to ensure optimal 
enzyme activity and exclude the possibility of endo-, exo-nuclease and phosphatase 
contamination in the enzyme preparations. Incomplete cleavage can result in vector 
self-ligation. However, no colonies were obtained when the bacteria were transduced 
with the digested pSFFV.IRES.eGFP vector plasmid control, excluding self-ligation. 
Further, the synthesised genes were successfully digested with the same enzymes.  
 
The most likely explanation for the unsuccessful cloning is poor DNA quality. The VEGF-
A165 gene and pSFFV-IRES-eGFP backbone plasmid were gel purified prior to ligation to 
remove the presence of contaminants. The bands were excised using an UV 
transilluminator at a low setting and for minimal periods of time to avoid UV-mediated 
mutations in gene sequences and to prevent DNA damage. However, both these 
measures still did not result in successful cloning. Following unsuccessful 
troubleshooting of the cloning process, it was decided to commercially synthesise the 
VEGF-A165 gene. The synthesised gene was subcloned into the pSFFV-IRES-eGFP 
backbone plasmid and a recombinant transfer plasmid was formed. This transfer 
plasmid was then used to produce the lentiviral vector delivering the VEGF-A165 gene.  
 
Following transduction with the lentiviral vector delivering the VEGF-A165 gene, the 
amount of VEGF-A165 produced by SCL4.1/F7 cells was quantified by ELISA. After 
confirming that the transduced cells produced a significantly larger amount of VEGF-A165 
compared to control untransduced cells, several bioassays were carried out to test the 
biological activity of the VEGF-A165 produced. Angiogenesis is a well-coordinated process 
involving endothelial cell proliferation, migration and differentiation. Therefore, the 
potential effects of VEGF-A165 on each of these endothelial cell behaviours were 
evaluated using an alamarBlue® assay, a scratch wound assay and a tube formation 
assay respectively.  
 
Recombinant VEGF-A165 protein was used a positive control in the in vitro bioassays. 
Authors cite the use of different concentrations of the protein when used as a control, 
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ranging from 5 - 100 ng/ml.  Silva and Mooney (2010) found that doses ranging from 5 
– 20 ng/ml of VEGF-A165 resulted in the same level of endothelial cell proliferation. They 
also reported that the cell proliferation rate increased in a dose dependent manner and 
reached a plateau at 50 ng/ml. No further increase was observed with a dose of 100 
ng/ml. Similarly, Hanjaya-Putra et al. (2010) reported that concentrations of VEGF-A165 
up to 25 ng/ml increased endothelial cell tube formation but optimal results were 
obtained with 50 ng/ml. It was therefore decided to use recombinant VEGF-A165 at a 
concentration of 50 ng/ml as a positive control in the current study. 
 
Conditioned media from the SCL4.1/F7 cells overexpressing VEGF-A165 improved 
endothelial cell viability, migration and tube formation to levels comparable to the 
positive control (VEGF-A165 recombinant protein at a concentration of 50 ng/ml). In 
order to determine that this effect was due to the VEGF-A165 in the conditioned media, 
conditioned media from control untransduced SCL4.1/F7 cells was also tested. This had 
a significantly lower effect on endothelial cell viability, migration and tube formation 
compared to the conditioned media from the transduced cells. These results are similar 
to others reported in the literature. VEGF-A165 has been shown to endothelial cell growth 
(Ferrara, 2004; Domigan et al., 2015), migration (Wang et al., 2011) and tube formation 
(Makarevich et al., 2012) in vitro. Makarevich et al. (2012) evaluated the angiogenic 
activity of VEGF-A165 produced by HEK293T cells following transfection with a plasmid 
delivering the VEGF-A165 gene. HUVECs on a Matrigel-coated surface were incubated 
with the conditioned media and the induction of tube formation was assessed after 12-
14 hours. Similar to the current study, HUVECs incubated with conditioned media from 
the cells overexpressing  VEGF-A165 showed comparable tube formation to HUVECs 
incubated with positive control recombinant human VEGF-A165.  
 
Conditioned media from the SCL4.1/F7 cells overexpressing VEGF-A165 also had a 
significant effect on Schwann cell migration in vitro. Similar results were obtained by 
Muratori et al. (2018) who carried out a transwell assay showing that VEGF-A165 
increased primary Schwann cell migration. This was a significant finding as the VEGF-A165 
produced by the transduced SCL4.1/F7 cells could potentially influence the migration of 
Schwann cells in vivo, which is an important step during the regeneration process. It was 
also observed that SCL4.1/F7 cells overexpressing VEGF-A165 had an increased 
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proliferation rate compared to control untransduced cells and cells transduced with a 
lentiviral vector delivering luciferase and eGFP. Similarly, Sondell et al. (1999b) reported 
that the addition of human recombinant VEGF-A165 (50 ng/ml) to explanted adult mouse 
superior cervical ganglia and dorsal root ganglia resulted in Schwann cell proliferation. 
This is another important result in the context of peripheral nerve regeneration. 
Following injury the surviving Schwann cells being to proliferate and this is a significant 
feature of Wallerian degeneration (Atanasoski et al., 2006). In addition to directing 
Schwann cell migration to the injury site, the secreted VEGF-A165 could also increase the 
proliferation rate of resident Schwann cells.  
 
Encouraging results were obtained from the in vitro studies testing the functionality of 
the VEGF-A165 produced by the transduced cells. It was decided that prior to in vivo 
testing, the functionality of the VEGF-A165 would be assessed in a 3D hydrogel, which 
provides a more tissue-like spatial and mechanical environment. There is increasing 
evidence suggesting that 3D assays offer a model which mimics the natural in vivo 
environment more closely than 2D assays (Edmondson et al., 2014).  Another important 
consideration was that Chen et al. (2010) have shown that VEGF-A165 is retained and 
remains active within a collagen matrix. In the current study, an ELISA revealed that a 
significant proportion of the VEGF-A165 was retained in the collagen based EngNT and 
not secreted into the media. It was therefore important to determine that the VEGF-A165 
in the current study retained its functionality within a 3D environment. This is because 
following implantation, host cells including axons and endothelial cells, infiltrate the 
EngNT and will come into contact with the VEGF-A165 in the collagen. In order to 
understand how VEGF-A165 may modulate the activity of cells in 3D cultures, SCL4.1/F7 
cells overexpressing VEGF-A165 were co-cultured with endothelial cells and PC12 cells in 
two separate 3D models. This is especially relevant in the context of peripheral nerve 
regeneration, where there is the interplay of several cell types, including neurons, 
Schwann cells and endothelial cells.  
 
Chen et al. (2009) found that HUVECs formed sprouts with longer processes when co-
cultured with glioma cells that secrete VEGF-A165. In agreement with this data, the 
presence of SCL4.1/F7 cells overexpressing SCL4.1/F7 cells increased the number of 
junctions and meshes as well as the total mesh area formed by HUVECs in the co-culture. 
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The increased presence of meshes confirmed the formation of a more extended 
endothelial network in the co-culture with the SCL4.1/F7 cells overexpressing VEGF-A165 
(Gholobova et al., 2015). However, no improvement in the total branching length 
compared to the co-cultures with the control SCL4.1/F7 cells was seen. Previous 
experiments by Muangsanit et al. (unpublished) have shown that an incubation time of 
4 days and a ratio of 4 x 106 HUVECs: 1 x 106 SCL4.1/F7 cells /ml yielded optimal tube 
formation. This suggests that for the given system and conditions tested, maximal 
branching length was reached independent of the additional VEGF-A165 supplied by the 
transduced SCL4.1/F7 cells.  
 
Genetos et al. (2010) showed that exogenous VEGF-A165 (50 ng/mL) increased the 
frequency of PC12 cells elaborating neurites under 2D culture.  The positive effect of 
VEGF-A165 on PC12 neurite length was replicated in a 3D culture in the current study. 
EngNT made with SCL4.1/F7 cells overexpressing VEGF-A165 increased PC12 neurite 
length compared to control SCL4.1/F7 cells. This confirmed the neurotrophic effect in 
addition to the angiogenic effect of the VEGF-A165 produced by the transduced cells. 
VEGF-A165 has also been reported to increase neurite length in other cell types, including 
chicken embryonic dorsal root ganglia (Zupanc et al., 2017), adult mouse dorsal root 
ganglia (Sondell et al., 1999a) and adult mouse trigeminal ganglia (Pan et al., 2013).  
 
6.9 Conclusion  
 
This study showed that SCL4.1/F7 cells transduced with a lentiviral vector delivering the 
VEGF-A165 gene results in the production of functional VEGF-A165 protein. Further, 
transduced SCL4.1/F7 cells incorporated into EngNT still produced the functional 
protein. As previously discussed, tissue engineered constructs seeded with genetically 
modified cells have the potential to enhance peripheral nerve regeneration. The next 
stage of this study is to therefore carry out an in vivo assessment of EngNT made with 
SCL4.1/F7 cells overexpressing VEGF-A165 to determine whether this promotes neuronal 
regeneration in a rat model of sciatic nerve injury.    
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Chapter 7: Effects of EngNT containing SCL4.1/F7 
overexpressing VEGF-A165 on peripheral nerve 
regeneration  
 
7.1 Introduction 
 
The previous chapter showed that conditioned media from SCL4.1/F7 cells transduced 
with a lentiviral vector delivering the VEGF-A165 gene improved HUVEC viability and 
induced HUVEC migration and tube formation in vitro. The conditioned media also 
increased SCL4.1/F7 migration in vitro. Further, SCL4.1/F7 cells overexpressing VEGF-
A165 showed an increased proliferation rate. The transduced cells were used to construct 
EngNT and it was confirmed that the cells were able to produce VEGF-A165 in a 3D 
environment.  When co-cultured with PC12 cells, EngNT made with SCL4.1/F7 cells 
overexpressing VEGF-A165 was shown to increase neurite length. Finally, a co-culture of 
HUVECs and SCL4.1/F7 cells overexpressing VEGF-A165 revealed that the presence of 
VEGF-A165 increased the number of junctions, meshes and mesh area formed by HUVECs 
within 3D hydrogels. Having demonstrated that the lentiviral vector successfully 
transduced SCL4.1/F7 cells, it was then decided to transduce clinically relevant cell 
types, namely CTX0E03 cells and ADSCs, with the vector. As the VEGF-A165 produced by 
the transduced SCL4.1/F7 cells was proven to have neurotrophic and angiogenic 
properties in 2D monolayers and 3D cultures in vitro, EngNT made with SCL4.1/F7 cells 
overexpressing VEGF-A165 was implanted into a rat model of sciatic nerve injury. The 
aims of this chapter were as follows:  
 
 To transduce clinically relevant sources of stem cells with the lentiviral vector 
delivering VEGF-A165. 
 To carry out a pilot study to assess whether EngNT made with SCL4.1/F7 cells 
overexpressing VEGF-A165 improved axonal regeneration and functional recovery 
in a model of rat sciatic nerve injury.  
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7.2 VEGF-A165 overexpression in clinically relevant sources of 
therapeutic cells  
 
Having transduced SCL4.1/F7 cells with the lentiviral vector delivering VEGF-A165, 
clinically relevant sources of therapeutic cells were sought. It was decided to transduce 
ADSCs and CTX0E03 cells as these had been previously used by the group (Georgiou et 
al., 2015; O’Rourke et al., 2017). CTX0E03 cells are manufactured according to Good 
Manufacturing Practice and are currently in phase II clinical trials for ischaemic stroke 
(Sinden et al., 2017). ADSCs have been extensively studied as an adjunct to nerve 
repair (Faroni et al., 2013) and various authors have reported improved regeneration 
following transplantation of ADSCs (di Summa et al., 2010. Georgiou et al., 2015, 
Masgutov et al., 2018).   
 
As expected, a higher VEGF-A165 concentration in the transduced ADSCs and CTX0E03 
cell lysate and media was seen compared to the control cell lysate and media, indicating 
that the cells had been successfully transduced. The VEGF-A165 concentration in the 
transduced CTX0E03 cell media was 1.6 fold higher than in the transduced SCL4.1/F7 cell 
media. A similar VEGF-A165 concentration was measured in transduced CTX0E03 cell 
lysate and transduced SCL4.1/F7 cell lysate, with means of 1552.2 and 1808.1 pg/ml 
respectively.  In the case of the transduced ADSCs, the VEGF-A165 concentration in the 
cell lysate and media were both 1.6 fold higher than the transduced SCL4.1/F7 cell lysate 
and media.  Compared to the transduced CTX0E03 cell lysate, the VEGF-A165 
concentration in the transduced ADSC lysate was 1.9 fold higher. A similar VEGF-A165 
concentration was measured in transduced CTX0E03 cell media and transduced ADSC 
cell media, with means of 73337.3 and 7298.3 pg/ml respectively.  The concentration of 
VEGF-A165 in the transduced cell media was 2.5 fold higher than in the transduced cell 
lysate for the transduced SCL4.1/F7 and ADSC and 4.7 fold higher for the transduced 
CTX0E03 (figure 92).  
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Figure 92. Quantifying the amount of VEGF-A165 produced by transduced CTX0E03, ADSCs and 
SCL4.1/F7 cells. The VEGF-A165 concentration in the lysate and media of control and transduced 
cells was measured by ELISA. A statistical significance was found between the transduced and 
control cell lysate as well as the transduced and control cell media for each cell type (two-way 
ANOVA, Tukey’s multiple comparisons test, 95 % confidence interval, p value = <0.0001). The 
amount of VEGF-A165 in the transduced cell media was significantly higher than that in the 
transduced cell lysate for all 3 cell types (p value = <0.0001). The VEGF-A165 concentration in the 
transduced ADSC cell lysate was significantly higher than in the transduced SCL4.1/F7 and 
CTX0E03 cell lysate (p value = <0.0004). Data is presented as the means ± SD (n = 4 for each 
group. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
7.2 Animal model  
 
A long gap (15 mm), 8 week experiment was used to establish whether EngNT made 
from SCL4.1/F7 cells overexpressing VEGF-A165 would increase regeneration compared 
to EngNT made from untransduced SCL4.1/F7 cells. For each experimental group, one 
EngNT rod (15 mm in length) was placed into a silicone tube to create an implantable 
device. The device was positioned in the gap of the rat sciatic nerve following a single 
transection and sutured at each end as described in section 3.17.3.  
 
The animals were monitored daily and showed no signs of distress. The animals were 
weighed weekly and continued to gain weight steadily over the course of the 
experiment. Continuous tracking of animal body weight is considered to be a sensitive 
and objective way of assessing the stress experienced by animals after surgical 
procedures and treatments and is useful method of monitoring the general health of 
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the animal (Brenneis et al., 2017). The animals in both groups had similar weights at all 
time points (figure 93). All animals survived the entire period of recovery post-
implantation (8 weeks). One animal displayed very mild autotomy which resulted in the 
removal of one toenail. This did not progress to more severe mutilation and so this 
animal was not excluded from the study.   
 
Figure 93. Rat body weight monitoring during the 8 week experiment. The rats gained weight 
throughout the 8 week period and animals in both groups had similar weights at all time points.  
 
 
 
After 8 weeks, the repaired nerves were excised under a dissecting microscope (figure 
94) and cryopreserved and processed as described in section 3.17.8.2.  
 
Figure 94: An explanted nerve repair device. EngNT in a silicone outer tube showing the 
proximal and distal nerve stumps after 8 weeks in vivo. 
 
 
 
 
 
 
 
 
 
 
Distal 
stump 
Proximal 
stump 
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7.3 Outcome measures 
 
Complete rat sciatic nerve transection is a well-established animal model used to study 
various aspects of nerve regeneration following injury (Kaplan et al., 2015). The degree 
of nerve regeneration is generally evaluated and quantified through three types of 
measures: histological analysis, electrophysiological studies and functional assessment. 
Nerve fibres may regenerate without making functional connections and axonal 
sprouting without pruning may result in an overestimation of functional connections. 
This implies that histological and electrophysiological data may not necessarily correlate 
with recovery of function (Nichols et al., 2005). In order to provide a complete picture 
of nerve regeneration in the current study, all three measures were evaluated. It was 
noted that the small sample size used in this pilot study generated difficulty in 
comparing the effects of EngNT made from SCL4.1/F7 cells overexpressing VEGF-A165 
and EngNT made from control SCL4.1/F7 statistically due to variation in the outcome 
measures. It was therefore decided not to perform statistical tests to establish 
significance between the two groups, instead a qualitative description of the results 
obtained is provided.  
 
7.3.1 Functional outcomes  
 
Varejão et al. (2004) argued that there is no general consensus on the type of 
assessment tool that provides the most accurate description of functional recovery 
following injury in animal models. Consequently, they suggest that several tests should 
be used in combination to give a more comprehensive picture of nerve function. 
According to Nichols et al. (2005), functional analysis may offer the most indisputable 
evidence to show that a nerve has regenerated and also made successful end organ 
connections. This section will describe the results obtained from three functional 
outcome measures tested in the current study, namely the SSI , von Frey analysis and 
gastrocnemius wet muscle mass. 
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7.3.1.1 Static sciatic index  
 
The SSI is a simple and non-invasive method for the evaluation of functional recovery of 
the sciatic nerve in rats (Bervar, 2000). It involves acquiring an image of the plantar 
aspect of the hind feet while the rat is in a static position and measuring the distance 
from the first to the fifth toe (the toe spread) and the distance from the second to the 
fourth toe (the intermediary toe spread) on both the injury and contralateral sides 
(figure 95).  The toe spread factor and the intermediary toe spread factor are then 
calculated and incorporated into the formula described in section 3.17.5.2. The SSI 
fluctuates around 0 for normal nerve function while a value of around -100 represents 
total loss of function (Amniattalab and Mohammadi, 2017).   
 
Figure 95. Calculating the SSI. Representative images for a) the animals treated with EngNT 
made from SCL4.1/F7 cells and b) the animals treated with EngNT made from SCL4.1/F7 cells 
overexpressing VEGF-A165. In each set, the image on the left shows the hind feet before the 
procedure and the image on the right shows the hind feet after 8 weeks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
Before the injury 8 weeks after injury 
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The SSI demonstrated that, although there was a trend for recovery over the 8 week 
period, the values were lower than the pre-operative values for both groups at the end 
of the study (figure 94). Both groups had similar SSI scores at the end of the study, with 
means of -57.6 and -52.2 for the animals treated with control cells and the animals 
treated with cells overexpressing VEGF-A165 respectively. Interestingly, the animals 
treated with EngNT made from the control cells displayed higher SSI values over days 7 
to 49, indicating that the control animals may have recovered faster (figure 96).  
 
Figure 96. SSI monitoring during the study period. Before the procedure, all animals had an SSI 
of around 0, indicating full function. The SSI improved throughout the 8 week period but was 
still lower than day 0 for both groups by the end of the experiment. Both groups had similar 
values on day 56. The animals treated with the control cells displayed higher SSI values than the 
animals treated with the transduced cells over days 7 to 49. Data shown as the mean ± SD (n = 
3 for each group).  
 
7.3.1.2 Von Frey  
 
The sciatic nerve is a mixed nerve, consisting of both sensory and motor axons 
(Schmalbruch, 1986). For this reason, the rat sciatic nerve transection model permits the 
evaluation of both motor and sensory recovery. The SSI described in the previous section 
is a useful indicator of motor recovery (Korte et al., 2011). In order to complement this, 
von Frey filaments were used to evaluate the return of sensory function following injury 
as described in section 3.17.5.1.  
  
The withdrawal force of the injury side was divided by that of the contralateral side to 
produce a normalised value. Unlike the SSI, the normalised withdrawal force had 
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returned to the pre-operative values for both groups by the end of the 8 week period. 
Both groups had similar normalised withdrawal forces at the end of the study, with 
means of 5.4 and 3.0 for the animals treated with control cells and the animals treated 
with cells overexpressing VEGF-A165 respectively. Interestingly, the animals treated with 
EngNT made from the transduced cells consistently showed lower withdrawal forces, 
indicating that these animals may have recovered faster (figure 97).  
 
Figure 97. Von Frey testing. The force required to cause paw withdrawal in response to von Frey 
filaments was measured over the 8 week period. The withdrawal force of the injury side was 
normalised by dividing over the contralateral side. The withdrawal force at the end of the study 
was similar to the pre-operative values for both. Both groups displayed similar withdrawal forces 
at the end of the study. The animals treated with the transduced cells displayed consistently 
lower withdrawal forces than the animals treated with the cells throughout the study. Data 
shown as the mean ± SD (n = 3 for each group). 
         
 
 
7.3.1.3 Gastrocnemius muscle mass 
 
The atrophy of the gastrocnemius muscle, innervated by the sciatic nerve, provides an 
indication of the extent of nerve regeneration. Percentage muscle recovery was defined 
as (gastrocnemius muscle mass from the injury side/ gastrocnemius muscle mass from 
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the contralateral control side) x 100, and was used to estimate the regeneration of the 
motor neuron component in sciatic nerve (figure 98).  
 
Figure 98. Gastrocnemius muscles harvest at 8 weeks. Representative images to show the 
gastrocnemius muscle after 8 weeks in a) the animals treated with EngNT made from SCL4.1/F7 
cells and b) the animals treated with EngNT made from SCL4.1/F7 cells overexpressing VEGF-
A165. In each set, the image on the left shows the gastrocnemius muscle harvested from the 
injury side and the image on the right shows the gastrocnemius muscle harvested from the 
contralateral side.  
 
 
                                                                             
 
 
              
 
The gastrocnemius muscle mass was lower on the injury side compared to the 
contralateral side in all animals. The percentage recovery was similar in both groups, 
with means of 26.6% recovery for animals treated with the transduced cells and 28.0% 
recovery for animals treated with the control cells (figure 99).  
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Figure 99. Gastrocnemius muscle mass following sciatic nerve repair.  The mass of the 
gastrocnemius muscle on the injury side was expressed as a percentage of the contralateral 
muscle to calculate the muscle recovery. A similar percentage recovery was obtained in both 
groups. Each data point represent the percentage muscle recovery from one animal (n = 3 for 
each group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2 Electrophysiological outcomes 
 
After 8 weeks animals were anesthetised and nerve function was assessed 
electrophysiologically by comparing the repaired nerve to the contralateral nerve in 
each animal. Functional recovery was assessed through stimulation of the sciatic 
nerve proximal to the repair site and recording of the compound muscle action 
potential (CMAP) in the gastrocnemius muscle as described in section 3.17.6. In one 
of the animals treated with EngNT made with SCL4.1/F7 cells and in two of the animals 
treated with EngNT made with SCL4.1/F7 cells overexpressing VEGF-A165, CMAP 
amplitude was below the threshold of detection. The latency of the evoked action 
potentials was greater in the repaired nerves compared with contralateral controls in 
all cases. The values recorded are shown in table 18. When expressed as a percentage 
of the contralateral, the amplitude of animal 2 was 23.4%. When expressed as a 
percentage of the contralateral, the amplitudes of animals 4 and 5 were 45 and 81.6% 
respectively.  
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Table 18. Electrophysiological evaluation of sciatic nerve 8 weeks postoperatively. CMAP 
amplitude values for repaired and contralateral nerves and the latency associated with 
evoked CMAP responses are shown.   
 
Animals treated with EngNT made with SCL4.1/F7 cells overexpressing VEGF-A165 
 Contralateral Injury 
 Latency (ms)  Amplitude (µV) Latency (ms) Amplitude (µV) 
Animal 1 1.51 8163 - - 
Animal 2 1.51 8540 8.91 2000 
Animal 3 10.73 99279 - - 
Animals treated with EngNT made with control SCL4.1/F7 cells 
 Contralateral Injury 
 Latency (ms) Amplitude (µV) Latency (ms) Amplitude (µV) 
Animal 4 2.03 1087 2.34 2415 
Animal 5 3.49 99824 8.7 81429 
Animal 6 1.61 15250 - - 
 
7.3.3 Histological outcomes  
 
In additional to functional and electrophysiological assessment, nerve regeneration was 
also studied histologically. Transverse cryostat sections (10 μm thick) were prepared 
from the middle of the device and the proximal and distal parts of the nerve stumps at 
a constant temperature of –20 oC. The transverse sections that were used for analysis 
were from positions 1 mm into the proximal and distal stumps, measured from the end 
of the nerve stump in each case, and from the middle of the device.  
 
7.3.3.1 Axonal counts 
 
Transverse sections through the regions described were used to determine the 
number of neurofilament-positive neurites present in the proximal and distal stumps 
as well as in the middle of the device (figure 100).  
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Figure 100. Axonal staining. Representative micrographs from transverse sections showing 
neurofilament positive axons at various positions in the repaired nerves. Scale bar: 100 µm, 
insert scale bar: 240 µm.  
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Immunostaining control (no secondary antibody) 
 
 
 
 
 
To assess axonal growth, all of the neurofilament positive axons present in each 
transverse section were counted using automated image analysis protocols in Volocity 
(figure 101). Similar numbers of axons were counted in both groups at the 3 different 
positions. Both groups showed similar numbers of axons in the proximal and distal 
stumps as well as in the middle of the device.   In both groups, the number of axons 
counted in the distal stump was lower than in the proximal stump, with means of 
around 11 000 and 6000 axons respectively. The mean number of axons in the mid-
device for both groups was approximately 7000.     
 
Figure 101. Quantification of neurites at different positions through repaired nerves.  Each 
data point represents the number of neurofilament positive axons at each position (n = 3 for 
each group).  
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7.3.3.2 Vascularisation 
 
The vascularisation of proximal and distal stumps and of the middle of the device was 
examined via immunofluorescence staining of transverse sections using RECA-1 
(figure 102).  
 
Figure 102. Blood vessel analysis. Representative micrographs from transverse sections 
showing blood vessels at various positions in the repaired nerves. Scale bar: 50 µm.  
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Analysis revealed the presence of blood vessels in all three regions examined. A mean 
of 7 and 6 blood vessels was counted in the proximal stump of the animals treated 
with the control and transduced cells respectively.  A mean of 6 and 5 blood vessels 
was counted in the middle of the device in the animals treated with the control and 
transduced cells respectively.  A lower number of blood vessels was counted in the 
distal stump of the animals treated with the transduced cells compared to the animals 
treated with the control cells, means of 7 and 12 respectively (figure 103). The blood 
vessel diameter in each region was also measured. Higher blood vessel diameter was 
observed at all three points in the animals treated with the transduced cells  (figure 
103). In both groups, the diameter of the blood vessels decreased distally. Blood 
vessels with a mean diameter of 37.3, 33.5 and 23.2 µm were measured in the 
proximal stump, mid-device and distal stump respectively in the animals treated with 
the transduced cells. In the animals treated with control cells, blood vessels with a 
mean diameter of 28.8, 21.7 and 19.5 µm were measured in the proximal stump, mid-
device and distal stump respectively.  Vasculature in contralateral nerves was 
examined, revealing an average of 17 blood vessels per nerve with a mean diameter 
of 18.35 µm. 
 
Figure 103. Examination of vasculature within repair site. Quantitative analysis of a) the 
number and b) the diameter of blood vessels in transverse sections through the proximal and 
distal stumps and the middle of the repair device.  
 
 
 
 
a) b) 
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7.5 Discussion 
 
Extensive research has been directed towards the development of tissue engineered 
constructs that can be used to replace the nerve autograft in repairing injured peripheral 
nerves. However, one of the current limitations of such constructs is insufficient 
vascularisation following implantation, leading to cell death. Further, vascularisation of 
tissue engineered constructs was found to increase peripheral nerve regeneration 
(Iijima et al., 2016). According to D’Arpa et al. (2015), vascularised tissue engineered 
constructs are more functional for the reasons that they can reduce intraneural fibrosis 
and increase clearance of debris, hence reducing obstruction to axonal growth as well 
as promoting faster Wallerian degeneration.  
 
This pilot study tested whether EngNT made from SCL4.1/F7 cells overexpressing VEGF-
A165 increased nerve regeneration through a 15mm gap in a rat sciatic nerve compared 
to EngNT made from control SCL4.1/F7 cells. These experiments, which used low 
numbers of animals, were performed to establish the safety and efficacy of VEGF-A165 
overexpression using the current experimental paradigm. Regeneration was assessed 
using motor and sensory outcomes, gastrocnemius muscle mass and nerve histology. As 
each group consisted of only 3 animals, the sample size was considered to be too low 
for reliable statistical analysis. It was thought that this study could be used for initial 
experiments to inform a power analysis to determine the group size for a future 
experiment.  
 
The rat sciatic nerve is the most commonly used model for the study of nerve 
regeneration using nerve repair devices (Angius et al., 2012). However, it is often 
difficult to compare results from different studies studying nerve regeneration, as 
researchers often use different gap lengths, rat strains and time points (Angius et al., 
2012). The 15 mm gap used in the current study created a challenging environment for 
testing regeneration as it represents a critical sized defect (Angius et al., 2012), in which 
no recovery will occur without the presence of grafting or bridging.  An 8 week recovery 
period was chosen as Georgiou et al. (2013) had previously shown, using histological 
analysis, that EngNT made from SCL4.1/F7 cells had supported robust neuronal 
regeneration across the gap by this time point. 
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Functional tests revealed that full motor and sensory recovery was not obtained by the 
end of the 8 week period in both groups. This observation is in general agreement with 
other studies, where full recovery during the study period was not achieved after 
repairing a complete transection with different nerve-gap bridging materials (Sinis et al., 
2009). Electrophysiological testing indicated that sufficient nerve regeneration to re-
establish functional connections with the gastrocnemius muscle had not occurred in two 
out of the three animals treated with EngNT made using SCL4.1/F7 cells overexpressing 
VEGF-A165  and  one out of the three animals treated with EngNT  made using control 
SCL4.1/F7 cells. It was revealed that these animals also had the lowest percentage of 
axons reaching the distal stump (section 7.3.3.1) and the highest gastrocnemius muscle 
atrophy (section 7.3.1.3). When expressed as a percentage of the contralateral, the 
amplitude of animal 2 was 23.4%. When expressed as a percentage of the 
contralateral, the amplitudes of the animals treated with the control untransduced 
SCL4.1/F7 cells were similar to values reported by O’Rourke et al. (2018), who implanted 
EngNT made from CTX0E03 cells into a rat model of sciatic nerve injury (gap length = 12 
mm). However, it should be noted that the electrophysiological analysis in the current 
study yielded highly variable results (table 17), as can be seen from the latency and 
amplitude obtained for the contralateral nerves which should be all approximately 
equal.  
 
Functional reinnervation was also confirmed indirectly by examining the 
gastrocnemius muscle mass. The percentage muscle recovery in the current study 
ranged between 20-33%, which was lower than expected since previous reports using 
autografts have shown muscle recovery of around 60% (Jin et al., 2013; Reid et al., 
2013). However, these studies tended to use a longer time point, 12 weeks or 18 
weeks (Reid et al., 2013) and a shorter (10 mm) gap (Jin et al., 2013; Reid et al., 2013). 
The values obtained in the current study were comparable to those obtained by   
O’Rourke et al. (2018), who reported a mean recovery of 24% for animals treated with 
EngNT made from CTX0E03 cells into a rat model of sciatic nerve injury. This was 
significantly lower than the animals treated with an autograft, but higher than the 
animals treated with an empty nerve conduit only.  
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Quantification of neuronal growth revealed the presence of a similar number of neurites 
in the distal stump in both groups. Histological analysis of cross sections through the 
proximal and distal parts of the repaired nerves showed that approximately 50% of the 
number of the neurites in the proximal stump reached the distal stump. This was 
comparable to previous studies using EngNT constructs made using SCL4.1/F7 cells 
(Georgiou et al., 2013), ADSCs (Georgiou et al., 2015) and CTX0E03 cells (O’Rourke et al., 
2018). However, the rat strain, gap length and conduit material may preclude direct 
comparison.  
 
The distribution of neuronal growth within the constructs is similar to that observed 
in earlier studies, with neurites located predominantly on or near the surface of the 
EngNT (Georgiou et al., 2013; Georgiou et al., 2015; O’Rourke et al., 2018).   Little 
neurite growth was observed in the middle of the EngNT itself, which was similar to 
observations made by O’Rourke et al. (2018) but differed from the original findings of 
Georgiou et al. (2013). However, this could be explained in terms of the implantable 
device design. In the current study, similar to the study by O’Rourke et al. (2018), one 
EngNT sheet was rolled up and inserted into the conduit.  In contrast, Georgiou et al. 
(2013) had used two rolled EngNT rods per conduit. This suggests the number of cells 
used, as well as the configuration of the EngNT within the conduit, could further 
increase regeneration.  
 
Unexpectedly, EngNT made of SCL4.1/F7 cells overexpressing VEGF-A165 did not increase 
the number of blood vessels in vivo despite promising in vitro data. However, it was 
noted that the blood vessels in the animals treated with EngNT made from SCL4.1/F7 
cells overexpressing VEGF-A165 had wider diameters than the control group. in vitro 
assays analyse distinct processes of angiogenesis, such as endothelial cell proliferation, 
migration and tube formation and do not faithfully recapitulate the complex process of 
angiogenesis as a whole. The results obtained from this study highlight the complexity 
of angiogenesis, in which in vitro results were not representative of in vivo data. 
Immunofluorescence staining for RECA-1 showed the presence of blood vessel 
structures in the proximal and distal stumps as well as in the middle of the device in 
both groups. While the presence of VEGF-A165 caused an increase in the blood vessel 
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diameter in the VEGF-A165 treated group, it is not known whether this effect was due to 
the small sample size.   
 
Early studies reported beneficial effects of VEGF on vascularisation, accompanied by 
increased regeneration in acellular or laminin-gel grafts (Sondell et al., 1999; Hobson et 
al., 2000; Rovak et al., 2004). Pereira-Lopes et al.  (2011) showed a positive relationship 
between increased vascularisation and enhanced nerve regeneration, indicating that 
VEGF-A165 administration can support and enhance the growth of regenerating nerve 
fibres, probably through a combination of angiogenic and neurotrophic. Hoyng et al. 
(2014) implanted nerve autografts genetically modified to overexpress VEGF-A165 in a 
10mm gap in a rat sciatic nerve model.  They reported that the overexpression of VEGF-
A165 in autografts induced the formation of blood vessels as early as 2 weeks and 
hypervascularisation was reported at 20 weeks. However, although enhanced 
angiogenesis was observed, no significant improvement in regeneration was seen. 
Conversely, Mohammadi et al. (2013) reported increased axonal regeneration at 12 
weeks when silicone graft filled VEGF-A165 was used to repair 10 mm in a rat sciatic nerve 
model. However, they did not investigate the effect of VEGF-A165 on angiogenesis.  
 
Nikolaev et al. (2013) implanted a poly(ε-caprolactone) conduit ﬁlled with ﬁbrin 
hydrogel matrix into a 5 mm gap in a rat model of sciatic nerve injury. Immediately after 
implantation, a double-cassette plasmid delivering the VEGF and FGF2 genes was 
injected proximally and distally of the reconstructed nerve. Compared to control animals 
which received the conduit without the therapeutic genes, animals which received the 
conduit in combination with the therapeutic genes showed an increased number of 
myelinated fibres in the proximal stump and S100 positive cells in the distal stump after 
30 days.  Improved motor and sensory recovery of the nerve function, as demonstrated 
by the sciatic functional index and pinch test, were also shown. An interesting 
observation made by Nikolaev et al. (2013) was that a poly(ε-caprolactone) conduit 
supported regeneration to a greater extent than a silicone conduit. Both conduits were 
used in combination with the therapeutic genes, but the porous and permeable nature 
of poly(ε-caprolactone) was thought to allow the entry of biomolecules required for 
regeneration, leading to better outcomes. This is particularly noteworthy as a silicone 
tube was used in the current study and regeneration was not improved in the animals 
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treated with EngNT made with SCL4.1/F7 cells overexpressing VEGF-A165 compared to 
EngNT made with control SCL4.1/F7 cells.  
 
Hoben et al. (2015) investigated whether the addition of VEGF improved axonal 
regeneration in acellular nerve allografts in a 20 mm gap in a rat model of sciatic nerve 
injury. 60 ng of human recombinant VEGF-A165 was delivered in a fibrin matrix in the 
acellular nerve allograft. However, the acellular nerve allografts in combination with 
VEGF-A165 did not increase axonal regeneration to the same extent as an isograft at 10 
weeks. A reduced number of total myelinated axons and nerve fibre density was seen in 
the distal stump of the animals treated with the acellular nerve allografts in combination 
with VEGF-A165.They suggested that this is due to inadequate dosing and delivery of 
VEGF-A165. According to Hoben et al. (2015), vascularisation is a key difference between 
acellular nerve allografts and autografts. Autografts become vascularised through 
inosculation within 72 hours of implantation via the existing endothelial cell-lined 
vasculature, while acellular nerve allografts depend on the more extended process of 
angiogenesis. 
 
Lee et al. (2016) repaired a 10-mm sciatic nerve defect in a rat model with an autologous 
nerve graft and implanted an osmotic pump delivering rat recombinant VEGF-A164 
adjacent to the graft.  The pump delivered a sustained release of 70 ng VEGF/hour for 3 
days. While the administration of VEGF-A164 increased blood vessel formation, no 
significant improvement in nerve fibre density or functional recovery at 16 weeks was 
noted. The authors hypothesised that in autologous nerve grafts, vascularisation may 
occur rapidly due to intact cells and blood vessels. Thus, the effect of the administered 
VEGF was minimal. Similar to Hoben et al. (2015), they postulate that the effect of VEGF 
on nerve regeneration may be dose dependent and suggest that the dose and route of 
administration of VEGF administered was insufficient to enhance axonal elongation 
across the entire length of the nerve graft. 
 
Man et al. (2016) transduced mesenchymal stem cells with a lentiviral vector delivering 
VEGF-A165.  In vitro assays revealed that the transduced cells significantly increased the 
proliferation of endothelial cells compared to control untransduced cells. However, 
when these cells were embedded within a 3D fibrin matrix and transplanted into a 4 mm 
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gap in a mouse sciatic nerve model, no significant effects on axon regeneration and 
angiogenesis compared to control cells were reported. The authors attributed this to 
the fact that while the transduced cells secreted higher levels of VEGF-A165 than control 
cells, the levels may have not been sufficient for increasing angiogenesis in vivo. They 
reported that in vitro cultures of 100 000 transduced cells in a 3D matrix secreted a peak 
3-day VEGF-A165 concentration of approximately 16 ng/ml. This is a significant 
observation as the transduced SCL4.1/F7 cells in EngNT in silicone tubes in the current 
study secreted just under 2 ng/ml of VEGF-A165 following one day of in vitro culture. A 
kinetic assessment of VEGF-A165 release from transduced SCL4.1/F7 cells in EngNT in 
silicone tubes was not carried out and therefore the peak concentration of the secreted 
VEGF-A165 is unknown.  
 
Therapeutic benefits of cell therapy have been shown in several experimental models of 
peripheral nerve injury (Fairbairn et al., 2015, Bhangra et al., 2016). Nonetheless, the 
identification and selection of the most suitable cell source to enhance regeneration 
remains a significant challenge. The current study investigated the use of SCL4.1/F7 cells 
overexpressing VEGF-A165 to enhance peripheral nerve regeneration. However, this did 
not result in improved regeneration compared to control SCL4.1/F7 cells. While this cell 
line has been previously shown to enhance peripheral nerve regeneration (Georgiou et 
al., 2013), other cell types may result in improved regeneration when used in 
combination with gene delivery. When ADSCs and CTX0E03 cells were transduced with 
the lentiviral vector delivering the VEGF-A165 gene, they produced significantly more 
protein than SCL4.1/F7 cells (section 7.4). This is a significant result because as described 
in this section, the effects of VEGF-A165 may be dose dependent. The higher amount of 
VEGF-A165 produced by these two cell types may significantly increase regeneration 
compared to untransduced controls.  Further, studies using rat ADSCs have shown that 
these cells can differentiate to a Schwann cell-like phenotype, making them ideal for use 
in peripheral nerve repair (Kingham et al., 2007; Jiang et al., 2008; Georgiou et al., 2015) 
and CTX0E03 cells are a clinically relevant stem cell source which can also be 
differentiated down a glial lineage (Sinden et al., 2017) 
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7.6 Conclusion  
 
The results obtained from this chapter revealed that clinically relevant sources of stem 
cells, namely CTX0E03 cells and ADSCs, were amenable to lentiviral transduction and 
produced high levels of VEGF-A165 in vitro. When implanted into a rat model of sciatic 
nerve injury, EngNT made with SCL4.1/F7 cells overexpressing VEGF-A165 did not 
improve regeneration compared to EngNT made from untransduced SCL4.1/F7 cells. 
Similar numbers of blood vessels were counted in both groups. It was noted that the 
blood vessels in the animals treated with EngNT made from transduced SCL4.1/F7 cells 
had a wider diameter. However, this did not result in an improvement in the number of 
regenerating axons reaching the distal stump. Similar results in terms of functional 
recovery, electrophysiology and histology were obtained in both groups. The 
overexpression of VEGF-A165 was not associated with any adverse effect in vivo.  
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Chapter 8: Discussion  
 
8.1 Overview 
 
Despite a substantially increased understanding of neuropathophysiology, insufficient 
functional recovery after peripheral nerve injury remains a significant clinical challenge. 
The autologous nerve graft is the current clinical gold standard treatment for nerve 
damage over a few centimetres in length (Pfister et al., 2011). The autologous nerve 
graft bridges the nerve gap and supplies Schwann cells necessary for regeneration, but 
it is also associated with several disadvantages, including the sacrifice of a healthy nerve.  
 
Tissue engineered nerve repair devices are emerging as a potential alternative to 
autologous nerve grafts (Bellamkonda, 2006). Successful tissue engineering strategies 
require the formation of a stable and mature vascular network following implantation 
of the tissue engineered construct. In the absence of such a network, the viability of the 
cells in the constructs is compromised due to mass transport limitations (Xia et al., 
2018). In the context of peripheral nerve injury, angiogenesis is also important for nerve 
regeneration. Studies have shown that vasculature can precede the outgrowth of axons 
from the proximal stump following injury, suggesting a close relationship between blood 
vessels and nerves (Hobson et al., 1997). Further, the formation of new blood vessels 
can support the increased metabolic demands of regenerating nerves (Lovett et al., 
2009). Therefore, while nerve repair devices may assist in in guiding regenerating 
nerves, satisfactory functional restoration may also require exogenous angiogenic 
factors.  
 
VEGF-A165 is a potent angiogenic factor that stimulates proliferation and migration of 
endothelial cells, formation of new blood vessels and enhances vascular permeability 
(Brockington et al., 2004). Additionally, it has also been shown to increase axonal 
outgrowth and Schwann cell proliferation (Haninec et al., 2012). Given the importance 
of VEGF-A165 in peripheral nerve tissue engineering, there has been an interest in the 
development of strategies for delivering it to the implant site. A promising approach is 
the use of genetically modified cells overexpressing VEGF-A165 which can be 
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incorporated into nerve repair devices to provide a localised and sustained release of 
VEGF-A165.   
 
The goal of this study was to develop an ex vivo gene delivery approach as one 
component of a comprehensive tissue engineering strategy to enhance peripheral nerve 
repair.  Firstly, it was envisaged that labelling cells with luciferase would allow real-time 
and sustained imaging of the cells in EngNT following implantation in vivo. Secondly, it 
was thought that combined gene delivery and tissue engineering would exert dual 
beneficial effects on peripheral nerve regeneration: the cellular EngNT would guide and 
support the regenerating axons while the overexpression of VEGF-A165 would exert 
angiogenic and neurotrophic effects.  
 
8.2 Summary of results  
 
An in vitro proof-of-concept study was carried out to deliver marker genes (luciferase 
and eGFP) to a rat Schwann cell line (SCL4.1/F7) using a lentiviral vector. After 
establishing that SCL4.1/F7 cells were transduced by monitoring eGFP expression using 
fluorescence microscopy, flow cytometry revealed a transduction efficiency of over 80%. 
Transduction did not affect cell morphology, viability or proliferation and long term 
transgene expression was observed in the transduced cells.   
 
The genetically modified cells were used to construct EngNT and a Z-stack confirmed 
that cell distribution was uniform throughout. Further, bioluminescence imaging 
confirmed that the cells were still viable in the EngNT. It was initially thought the 
presence of the luciferase gene in the expression cassette would allow real-time and 
sustained imaging of the cells in the EngNT. Bioluminescence imaging provided a reliable 
method of monitoring the viability of cells in the EngNT in vitro but proved to be 
ineffective for in vivo imaging and yielded highly inconsistent data for ex vivo imaging. 
 
Having established that SCL4.1/F7 cells were amenable to lentiviral transduction, a 
lentiviral vector delivering the VEGF-A165 gene was designed and produced. Flow 
cytometry once again confirmed a transduction efficiency of over 80%. The VEGF-A165 
produced by the transduced SCL4.1/F7 cells increased endothelial cell viability, 
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migration and tube formation in vitro. VEGF-A165 also increased SCL4.1/F7 cell 
proliferation and migration. SCL4.1/F7 cells overexpressing VEGF-A165 were found to 
increase the number of junctions and meshes as well as the total mesh area formed by 
endothelial cells in a 3D co-culture model. A co-culture consisting of EngNT made from 
SCL4.1/F7 cells overexpressing VEGF-A165 was found to increase PC12 neurite length. 
Taken together, these results demonstrated that the VEGF-A165 produced had positive 
effects on endothelial cells, Schwann cells and neuron like cells. It was therefore 
postulated that implanting EngNT made from SCL4.1/F7 cells overexpressing VEGF-A165 
into a 15 mm gap rat model of sciatic nerve injury would enhance regeneration. 
Unexpectedly, this did not improve functional recovery, axon counts or overall 
angiogenesis compared to EngNT made from control SCL4.1/F7 cells. CTX0E03 cells and 
ADSCs were also successfully transduced with the lentiviral vector delivering VEGF-A165, 
and produced significantly more VEGF-A165 than SCL4.1/F7 cells.  
 
8.3 Study limitations  
 
The current study reported a transduction efficiency of over 80% following transduction 
with the lentiviral vector delivering VEGF-A165, resulting in a mixed population of 
transduced and untransduced cells. Further, different cells in the transduced population 
potentially express different VEGF-A165 levels depending on the vector copy number and 
on the transcriptional activity resulting from the chromatin organisation around the 
random integration site (Emery, 2011). Ozawa et al. (2004) suggest selecting clones 
which produce homogenous amounts of VEGF-A165 to reduce the risk of aberrant 
angiogenesis. They showed that VEGF-A165 induced angiogenesis depends on the micro 
environmental amount of VEGF-A165 secreted rather than the total number of VEGF-A165 
expressing cells.  
 
The SCL4.1/F7 Schwann cell line used in the present study was an ideal tool to develop 
a gene delivery protocol. However, it is a clonally derived diploid immortal rat cell line 
(Haynes et al., 1994) and is not useful beyond the scope of testing the hypothesis of this 
study. A key factor limiting the translation of cellular tissue-engineered constructs 
towards clinical application is the source of therapeutic cells. The current study 
established that two types of clinically relevant cell types, namely CTX0E03 cells and 
   235 
 
ADSCs, are amenable to lentiviral transduction and produced significantly more VEGF-
A165 than SCL4.1/F7 cells. Given the importance of the concentration of VEGF-A165, these 
cell types could potentially increase regeneration to a greater extent than what was 
observed in the current study. However, due to time constraints the effect of CTX0E03 
cells and ADSCs in vivo was not investigated.  
 
Silicone tubes have been traditionally used to investigate peripheral nerve regeneration 
following injury (Lundborg et al., 1982). While silicone tubes are generally well-
tolerated, (Dahlin et al., 2001; Gu et al., 2011), the main problem associated with their 
use is that they are non-biodegradable and a second surgery is required for their 
removal (Merle et al., 1989). Further, the impermeability of silicone may limit the 
diffusion and transport of growth factors through the wall (Stang et al., 2009). The 
results obtained from the bioluminescence imaging carried out in the current study 
suggest that the silicone tube acts as a barrier between the cellular EngNT and the 
surrounding microenvironment. This could have potentially limited the utility of the 
overexpression of VEGF-A165 by limiting its paracrine activity. This highlights the need 
for more epineurium like material to surround and support the EngNT.  
 
8.4 Future work 
 
Several suggestions for future work have already been made throughout this chapter, 
including the use of a pure cell population in tissue engineered constructs, genetically 
modifying clinically relevant cell types and replacing the silicone tube with a biomimetic 
marterial. However, further considerations which can improve the results presented in 
this thesis are discussed here. The tight control of regeneration and repair is one of 
the ultimate goals in tissue engineering research. Gene delivery offers the potential 
for both precise and adjustable regeneration enhancement, and is becoming a 
popular tool in tissue engineering strategies (Balmayor and van Griensven, 2015; 
Cucchiarini et al., 2016; Betz et al., 2018). However, research has revealed that 
continuous overexpression of genes used to enhance regeneration can have 
deleterious consequences if expressed long-term (Hoyng et al., 2014). There are 
several ongoing areas of research aimed at further improving gene delivery with the 
development of novel viral vector designs.  
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An area of interest is the use of non-integrating lentiviral vectors which have been 
developed to overcome the risk of insertional mutagenesis (Shaw and Cornetta, 
2014). These vectors are deficient in the viral integrase protein and rather than 
integrating into the host genome DNA, the viral genome remains episomal (Philippe 
et al., 2006). While gene expression may be expected to be short-lived in dividing 
cells, this may be useful when high long-term gene expression is not required (Milone 
and O’Doherty, 2018). According to Blesch and Tuszynski (2007), high levels of 
angiogenic and neurotrophic factors are only necessary to induce growth and low levels 
are sufficient to sustain axons that have extended into a cellular graft. Thus, the use of 
a non-integrating virus can mitigate the prolonged expression of such factors.  
 
In a clinical setting, the SFFV promoter used in the current study is not favourable as it 
is derived from a gamma retrovirus and may cause safety concerns due to its potential 
for activating nearby genes leading to malignancy (Modlich et al., 2009). Cellular 
promoters derived from human housekeeping genes, such as elongation factor‐1α or 
phosphosglycerate kinase, can reduce this risk (Everson et al., 2018). The human 
phosphoglycerate kinase promoter has been successfully used in a clinical trial for 
metachromatic leukodystrophy with promising results (Biffi et al., 2013). In light of this, 
viral vectors used in future studies aiming to improve peripheral nerve regeneration 
should incorporate a clinically relevant promoter.  
 
Another means of regulating the expression of angiogenic and neurotrophic factors is 
the use of duration-controlled inducible gene expression. Ma et al. (2016) have 
described the used of genetically modified mesenchymal stem cells lines comprising 
two independent inducible gene expression modules, expressing the anti-apoptotic 
bcl-2 gene and the chondrogenic master regulatory gene sox9 for cartilage tissue 
engineering. Two non-toxic small molecules for specific induction were assembled in 
controlled-release modules with the gelatin sponge scaffold to permit controlled-
duration gene expression. They showed that the anti-apoptotic effect of Bcl-2 could 
be restrictively activated within the first week upon implantation, while relatively 
long-term expression of Sox9 to facilitate chondrogenic commitment could persist for 
up to 4 weeks after implantation. This system was found to better mimic the in vivo 
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expression of these genes and resulted in improved cell cellularity and chondrogenic 
matrix secretion and prevented potential oncogenic and toxic effects associated with 
persistent expression of these genes. Time-course gene delivery may also be 
beneficial in peripheral nerve regeneration and warrants further investigation. In  fact, 
promising results have been reported in a recent study by Mozafari et al. (2018). 
Human embryonic stem cells genetically modified to inducibly overexpress FGF-2 in a 
fibrin matrix were implanted in a mouse model of sciatic nerve injury.  This treatment 
strategy was successful in the regeneration of sensory and motor fibres, as shown by 
von Frey testing and immunohistochemistry analysis. Similar results have also been 
previously reported by Shakhbazau et al. (2013) and Wu-Fienberg et al. (2014).  
 
While VEGF-A165 plays a significant role in angiogenesis, it is unclear whether VEGF-A165 
is sufficient to promote the formation of mature vessels that can provide adequate 
blood flow to tissue engineered constructs. Further, it has been shown that excessive 
administration of VEGF-A165 induced the formation of immature and leaky vessels 
(Springer et al., 1998). It has therefore been suggested that the co-delivery of angiogenic 
factors may have a synergistic effect on therapeutic angiogenesis. Previous studies have 
reported the use of VEGF-A165 in combination with placental growth factor (Cheng and 
Sefton, 2009), platelet-derived growth factor (Chen et al., 2007), transforming growth 
factor-β1 (Freeman and Cohen, 2009) and basic fibroblast growth factor (Jiang et al., 
2016) in a number of animal models. In the context of peripheral nerve tissue 
engineering, it would be worth investigating whether the delivery of VEGF-A165 in 
combination with another angiogenic factor increases angiogenesis and regeneration 
compared with the delivery of a single factor.   
 
8.5 Conclusion 
 
While there is a large body of preclinical evidence showing the benefits of gene delivery 
and tissue engineering to enhance peripheral nerve regeneration, the results in each 
study were contingent on the animal model used as well as the well as the concentration 
and duration of the expression of the growth factors used. While the combination of 
gene delivery and tissue engineering did not improve regeneration in the current study, 
it emphasised several areas of research which are yet to be fully elucidated. These 
   238 
 
include the identification of the best suited therapeutic gene(s), viral vector, cell type 
and biomaterials. It also highlights that attention needs to be paid to the dose and 
duration of expression of VEGF-A165 to optimise both its angiogenic and neurotrophic 
effects.  
 
The nerve injury site represents a complex environment with several growth factors and 
different cell types and a central requirement for successful peripheral nerve repair is 
the fast and adequate directing of regenerating axons to the correct target organ. An 
effective therapy may require a combinatorial approach that provides optimised guiding 
structures, ECM substrates, stimulatory factors and supporting cells. This study 
represents an important building block in designing a nerve repair device which 
incorporates all these factors.  
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